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Abstract 
Kaushal, Akhilesh. Ph.D. The University of Memphis. August 2017. Epigenetic Marker 
Identification and Assessment of Methods on Cell Type Compositions at the Epigenome-Scale. 
Major Professor: Dr. Hongmei Zhang. 
Epigenetics is the study of heritable changes in genes which are caused by chemical 
compounds derived from natural and man-made sources. DNA methylation an epigenetic 
phenomenon, is most vulnerable to environmental factors during embryogenesis, which is a 
period of rapid cell division and epigenetic remodeling. Given the recent increase in the 
incidence of childhood diseases, it is crucial to understand the role of environmental factor 
through epigenetic study in causing adverse health effects. This dissertation revolves around 
three major hypotheses. In the first hypothesis we evaluated the association between in utero 
arsenic exposure and genome-wide DNA methylation in cord blood from the birth cohort data of 
Taiwan. The identified CpG sites were replicated in an independent birth cohort (New 
Hampshire birth cohort study; NHBCS) and further assessed longitudinal associations of DNA 
methylation with disease biomarkers measured at later ages in our cohort from Taiwan. In the 
second hypothesis we assessed the association between Immunoglobulin E (IgE) production and 
DNA methylation at birth via cord blood in a longitudinal study. The study was conducted from 
the birth cohort data of Taiwan and the findings were replicated in an independent birth cohort 
(Isle of Wight; IoW), and further the stability of identified CpG sites was assessed based on 
intra-class (ICC) correlation measure. In the third hypothesis we assessed the confounding effect 
in epigenome wide association study due to underlying cell composition and evaluated several 
methods and algorithms proposed to adjust for this confounding effect. 
v 
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1 
1 Introduction 
The dissertation focuses on the identification of epigenetic markers from cord blood DNA 
methylation at birth associated with in utero arsenic exposure and immunoglobulin E (IgE). 
There is increasing evidence that in-utero arsenic exposure causes adverse health effects later in 
life [1, 2]. Arsenic is a potent human toxicant and carcinogen, but knowledge of the mechanism 
through which it exerts long term adverse health effects is limited. Inorganic arsenic and its 
methylated metabolites can easily cross the placenta and thus producing arsenic concentrations in 
cord blood similar to maternal blood [3]. The study of epigenetic changes such as DNA-
methylation alterations that can affect gene activity may provide insight into mechanism through 
which arsenic exerts its adverse effects [4]. 
Immunoglobulin E (IgE) is known to play a major role in many of the allergic diseases 
such as asthma, atopic dermatitis (eczema) and hay fever. IgE production leads to type I 
hypersensitivity, which manifests various allergic diseases. However, the mechanism underlying 
IgE production is poorly understood. There is evidence that DNA methylation is associated with 
total IgE. An epigenome wide association study has a potential to shed more lights on the 
production of IgE. 
Epigenome wide association studies are known to be influenced by the underlying cell 
compositions. Several algorithms and methods have been proposed to estimate or adjust for these 






Epigenetics is the study of heritable changes in genes, which are caused by chemical compounds 
derived from natural and man-made sources. These heritable changes regulate genome by: (a) 
methylating DNA in genome, (b) modifying the histone, a protein that enables DNA to form 
long molecules. The chemical compounds that cause heritable changes in genome are known as 
epigenome. Much of the epigenome is reset when parents pass their genomes to their offspring; 
however, under some circumstances, some of the chemical tags on the DNA and histones of eggs 
and sperm may be passed on to the next generation [5-7]. When cells divide, often much of the 
epigenome is passed on to the next generation of cells, helping the cells remain specialized [7]. 
 DNA methylation is an epigenetic phenomenon wherein the nucleotides in DNA is 
modified by addition of methyl group through covalent bond. In DNA methylation a methyl 
group is attached to the 5th atom in the 6-atom ring of cytosine leading to 5 methyl cytosine 
(5mC) or at 6th position of adenine ring leading to 6-methyl adenine (6mA). The term CpG refers 
to the base cytosine (C) linked by a phosphate bond to the base guanine (G) in the DNA 
nucleotide sequence. In the human genome, it predominantly occurs at cytosine–guanine 
dinucleotide (CpG) sites, and serves to regulate gene expression and maintain genome stability 
DNA [8, 9]. Methylation is heritable and stable from one cell to another during cell division and 
thus leads to formation of epigenetic memory [10]. 
 The epigenome is most vulnerable to environmental factors during embryogenesis, which 
is a period of rapid cell division and epigenetic remodeling [11-13]. Given the recent increase in 
the incidence of childhood immune-based diseases, it is crucial to understand the role of 
environmental stressors [14]. A stressor is a chemical or biological agent, environmental 




have shown that DNA methylation could be altered under environmental stress, by overall 
genome-wide reduction in DNA methylation content (global hypo methylation). This alteration 
in DNA methylation can alter the expression of underlying gene.  
 Arsenic (As) is one such environmental stressor whose exposure is known to alter DNA 
methylation both globally and in the promoter regions of certain genes [15, 16]. Upon entering 
the human body, inorganic As is methylated for detoxification. This detoxification process uses 
S-adenosyl methionine (SAM), which is a universal methyl donor for methyltransferases 
including DNA methyltransferases (DNMTs) that determine DNA methylation. 
1.2 Arsenic 
Arsenic is a metalloid found in numerous minerals usually in combination with sulfur and other 
metals. In reducing and oxygenated conditions, arsenite (AsIII), and arsenate (AsV), are the main 
oxidation states, respectively. Compounds of arsenic are divided into three major groups.  
a) Inorganic arsenic compounds (arsenic trioxide, sodium arsenite, arsenic trichloride, arsenic 
acid, and arsenic pentoxide),  
b) Organic arsenic compounds (arsanilic acid, methylarsonic acid, dimethylarsinic acid, 
arsenobetaine and arsenosugars), and  
c) Arsine gas.  
 Arsenite and arsenate are the most common inorganic forms in water. Arsenic is mainly 
transported in the environment via water from both natural and anthropogenic sources. In some 
regions of the world, groundwater (used for drinking water) is naturally contaminated with 
arsenic due to arsenic rich geological formations. These areas include Bangladesh, China, 
Taiwan, West Bengal (India), and some parts of Argentina, Chile, Mexico, Vietnam, Australia, 




ground water, whereas, in affected areas, the levels may range from tens to thousands of 
micrograms per liter [17]. 
 Ingestion of arsenic contaminated water is the primary route of inorganic arsenic 
exposure for the general population. Approximately hundred million individuals world-wide are 
at risk of elevated arsenic exposure, mainly via drinking water. 
 Most of the ingested inorganic arsenic is absorbed in the gastrointestinal tract and then 
reduced in the blood. In humans, inorganic arsenic is metabolized through the conversion of AsV 
to AsIII, followed by methylation to monomethylated and dimethylated arsenicals (MMA and 
DMA, respectively) [18]. 
1.3 Immunoglobulin E (IgE) 
Immunoglobulin E (IgE) is one of five isotypes of human immunoglobulins and is produced by 
plasma cells. Immunoglobulin E (IgE) is known to play a major role in many of the allergic 
diseases such as asthma, atopic dermatitis (eczema) and hay fever. IgE production leads to type I 
hypersensitivity, which manifests various allergic diseases. Thus understanding the mechanism 
leading to the IgE production is a key to understanding the pathophysiology of various allergic 
disease. 
1.4 Underlying cell compositions in cord blood 
Cord blood is the blood that remains in the vein of the umbilical cord and placenta at the time of 
birth. Umbilical cord blood consists of various cell types such as nucleated red blood cells, 
granulocytes, monocytes, natural killer cells, B cells, CD4+ T cells, and CD8+ T cells. Thus, 
DNA methylation measured in cord blood represents weighted averages of these cell-type 
specific methylation levels, with weights corresponding to the proportion of the different cell 




between cord blood and an exposure of interest could be confounded by cellular heterogeneity. 
Identifying and sub setting each cell types is not practical in larger epidemiological studies. 
Thus, several algorithms have been developed to measure and adjust for cellular heterogeneity in 
whole blood. 
1.5 Contribution 
Epigenome wide association study can identify epigenetic markers that will help reveal the 
adverse developmental effect of in utero arsenic. Also the longitudinal study predicting the 
production of IgE associated with cord blood DNA methylation can provide useful insight into 
the developmental origin of immunity based disease. The main contributions of the work 
presented in this dissertation can be summarized as below 
1. Identification of epigenetic markers at birth associated with in utero arsenic exposure. 
2. Identification of epigenetic markers at birth linking in utero arsenic exposure to cardiovascular 
disease. 
3. Identification of epigenetic markers at birth predicting the production of immunoglobulin E 
(IgE) at later ages. 











1.6 Organization of the dissertation 
The dissertation is organized as self-explanatory chapters related to the epigenetic marker 
identification. Chapter 2 presents the role of in utero arsenic exposure on fetal developmental 
programming and its adverse influence in later life. Chapter 3 discusses the role of DNA 
methylation at birth in predicting the IgE production at later ages. Chapter 4 compares several 
methods and algorithms to adjust for underlying cell compositions in epigenome wide 



















In utero arsenic exposure may alter fetal developmental programming by altering DNA 
methylation, which may result in a higher risk of disease in later life. We evaluated the 
association between in utero arsenic exposure and DNA methylation (DNAm) in cord blood and 
its influence in later life. 
Methods 
Genome-wide DNA methylation in cord blood from 64 subjects in the Taiwanese maternal infant 
and birth cohort was analyzed. Robust regressions were applied to assess the association of DNA 
methylation with in utero arsenic exposure. Multiple testing was adjusted by controlling false 
discovery rate (FDR) of 0.05. The DAVID bioinformatics tool was implemented for functional 
annotation analyses on the detected CpGs. The identified CpGs were further tested in an 
independent cohort. For the CpGs replicated in the independent cohort, linear mixed models 
were applied to assess the association of DNA methylation with low-density lipoprotein (LDL) 
at different ages (2, 5, 8, 11 and 14 years).  
Results 
In total, 579 out of 385,183 CpGs were identified after adjusting for multiple testing 
(FDR=0.05), of which ~60% were positively associated with arsenic exposure. Functional 
annotation analysis on these CpGs detected 17 KEGG pathways (FDR=0.05) including pathways 
for cardiovascular diseases (CVD) and diabetes mellitus. In the independent cohort, about 46% 
(252 out of 553 CpGs) of the identified CpGs showed associations consistent with those in the 




to CVD and diabetes mellitus. Via longitudinal analyses, we found at 5 out of the 12 CpGs 
methylation was associated with LDL over time and interactions between DNA methylation and 
time were observed at 4 of the 5 CpGs, cg25189764 (coeff=0.157, p-value=0.047), cg04986899 
(coeff. for interaction [coeff.int]=0.030, p-value=0.024), cg04903360 (coeff.int=0.026, p-
value=0.032), cg08198265 (coeff.int = -0.063, p-value=0.0021), cg10473311 (coeff.int = -0.021, 
p-value=0.027).  
Conclusion 
In utero arsenic exposure was associated with cord blood DNA methylation at various CpGs. 
The identified CpGs may help determine pathological epigenetic mechanisms linked to in utero 
arsenic exposure. Five CpGs (cg25189764, cg04986899, cg04903360, cg08198265 and 
cg10473311) may serve as epigenetic markers for changes in LDL later in life.  
2.2 Background 
Arsenic, a widespread element in the environment, poses a serious threat to human health. 
Millions of people around the globe are exposed to arsenic from drinking water that exceeds the 
safe limit of 10 ppb as recommended by World Health Organizations [19]. Arsenic is known to 
easily pass through the placenta in humans and other mammals, producing arsenic concentrations 
in cord blood similar to maternal blood [3]. Epidemiological studies have reported that 
gestational arsenic exposure is associated with increased risk of non-cancerous and cancerous 
diseases in adulthood [20, 21]. For instance, a number of studies have shown that early life 
arsenic exposure is associated with later cardiovascular diseases (CVDs) [22-24]. In animal 
studies, in utero exposure to low level arsenic in the womb and in adulthood was found to be 




The mechanisms through which in utero exposure to arsenic may result in a higher risk of 
various diseases are not well understood. However, harmful effects such as the generation of 
reactive oxygen species (ROS), which causes oxidative DNA damage, binding and inhibition of 
arsenic metabolites to enzymes, and perturbation of key signaling pathways, are thought to play 
certain roles in disease development [26]. In addition, clinical and epidemiological studies have 
observed that environmental exposure in early life can affect the risk of disease later in life 
through a phenomenon known as developmental programming [21, 27, 28]. The study of 
epigenetic changes such as DNA-methylation alterations that can affect gene activity may 
provide insight into developmental programming [4].    
Studies found that chronic arsenic exposure in adults is associated with increased DNA 
methylation extracted from whole blood leukocytes [29, 30]. Experimental studies in animals 
have also shown that intra-uterine exposure to arsenic alters DNA methylation in offspring [31]. 
Some studies examined the association of genome-wide DNA methylation in cord blood with in 
utero arsenic exposure.  Most of them were based on cohorts established in the United States and 
Bangladesh. These studies did not identify any statistically significant CpGs at the whole 
epigenome level and thus focused on the top 100 [32] or 500 CpG sites [16] potentially 
associated with in utero arsenic exposure, while the study by Kile et al [33] investigated the 
association of CpG sites in p16, p53, LINE-1 and Alu repetitive elements.  
Our study, based on data from a prospective birth cohort study established in Taiwan, 
aimed to comprehensively assess genome-wide DNA methylation in cord blood in association 
with in utero arsenic exposures (using maternal urinary arsenic concentrations), identify CpG 
sites showing such statistically significant associations after adjusting for multiple testing by 




identified CpGs. Additionally, we attempted to replicate our finding in an independent birth 
cohort (New Hampshire birth cohort study; NHBCS) and further assessed longitudinal 
associations of DNA methylation with disease biomarkers measured at later ages in our cohort 
from Taiwan. The findings will contribute to an improved understanding of the adverse 
mechanisms of in utero arsenic exposure on genome-wide epigenetic variation and whether 
epigenetic markers in cord blood can influence children’s diseases risk later in life.  
2.3 Methods 
2.3.1 Data collection and pre-processing of birth cohort data from Taiwan 
Taiwanese maternal infant and birth cohort description 
The data resulted from the Maternal and Infant Cohort Study in Taiwan investigating various in 
utero and postnatal factors considered to affect child health outcomes [21]. All pregnant women 
participating in this study signed informed consent forms explaining the benefits and risks of 
participation. This study was approved by Human Ethical Committee of the National Health 
Research Institutes in Taiwan. Pregnant women who received medical care at a local medical 
center were invited to join this study between December 2000 and November 2001. At the 
beginning, 430 of 610 pregnant women volunteered to participate, on average at 8 weeks 
gestation. Of the 430 pregnant women, 127 were excluded due to non-compliance of providing 
samples. Thus, urine samples were obtained from 313 pregnant women during the third trimester 
(28-38 weeks of gestation). Five newborns could not be included due to loss to follow up. Of all 
mother-newborn pairs, 299 have cord blood samples collected and DNA methylation data was 






Assessment of arsenic exposure 
Participants provided a spot urine sample at the time of enrollment in this study (at eight weeks 
of gestation). Urine was frozen at -20 °C in a 10-ml polypropylene tube. Arsenite (AsIII), arsenate 
(AsV), monomethylarsonic acid (MMA), and dimethylarsinic acid (DMA) were quantified by 
high-performance liquid chromatography/inductively coupled plasma mass spectrometry 
(HPLC-ICP-MS) and anion exchange columns (Hamilton PRP X-100 [10 mm particle size, 250 
mm64.1 mm]). Total urinary arsenic (TUA) was calculated by adding iAs (AsIII + AsV) + MMA 
+ DMA. The limitations of detection (LOD) for the various species were 0.09 mg/L for AsIII, 
0.05 mg/L for AsV, 0.05 mg/L for MMA, and 0.04 mg/L for DMA. Creatinine was measured by 
the Beckman Synchron LX20 auto-system (Beckman Coulter, Brea, CA, USA) in the central lab 
of Chung-Ho Memorial Hospital of Kaohsiung Medical University using a spectrophotometric 
method with picric acid as the reactive at 520 nm. We used total arsenic (tAs) as the sum of 
inorganic arsenic (AsIII + AsV) and organic arsenic (MMA and DMA) divided by urinary 
creatinine; this ratio was used in the subsequent analyses. 
Assessment of creatinine 
Creatinine was measured by the Beckman Synchron LX20 auto-system (Beckman Coulter, Brea, 
CA, USA) in the central lab of Chung-Ho Memorial Hospital of Kaohsiung Medical University 
using a spectrophotometric method with picric acid as the reactive at 520 nm. 
Assessment of low density lipoprotein (LDL) 
The LDL Cholesterol Direct (DLDL) method was used to measure LDL cholesterol from the 






DNA methylation  
DNA was isolated from cord blood samples using buffy coat isolated from EDTA-treated blood 
(Gentra Puregene; Qiagen, Hilden, Germany) and bisulfite converted using the EZ DNA 
Methylation kit. Samples were randomized across several plates for epigenome-wide DNA 
methylation assessment using the Illumina Infinium Human Methylation 450 BeadChip which 
simultaneously profiles the methylation status of > 485,000 CpG sites with single-nucleotide 
resolution across the human genome.  
DNA methylation is measured using beta values, calculated as M/ (M+U+ε), where M is 
the methylation signal of the target CpG, U is the unmethylated signal and ε=100, is a constant to 
protect division by zero. Thus, average beta-value (β) represents the percent methylation of the 
target CpG site and its value ranges between 0 and 1.  
Quality control 
The raw data of DNA methylation were pre-processed to achieve high quality for data analyses. 
The function PreprocessSWAN in the Bioconductor package minfi was used for normalization, 
background correction and peak correction. The function preprocessSWAN uses subset within 
array normalization (SWAN) technique, which normalizes Infinium type I and type II probes 
together within a single array. This technique reduces technical variability between arrays by 
accounting for differences in the comparison of the two probe types between arrays [34]. CpG 
sites located on sex chromosome and annotated probe SNPs within 10bp of the target CpGs were 







2.3.2 Data collection and pre-processing of birth cohort data from NHBCS (Replication 
Study sample) 
NHBCS Cohort Description: 
The New Hampshire Birth Cohort Study (NHBCS) is an ongoing prospective study that began in 
2009 and includes over 1500 women from two regions of New Hampshire, USA, enrolled 
between 24-28 weeks gestation. Mothers were recruited into the cohort if they were literate in 
English, mentally competent, between 18–45 years old, and reported using a private, unregulated 
well as the primary source of home drinking water. Infants included in the cohort were singleton 
pregnancies. Pre- and post-delivery questionnaires were administered to collect self-reported 
sociodemographic, lifestyle, and medical history data, and a structured medical records review 
was employed to collect information from the pregnancy and delivery. Cord blood samples are 
collected on >80% of all deliveries. This study consisted of the first participants born in the study 
with available cord blood samples for DNA methylation analysis and mothers that were not 
missing for urinary arsenic or any of the covariate data (n=109). 
Arsenic in maternal urine: 
Measures of maternal urinary arsenic have been described thoroughly elsewhere [1]. Briefly, 
spot urine samples were collected between 24–28 weeks gestation with 30 μL of 10 mM 
diammonium diethyldithiocarbamate, then samples were frozen at –80°C until analysis. High-
performance liquid chromatography inductively coupled plasma mass spectrometry (ICP-MS) 
system measured individual arsenic species. Samples with values below the limit of detection 
(LOD) were assigned a value equal to the LOD divided by the square root of two [2]. Total 




(AsIII & AsV), monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV), which was 
then log10-transformed prior to analyses. 
Cord blood DNA-M processing and QA/QC: 
DNA was bisulfite converted using the EZ DNA Methylation kit and subsequently subjected to 
epigenome-wide DNA methylation assessment using the Illumina Infinium® 
HumanMethylation450 BeadChip (Illumina, San Diego, CA) at the University of Minnesota 
Genomics Core Facility (Minneapolis, MN) following standardized protocols. Post-array 
processing was conducted in the ‘minfi’ package in R. Samples in which >2% of probes had 
poor detection p-values were excluded; probes with detection p-values > 0.01 in at least one 
sample were also removed. Functional normalization (funNorm) and ComBat were utilized to 
remove technical variations in the data; removal of batch effects was confirmed with principal 
components analysis. The normalized and batch-corrected beta-values were then transformed 
into M-values via log2(β/(1-β)) prior to statistical analyses. 
Covariates: 
Maternal age, maternal BMI, and estimated cell proportions were included as continuous 
covariates. Child gender and mother’s education were included as dichotomous covariates. 
Maternal education was defined as those with at least a college degree vs. those without a college 
degree. Cell type proportions were estimated with the current gold standard method [3] via the 
minfi package in R. In regression models, 5 of the 6 cell types were included as covariates (NK 








In total, 109 cord blood samples for which DNA-M had been obtained and complete arsenic and 
covariate data were available. Of the 579 CpG sites identified in the cohort in Taiwan, 553 were 
available for replication analyses within the NHBCS. 
2.3.3 Correction for cell mixture proportion  
Blood is a mixture of functionally and developmentally distinct cell populations [35]. Adjusting 
for this cell type will remove potential confounding effects of cell heterogeneity in DNA 
methylation in blood samples [36]. Cell type composition of the blood sample was calculated 
using function estimateCellCounts in the R package minfi [37, 38]. IDAT files from 450k 
Illumina DNA methylation were used to estimate the proportion of 6 cell types: CD8T, CD4T, 
NK, Monocyte, Granulocyte and B-cell. Cell type proportions are provided in supplemental 
Table A1.2. 
2.3.4 DAVID 
Illumina Infinium 450K Human Methylation Beadchip array version 1.2 was used to map the 
significant CpG sites to USCS reference genome and identify genes associated with these CpG 
sites. Functional enrichment and pathway analysis of resulting genes was carried out using 
DAVID gene functional classification tool [39]. DAVID is a large gene-centered knowledgebase 
which integrates the diverse annotation resources in a centralized location. DAVID 
knowledgebase is based upon single-linkage algorithm called the DAVID Gene Concept, and it 
serves as a gene/protein IDs database. The DAVID gene functional classification tool aggregates 
a list of genes or associated biological terms into organized classes of related genes or biology. 
For a given gene list, DAVID identifies enriched functional-related gene groups and provides a 




collection of manually drawn pathways based upon knowledge gained from experiments on 
functions of the cell and its metabolism. Genetic interaction in KEGG pathway represents the 
network of molecular interaction and reactions of gene products. 
2.3.5 GeneMANIA 
GeneMANIA [41] is used to build the network between query genes, based upon genes that are 
functionally similar. This connection between genes is established based upon their similar 
expressions and functional association across different conditions via published data. 
GeneMANIA uses the publicly available genomics and proteomics data, as well as organism-
specific functional genomics data sets. Six organisms are currently supported by GeneMANIA 
(Arabidopsis thaliana, Caenorhabditis elegans, Drosophila melanogaster, Mus musculus, Homo 
sapiens, and Saccharomyces cerevisiae). 
2.3.6 Statistical Analyses 
The dataset consists of 64 samples from cord blood specimen with DNA methylation (DNA-M) 
data for 485,577 CpG site. After quality control using Bioconductor package minfi 385,183 CpG 
sites were retained for statistical analysis. The pre-processed DNA-M data in beta values were 
transformed to M values, approximated as log2 [β/(1-β)], in order to ensure a better fit to 
statistical model assumptions used in our analyses.  
To identify CpG sites whose DNA-M is influenced by in utero arsenic exposure (tAs), 
robust regressions (lmFit function R-package limma) [42] were applied to model the association 
of DNA-M with urinary creatinine-adjusted total arsenic (tAs). Child’s sex, batch effect, 
mother’s age, BMI, and education level, and estimated blood cell proportions (CD8T, CD4T, 
NK, and B-cells, monocytes and granulocytes [37, 38]) were included as covariates. Robust 




which provides stable inference when the number of arrays is small [43]. In the robust regression 
analyses, multiple testing is adjusted by controlling FDR of 0.05. For the replication analyses we 
reproduced the statistical models described above in the NHBCS sample (detailed description is 
given below). CpGs with regression coefficients are in the same directions were considered to be 
successfully replicated, and we attempted to control for multiple testing via FDR of 0.05. 
To assess the association of DNA methylation at CpGs of genes in some of the identified 
pathways with longitudinal (2, 5, 8, 11 and 14 years) low-density lipoprotein (LDL), a biomarker 
for CVD and diabetes, we applied linear mixed models. Log10 LDL concentrations at different 
ages were the dependent variable and residuals of DNA methylation, age, as well as interaction 
between age and DNA methylation were included in the model as predictors, and child’s age, 
sex, and birth weight were treated as covariates. A statistical significance level was set at 0.05. 
The residuals of DNA methylation were obtained by regressing DNA-methylation at each of 12 
CpG sites on proportions of each of the six cell types (CD8T, CD4T, NK, and B-cells, 
monocytes and granulocytes) and batch.  
2.3.6.1 Statistical Analyses in NHBCS: 
For all 553 regressions, we tested the linear relationship between maternal total urinary As and 
cord blood DNA-M M-values while adjusting for confounders. Since batch effects were removed 
via ComBat during data processing, no batch variable was included in these analyses. The 
following model, consistent with the model used in the study based on data from Taiwan, was fit 
using robust regression via the lmFit function in the limma package in R (version 3.2.2), 
confidence intervals were extracted using the confint=TRUE option. 
M-values = log10 (U-As) + Child Gender + Urine Creatinine + Mother’s Age + Mother’s BMI + 





The data are from a birth cohort study examining multiple in utero and postnatal factors in 
relation to child health outcomes as part of the nationwide Taiwan Maternal and Infant Cohort 
Study established in Taiwan in 2000-2001 [21]. In total, 64 subjects with genome-wide DNA 
methylation in cord blood, level of maternal urinary arsenic exposure, urinary creatinine, along 
with a child’s sex, gestational age, maternal age, maternal pre-pregnancy body mass index (BMI) 
and the mother’s educational level were available and utilized in the study. Table 2.1 presents the 
characteristics of pregnant women and newborns by sex. Of the 64 newborns, 38 (59.4%) were 
male. Maternal characteristics are comparable between male and female newborns, and there is 



















Table 2.1. Characteristics of mothers and their newborns by newborn sex in Taiwan during 2000-
2001 (n=64) 
  Sex of the infant  
Characteristics All (n=64)a Male (n=38)a Female (n=26)a p-valueb 
Pregnant Women 
    
Age (years) 28.9±4.8 28.6±4.1 29.5±5.7 0.492 
Pre-pregnant BMI (Kg/m2) 
20.5±2.6 20.2±2.4 21.0±2.9 0.244 
Urinary Creatinine (mg/dL) 63.6±41.7 70.9±46.0 53.0±32.9 0.078 
Maternal Education 
   
0.303 
high school + 2 years 25(39) 13(34) 12(48) 
 
≥high school + 4 years 39(61) 25(66) 14(52) 
 
Newborns 
    
Gestational Age (weeks) 39±1.2 39±1.1 39±1.4 0.791 
aPresented as the mean±SD or number (percentage). 
bp-value for difference between male and female newborns using t-test for continuous variables 
and χ2 or Fishers Exact Test for categorical variable 
 
 The levels and distribution of arsenic metabolites in maternal urine after adjusting for 
creatinine levels are shown in Table 2.2, distinguishing between mono-methylated arsenic 
(MMA), di-methylated arsenic (DMA), inorganic arsenic (iAs), and the sum of the three (total 
arsenic or tAs). Concentrations of each urinary arsenic species showed a large variation among 




is severely skewed with a median of 23.19 µg per gram creatinine (µg g-1 crea [creatinine]), and 
5th and 95th percentiles being 3.76 µg g-1 crea and 76.02 µg g-1 crea, respectively (Table 2.1 and 
Supplemental Figure A1.2). The results reported in this article are based on log10-transformed 
total arsenic concentration. 
Table 2.2. Distribution of creatinine-adjusted concentrations of urinary arsenic species (iAs, 
MMA, and DMA) (n=64) 
Exposure variablesa \ Percentileb Min  5th 25th 50th 75th 95th Max 
As metabolites (µg g-1 crea) 
MMA 0.06 0.08 0.19 0.40 (1.10) 1.67 6.14 28.5 
DMA 0.07 3.09 11.27 20.73 (14.58) 29.5 70.75 129.1 
iAs 0.11 0.19 0.41 0.83 (0.61) 1.33 4.74 6.55 
tAs  0.34 3.76 12.09 23.19 (16.29) 33.29 76.02 137.5 
aAbbreviations: iAs represents the sum of As3+ and As5+; MMA: methylarsonic acid; DMA: 
dimethylarsinic acid; tAs: the sum of iAs, MMA, and DMA; µg g-1 crea: µg per g creatinine 
bThis study. Pregnant women from Maternal Infant cohort in Taiwan (n = 64) 
LOD of detection for As3+ is 0.09 µg/L, As5+ is 0.05 µg/L, for MMA it is 0.05 µg/L and for 
DMA it is 0.04 µg/L 
The values inside parenthesis are the average value of unadjusted arsenic expressed as µg/L. 
The standard deviation for unadjusted tAs is 16.22 µg/L and interquartile range for adjusted tAs 
is 21.21 µg g-1 cre. 
After pre-processing the DNA methylation data as depicted in Figure 2.1, 385,183 CpG sites were 





Pregnant mother recruited 
(Central Taiwan; n= 430) 
Urine sample collected (third 
trimester; n=313) 
Cord blood samples collected 
(newborns; n=299) 
Cord blood DNA-methylation 
(n=64 available; 485,577 CpGs) 
127 excluded (non-
compliance) 
5 loss to follow up 
Final DNA methylation data 
(n=64; 385,183 CpGs) 
Measuring DNA methylation 
(Illumina 450K) 
Figure 2.1. Subject recruitment and preprocessing of DNA methylation data in 









Identify CpGs associated with prenatal 
total arsenic exposure (Taiwan cohort, 
385,183 CpGs from cord blood, 64 subjects) 
 
579 CpGs identified after multiple testing 
adjustment (FDR=0.05). 
 
DAVID analysis for pathways (579 CpGs 
mapped to 437 genes) 
 
17 significant KEGG pathways identified at 
FDR=0.05 (connected to 58 CpGs in 56 genes).  
Test the 579 CpGs in an independent 
cohort, NHBCS (553 CpGs are available, 
109 subjects) 
252 out of 553 (~46%) CpGs showed 
regression coefficients consistent with those in 
the Taiwan cohort.  
Longitudinal test of CpGs with LDL, a marker for CVD and 
diabetes (12 out of 58 CpGs on genes in pathways associated with 
CVD and diabetes, LDL measures at ages 2, 5, 8 ,11 and 14 of 64 
subjects): 
 
Five CpGs identified: cg25189764, cg8198265, cg04986899, 
cg10473311 and cg04903360 located on genes FYN, BST1, XYLT1, 
PTPRN2 and PARD3 respectively (nominal p-value <=0.05) 
Assess the inclusion of the 58 CpGs in the 
252 CpGs 
 
27 out of the 58 (47%) are included in the 252 
CpGs. High percentages of the 27 CpGs are in 
these four pathways: Endocytosis (75%), 
Adherens junction (75%) and axon guidance 
(71%) known to be associated with CVD 
and/or diabetes 
 Discovery phase 
Validation    phase 
Link the CpGs to CVD and diabetes biomarker 




 Epigenome-wide assessments of statistical associations between log10 creatinine-adjusted 
maternal urinary arsenic level and logit transformed DNA methylation (also noted as M values) 
were conducted via robust regressions.  Covariates included in robust regressions were child’s 
sex, batch of DNA methylation analyses, mother’s age, mother’s pre-pregnancy BMI, mother’s 
education level, and estimated proportions of six blood cell-types (Appendix Table A1.2, related 
methods are in the Methods section). Figure 2.3 shows the Manhattan plot of p-values for testing 
on the 385,183 CpG sites, with a dashed blue line indicating the p-value threshold corresponding 
to FDR of p=0.05 [44]. In total, 579 CpG sites showed statistically significant associations at 
FDR of 0.05. Supplemental Table A1.1 lists these 579 CpG sites along with their regression 
coefficients, p-values, and corresponding chromosomes, locations on the chromosomes, 
corresponding genes, and location on the genes. About 60% of these 579 CpGs showed a 
positive association between DNA methylation and in utero tAs. The majority of the CpG sites 
located in the North shore regions of the CpG Island had higher DNA methylation associated 
with higher in utero tAs and about 39% of these CpG sites were located upstream of transcription 






Figure 2.3. Manhattan plot for Genome-wide DNA methylation associated with creatinine 
adjusted urinary arsenic concentration. The horizontal dashed blue line corresponds to the 
significance threshold p = 7.51E-05 (FDR Adjusted p-value <= 0.05), red color stars represent 
the CpG sites corresponding to genes enriched in KEGG pathways from DAVID analysis. Blue 
and golden colors are used to differentiate the chromosomes. 
 
The 579 CpG sites were mapped to 437 genes (Appendix Table A1.1), which were 
further analyzed using the bioinformatics tool DAVID [45, 46]. This analysis led to 17 
significantly enriched KEGG pathways (at FDR=0.05) and 58 CpGs were within the genes 
involved in these pathways , including pathways connected to CVDs and diabetes [47] (e.g., 
Type I and Type II diabetes mellitus, focal adhesion, calcium signaling pathway, adherens 
junction, and chondroitin sulfate biosynthesis [48]), pathways linked to neurological and 
cognitive abilities (Alzheimer’s disease and amyotrophic lateral sclerosis [ALS]), and pathways 
in cancer (the 58 CpG sites involved in these pathways are marked by red stars in Figure 2.3). 
The network, constructed using GeneMANIA [41] based on the genes enriched in DAVID 
analysis, indicated inter-connections among the genes (Supplemental Figure A1.3) via co-




in KEGG pathways, most of them are located in the body region of a gene (Figure 2.4). Majority 
of these 58 CpGs are located in the island region (~57%) or north Shore (~22%). Furthermore, in 
approximately 55% out of the 58 CpG sites, we found that higher in utero tAs were linked to 
higher DNA methylation in cord blood, as indicated by positive regression coefficients in Figure 
2.4. The strongest association between in utero tAs and cord blood DNA methylation occurred at 
CpG cg23767840, which is in the 5’UTR region of gene EPN2 (coding for the Epsin-2 protein). 
 
Figure 2.4. Association of arsenic exposure with the DNA methylation based on M-values of the 
58 CpG sites mapped to 56 genes. The x-axis has the 56 genes enriched in KEGG pathways at 
FDR level of p=0.05, while the y-axis shows the estimates of total arsenic coefficients related to 
58 CpG sites from robust regression. Adjusting factors include cell counts, child’s sex, batch 
effect, mother’s age, mother’s BMI and mother’s education level. M-values are defined as log2 





The resulting 579 CpG sites from our study were further tested in the independent New 
Hampshire Birth Cohort Study (NHBCS) (n=109). Of the 579 CpG sites 553 were available for 
analyses in NHBCS. We applied robust regression models with covariates comparable to those 
included in our study to assess the association of tAs with cord blood DNA methylation at these 
553 CpG sites. At 46% of the 553 CpG sites (252 CpGs), the associations of in utero tAs with 
cord blood DNA-methylation levels were consistent with those found in our study in terms of 
direction of regression coefficients, although none survived multiple testing. In addition, 27 of 
these 252 CpGs are in the list of 58 CpGs (27/58=~47%) noted earlier that are involved in the 
enriched KEGG pathways (Table 2.3). Genes corresponding to these 27 CpGs are more often 
linked to pathways involved in endocytosis, adherens junction, axon guidance (a neural 
developmental process in which neurons send out axons to reach the correct targets) and 
















Table 2.3.  KEGG pathways identified using DAVID that are more specific to arsenic exposure 
based on data from n=64 pregnant women from the maternal infant cohort in Taiwan. 
KEGG-Pathways Genes Adjusted p-
value 
(FDR=0.05) 




Endocytosis PARD3*, AP2A2*, RNF103, 
PSD3, GRK6*, HGS*, IQSEC1*, 
EPN2 
0.0000010 
Axon guidance NGEF*, LIMK2, FYN*, EFNA2*, 
EPHB3*, EPHB4, SLIT2* 
0.000015 
Alzheimer's disease NDUFB3, NOS1*, LRP1, GRIN1, 
MME, CACNA1C, NDUFS2* 
0.000033 




Regulation of actin cytoskeleton LIMK2, INS-IGF2, SSH3, 
CYFIP1*, IGF2, MYH9*, FGF3 
0.0019 
Type I diabetes mellitus ICA1*, INS-IGF2, PTPRN2*, 
IGF2, GAD1 
0.0018 
Amyotrophic lateral sclerosis (ALS) NOS1*, GRIN1, TOMM40, 
DAXX* 
0.0037 
Adherens junction TCF7, PARD3*, FYN*, ERBB2* 0.0087 
Pathways in cancer WNT16*, TCF7, ERBB2*, 
VEGFA, BIRC5, FGF3 
0.0091 
ErbB signaling pathway ERBB2*, NRG1, NRG2, SHC4 0.01 
Focal adhesion TNXB*, FYN*, ERBB2*, VEGFA, 
SHC4 
0.0097 
Chondroitin sulfate biosynthesis CSGALNACT1*, B3GAT1, 
XYLT1* 
0.01 
Neuroactive ligand-receptor interaction PARD3*, GRIN1, NPBWR2, 
GRIN3B*, ADRA1D 
0.017 
Lysine degradation DOT1L*, SETD1B, EHMT2* 0.034 
Type II diabetes mellitus INS-IGF2, CACNA1G, IGF2, 
CACNA1C 
0.038 
Huntington's disease NDUFB3, AP2A2*, GRIN1, 
NDUFS2* 
0.045 
* CpG sites of these genes were consistently associated (in terms of regression coefficient) with 




Given the connection of arsenic exposure with CVDs and diabetes [24, 25, 49, 50] , 
findings from the pathway analyses, and findings in the replication study, we further investigated 
the CpG sites of the genes enriched in KEGG pathways that are potentially linked to 
cardiovascular diseases and diabetes in our Taiwan cohort. In particular, 12 CpGs (located on 11 
genes, Appendix table A1.1) were included in this analysis and these 12 CpGs were among the 
27 CpGs replicated in the NHBCS cohort. We assessed the association of cord blood DNA 
methylation at these CpGs with a biomarker of CVDs and diabetes, plasma low density 
lipoprotein (LDL). LDL was measured at multiple ages of the children (at 2, 5, 8, 11, and 14 
years). Plasma LDL concentration is the most stable in humans, with or without fasting, among 
blood lipids such as triglycerides. Among the 12 CpGs, cord blood DNA methylation at some 
CpGs showed a pattern of positive correlations with LDL at each age.  While some were 
negatively correlated with LDL at age 2 and positively correlated at later ages (Figure 2.5), for 
most CpGs, the strongest correlations (positive or negative) occurred at age 2. In particular, the 
heatmap (Figure 2.5) indicated that DNA methylation levels at two CpGs, cg06419180 and 
cg25189764, were positively correlated with the LDL at different ages, while the directions of 
correlations at the rest of the CpG sites seemed to change over time. Via linear mixed models, 
we tested the association of LDL with DNA methylation (with LDL at ages 2, 5, 8, 11 and 14 as 
the outcome, cell type compositions and batch-effect adjusted DNA methylation as the predictor, 
and child’s age, sex of the child, and birth weight as covariates) as well as the interaction effect 
between DNA methylation and age. We found that CpG cg25189764 had a statistically 
significant association with LDL (coefficient=0.157, p-value=0.047). DNA methylation at 
another 4 CpG sites showed statistically significant interaction with time, cg08198265 




0.063, p-value=0.002), cg04986899 (coeff.m = -0.36, coeff.int = 0.030, p-value=0.024), 
cg10473311 (coeff.m= 0.145, coeff.int= -0.021, p-value=0.027) and cg04903360 (coeff.m= -
0.189, coeff.int=0.026, p-value=0.032). It is worth noting that DNA methylation at these 5 CpG 
sites was found to be stable across the life course. The stability was assessed using Accessible 
Resource for Integrated Epigenomic Studies (ARIES) explorer [51]. 
 
Figure 2.5. Heatmap of the correlations between cord blood DNA methylation and LDL across 





The overall aim of this study was to identify CpG sites that would represent biomarkers of 
possible adverse effects of arsenic in newborns and of future health outcomes. In total, at 579 
CpGs identified from a cohort in Taiwan DNA methylation was associated with in utero arsenic 
exposure. To further understand the biological mechanisms of genes linked to these 579 CpG 
sites, a gene annotation analysis using DAVID was performed, which led to an identification of 
17 statistically significant KEGG pathways. Genes corresponding to the identified CpGs are 
known to be involved in arsenic-associated diseases including neuronal [52-54], immune [55], 
cancer [56], cardiovascular and diabetes [25, 49, 50]. Experimental models have demonstrated a 
role of in utero acquired somatic epigenetic alternations in diseases [57-59]. Given the regulatory 
functionality of DNA methylation on different genes, the identified CpG sites may serve as 
epigenetic biomarkers of potential harmful effects of in-utero arsenic exposure among newborns. 
Findings at 46% of the identified 579 CpG sites were replicated in an independent cohort, 
the NHBCS, with respect to directions of associations, though these did not survive multiple 
testing adjustments. However, the median tAs (without creatinine adjustment) in NHBCS was 
2.8 µg/L with interquartile range (IQR) of 3.64 µg/L, which is substantially lower than that in the 
Taiwanese cohort (median= 11.51 µg/L and IQR= 16.80 µg/L). This difference, small sample 
sizes from both studies, differences in ancestry and unmeasured confounding may explain the 
limited agreement in the findings between the two cohorts.  
The post hoc analysis on CpG sites replicated in the NHBCS cohort and related to genes 
enriched in KEGG pathways for cardiovascular disease and diabetes led to the identification of 
five CpG sites cg25189764, cg08198265, cg04986899, cg10473311 and cg04903360 located on 




whole body metabolism and is known to be associated with insulin sensitivity in mice [60]. BST-
1 is a glycosyl-phosphatidylinositol (GPI) and is expressed in abundant in pancreatic islet cells 
[61]. Proteins containing a GPI anchor play key roles in a wide variety of biological processes 
[62]. XYLT1 is involved in heparan sulfate (a type of glycosaminoglycan; GAG) biosynthesis 
[63, 64]. GAGs have been studied for their role as a potential target in treating CVDs [65, 66]. 
Protein encoded by PTPRN2 (also known as IAR) is a known autoantigen in insulin-dependent 
diabetes mellitus [67]. PARD3 has been identified as candidate gene for its association with type 
2 diabetes in Mexican study [68]. Out of these five CpGs, cg25189764 is located in the 5’UTR 
of gene FYN, and the other four CpGs were located in the body of the genes.  We observed that 
most CpG sites on genes enriched in KEGG pathways were located in the body region of a gene 
(Figure 2.4). The regulatory functionality of DNA methylation on genes at those CpG sites is 
likely to be different from the functionality at CpG sites in the promoter region [69, 70]. Further 
assessment on their associations with gene expressions will improve our understanding of their 
regulatory functionality. 
The temporal stability in DNA methylation at the five CpG sites (cg25189764, 
cg08198265, cg04986899, cg10473311 and cg04903360) showing associations with LDL across 
different ages raised a possibility of  long term consequences of DNA methylation, established in 
utero, on LDL at later life. More interestingly, for the four CpGs (cg08198265, cg04986899, 
cg10473311 and cg04903360) showing interactions with age, the turning point of DNA 
methylation effects (from negative to positive effects or from positive to negative effects over 
time) are always around the age of 8 years. Of interest, ages 11 and 14 are during adolescence, a 




A previous study in utero arsenic exposure in the NHBCS was reported by Koestler et al. 
[32]. The top 100 CpGs identified in Koestler et al. did not overlap with the 579 CpGs, although 
25% of their 100 CpGs showed statistical significance at the 0.05 level in our study (not 
surviving multiple testing). The disagreement could have been driven by some key differences in 
the analytical methods. Koestler et al. categorized arsenic exposure levels into quartiles and 
applied analysis of covariance with tests for trends, while our study applied robust regressions to 
log10-transformed arsenic concentrations to take into account possible outliers. By categorizing 
a continuous variable, statistical testing power for testing the associations might have been 
reduced. In addition, Koestler et al. did not adjust for maternal BMI, nor the cell type proportions 
estimated using the minfi R package [37, 38], though they did explore associations between 
urinary arsenic and estimated cell-type proportions in cord blood.  
We also compared the findings from our study with another epigenome-wide study by 
Broberg et al [16]. The focus of that study also concentrated on the top CpG sites ranked by 
statistical significance on their association with in utero arsenic exposure, although none of the 
top CpG sites survived multiple testing corrections. The top CpG sites determined by Broberg et 
al. did not overlap with those identified in our study, nor overlapped with the top CpGs in 
Koestler et al. [32]. Broberg et al [16] utilized linear regression and did not adjust for cell type 
heterogeneity. In addition, some top CpG sites discussed in Broberg et al. included annotated 
probe-SNPs (single nucleotide polymorphisms) located within 10 base-pairs of the target CpG. 
They can result in biased methylation measurements, and were excluded from our analysis.  
It is worth noting that the three studies we discussed herein (Koestler et al. [32], Broberg 
et al. [16], and ours) were conducted in different regions (United States, Bangladesh, and 




limited replicability (for tAs, in Koestler et al., median=4.1 µg/L, in Broberg et al., median=66 
µg/l, and in our study, median= 11.51 µg/L). It is also possible that ancestry, race/ethnicity or 
other regional differences may have contributed to the disagreement in the findings. In addition, 
all studies had small sample sizes (less than 200), so some of the findings are also likely to be 
false-positives. A large-scale study incorporating different races/ethnicities, with a wide 
exposure range, is well deserved. Our study had a benefit of replicating results using standard 
statistical approaches. Nonetheless, replicating DNA methylation analyses in additional 
populations, harmonizing, and comparing different DNA methylation studies on in utero arsenic 
exposure will help to assess the generalizability of the results.  Future studies also should be 
directed at examining whether arsenic-related health outcomes are associated with cord blood 
DNA methylation in a long-term follow-up of the children in multiple cohorts. 
2.6 Conclusion 
We found that in utero arsenic exposure was associated with cord blood DNA methylation. The 
genes corresponding to the identified CpG sites were involved in various pathways including 
signaling pathways, Type I and Type II diabetes mellitus, and neuroactive ligand-receptor 
interactions. Cord blood DNA methylation at cg25189764, cg08198265, cg04986899, 
cg10473311 and cg04903360 were associated with low-density lipoprotein (LDL) at later life. 
These CpGs need to be studied further for their role in cardiovascular disease and diabetes in 
arsenic-exposed populations. Although larger studies are needed, results from this study 
contribute to a better understanding of epigenetic mechanism of diseases related to in utero 





3 Epigenetics markers at birth longitudinally associated with Immunoglobulin 
E (IgE) 
3.1 Abstract 
Background: Immunoglobulin E (IgE) is known to play a major role in allergic diseases. 
Epigenetic markings acquired due to modification of DNA methylation in early life may have 
phenotypic consequences later in development through their role in transcriptional regulation 
with relevance to the developmental origins of diseases including allergy. However, epigenome-
wide studies on the association of cord blood DNA methylation and IgE over time are lacking. 
Method: A total of 64-cord blood samples from Taiwan Maternal and Infant Cohort Study were 
analyzed using the Infinium Human Beadchip to obtain DNA methylation at ∼450K Cytosine-
phosphate-Guanine (CpG) sites. Linear mixed models were implemented to assess the 
association between preprocessed, batch and cell type corrected cord blood DNA methylation at 
>380k CpG sites with IgE levels at 5,8 and 11 years of age, adjusting for cord blood IgE. 
Identified statistically significant (at a false discovery rate, FDR, of 0.05) CpGs were replicated 
in an independent cohort, Isle of Wight (IoW) dataset. Gene ontology analysis was performed 
using DAVID to identify significantly enriched biological process of genes associated with 
resulting CpG sites. Stability assessment of the identified and replicated CpG sites was measured 
using ICC. 
Results: DNA-methylation of 458 CpG sites were significantly (FDR <= 0.05) associated with 
IgE levels at different ages. Among the identified CpG sites available in both cohorts (n=241), of 
which, about 50% of CpGs were replicated in the IoW cohort in terms of consistency in direction 
of association between DNA methylation and longitudinal IgE levels.  Gene ontology analysis of 
84 genes linked to 124 CpG sites led to the enrichment of statistically significant biological 




alternative splicing, phosphoprotein, disease mutation, glycoprotein, protein transport, 
transcription regulation.  Further temporal stability assessment of the 124 CpG sites identified 59 
CpGs with significant ICC values (p-values<=0.05) at least 0.5. 
Conclusion: Biological finding combined with the temporal stability measures for 59 CpG sites 
suggest them as a potential epigenetic marker for predicting later IgE production. 
3.2 Background: 
The prevalence of allergic diseases is increasing worldwide and the severity of allergic diseases, 
including asthma, continues to increase in children and young adults. About fifty percent of 
school children are sensitized to one or more common allergens [71]. Allergic disease is 
known to be hereditary implying individual’s susceptibility to the genetic factors [72].  
 The gene-environment interaction during critical periods of immune development is 
assumed to be one of the causes of this disease later in life. Epigenetic variation is postulated to 
be an important mechanism through which these interactions are mediated [73]. Epigenetic 
processes regulate gene expression during immune development, and evidence suggests 
disruption in these processes can modify disease risk in a manner analogous to single nucleotide 
polymorphisms (SNPs) [74]. DNA methylation is one such epigenetic process which is 
associated with gene silencing and with the patterning of gene expression that determines 
cellular types and functions.  
 Immunoglobulin E (IgE) is known to play a major role in many of the allergic diseases 
such as Asthma, atopic dermatitis (eczema) and hay fever. IgE production leads to type I 
hypersensitivity, which manifests various allergic diseases. However, the mechanism underlying 
IgE production is poorly understood. There is evidence that DNA methylation is associated with 




identified CpG loci from peripheral blood associated with total serum IgE [75]. Cross sectional 
study using peripheral blood of 18 year old men and women was used to identify association 
between CpG loci and serum IgE [76]. However, longitudinal epigenome-wide studies on the 
association of DNA methylation at birth via cord blood and IgE over time are lacking. Thus, it is 
unknown whether and how DNA methylation in cord blood is associated with IgE during the 
course of early life.  
 In this study we aimed at assessing genome-wide DNA methylation with respect to their 
association with IgE levels of child at ages 5, 8 and 11 years via linear mixed models adjusting 
for multiple testing by controlling FDR, and examine possible pathways of genes involved in the 
identified CpGs. We tested the identified CpGs in an independent cohort, the Isle of Wight 
(IoW) birth cohort in the United Kingdom. The findings will contribute to an improved 
understanding of in utero epigenetic development (or mechanism) leading to IgE changes later in 
life. 
3.3. Method 
3.3.1 Data collection and pre-processing of birth cohort data from Taiwan 
In this section, we focus on the assessment of IgE. For other contents of this cohort including 
information related to DNA methylation measurement, quality control, and cell type 
compositions, please refer to Chapter 2, the Method Section.  
Assessment of Immunoglobulin E 
To determine serum IgE levels in children at 5, 8 and 11 years, blood samples (0.5 mL) obtained 
via venipuncture were centrifuged and the sera stored at −20°C prior to analysis. Serum total IgE 
(tIgE) levels were measured using the ADVIA Centaur chemiluminescence immunoassay system 





3.3.2 Data collection and pre-processing of birth cohort data from IoW 
Participant selection and sample collection 
The Isle of Wight (IOW) birth cohort was established to study the natural history of asthma and 
allergies in children born between January 1, 1989 and February 28, 1990 on the Isle of Wight, 
UK. The study was approved by the local research ethics committee (now named the National 
Research Ethics Service, NRES Committee South Central – Southampton B, 06/Q1701/34) and 
written informed consent was provided by the infants’ parents (F1 generation). Details about the 
birth cohort have been described in detail elsewhere [32–34].  
Immunoglobulin E (IgE) measurement: 
Cord blood was taken from 1023 infants. Blood was collected from umbilical cord using fine 
needle in a specimen bottle containing dipotassium EDTA as anti-coagulant. Duplicate 
measurements of cord IgE were made using ULTRA EIA® kit (Pharmacia Diagnostics AB, 
Uppsala, Sweden) unmodified, designed to measure IgE between 0.2 and 50 ku/l on 0.1 ml of 
serum or plasma. Total IgE was measured in samples of serum collected at age 10 (n = 923) and 
age 18. IgE at age 10 and at age 18 were determined using PRIST® (Pharmacia Diagnostics AB, 
Uppsala, Sweden) designed to measure IgE between 2.0 to 1000 kU/L. 
DNA sample collection and processing 
Blood samples for the F1 generation were obtained from Guthrie card (n=34) of newborn babies. 
For methylation assays, DNA was extracted from whole blood using a standard salting out 
procedure [38]. DNA concentration was determined by the PicoGreen dsDNA quantitation kit 
(Molecular Probes, Inc., OR, USA). One microgram of DNA was bisulfite-treated for cytosine to 
thymine conversion using the EZ 96-DNA methylation kit (Zymo Research, CA, USA), 




into thymines (T) while leaving methylated cytosines (C) unaltered, allowing the array 
technology described below to distinguish between unmethylated and methylated sites by 
sequence (C vs. T) recognition [39]. Probes, 50 nucleotides in length, were developed to target 
specified CpGs throughout the genome with the CpG at the very end of the probe. Multiple 
copies of each probe were attached to a BeadChip, allowing for the interrogation of multiple 
DNA reads for each target CpG site [39,40]. After bisulfite conversion, the DNA samples 
underwent whole genome amplification, then each sample was washed over an array containing 
many BeadChips to identify the proportion of methylated probes for each target CpG. 
Genome-wide DNA methylation was assessed using the Illumina Infinium 
HumanMethylation450K BeadChip (Illumina, Inc., CA, USA), which interrogates >484,000 
CpG sites associated with approximately 24,000 genes. Arrays were processed using a standard 
protocol as described elsewhere [40], with multiple identical control samples assigned to each 
bisulphite conversion batch to assess assay variability and samples randomly distributed on 
microarrays to control against batch effects. The BeadChips were scanned using a BeadStation, 
and the Methylation Module of BeadStudio software calculated the methylation level for each 
queried CpG as beta () values. They represent the proportions of methylated (M) over 
methylated (M) and unmethylated (U) sites (β=M/[c+M+U] with constant c introduced for the 
situation of too small M+U).  
 Quality control (QC) measures were employed to improve the reliability of data prior to 
analysis. In our study, the detection P-value reported by BeadStudio (Illumina software to 
process raw intensities) was used as a QC measure of probe performance, in which large P-
values were deemed to be unreliable measures of methylation. Probes whose detection P-values 




using the Bioconductor IMA package for peak correction, background noise removal and batch 
effect correction [77]. The program for data cleaning was written in R (R Development Core 
Team, 2012). Some probes may overlap with known single nucleotide polymorphisms (SNPs), 
which may result in measurement errors [43]. SNPs at the target CpG [44,45] or within close 
proximity to the target CpG appear to be most likely to affect measurement of methylation, thus 
probes with SNPs within 5 nucleotides of the target CpG [46,47] and within the probe binding 
region were excluded from further analyses. Probes more than 5 nucleotides from the target 
CpG, but still within the binding region will be flagged with an indicator variable, and followed 
up if selected from the GWAS analysis. 
3.3.3 Functional annotation and pathway analysis 
DAVID analyses were performed in this study, and the method was discussed in Chapter 2. In 
the following, I focus on the statistical methods.  
3.3.4 Statistical analyses 
The final dataset consisted of 64 samples from cord blood specimen with DNA methylation data 
for 485,577 CpG site. After quality control using Bioconductor package minfi 385,183 CpG sites 
were retained for statistical analysis. The pre-processed DNA-M data in beta values were 
transformed to M values, approximated as log2 [β/(1-β)], in order to ensure a better fit to 
statistical model assumptions used in our analyses. To identify CpG sites whose DNA-M could 
predict IgE levels in children at 5, 8 and 11 years of age, the analysis was performed in two 
stages. In stage 1 we obtained the residuals of DNA-M by regressing DNA-M of each CpG 
(385,183) on cell proportions and batch effect. In stage 2 we used residuals of DNA-M to predict 
the IgE in longitudinal setting using linear mixed model, while adjusting for cord blood IgE, 




9.4. Covariance structure was determined by comparing the Schwarz’s Bayesian information 
criterion (BIC) of four covariance structure: Compound symmetry, Toeplitz, Unstructured and 
Auto-regressive1. To determine the best covariance structure 100 CpG sites were randomly 
selected to fit mixed model under each of the four covariance structure, and covariance structure 
with the smallest BIC was chosen for the final model. In all analyses, multiple testing is adjusted 
by controlling false discovery rate of p=0.05. Statistically significant CpG sites were further 
replicated in an independent cohort Isle of Wight (IoW), using the statistical method similar to 
our study.  
 An R package irr was used to estimate intra-class correlations of DNA-M at 124 CpG sites 
at birth via Guthrie card, at ages 10 and age 18 years in the IoW cohort. 
3.3.4.1 Statistical analyses in the IoW 
Analysis similar to described in 3.3.5 was performed for data from the IoW cohort. In the IoW, 
DNA methylation at birth was assessed from Guthrie cards. IgE was assessed at birth from Cord 
blood, at age 10 and age 18 years. Longitudinal association between residuals of DNA 
methylation and log10 IgE was assessed using proc mixed in SAS 9.4. 
3.4 Results 
The data are from a birth cohort study examining multiple prenatal and postnatal factors in 
relation to child health outcomes as part of the nationwide Taiwan Maternal and Infant Cohort 
Study [78, 79] established in Taiwan in 2000-2001. In total, 64 subjects with genome-wide DNA 
methylation from cord blood, child’s gender, batch effect, and birth weight were available and 
utilized in the study.  
 Table 2.1 as described in Chapter 2 presents the characteristics of pregnant women and 




and distribution of cord blood and serum IgE for children’s at ages 5, 8 and 11 years is provided 
in Table 3.1. 
Table 3.1. Distribution of IgE across different time points 
Outcome Variable\Percentile Min 5th 25th 50th 75th 95th Max 
IgE in Cord blood (IU/ml) 0.03 0.03 0.06 0.215 0.885 22.9 61.4 
IgE at 5 years (IU/ml) 5.7 7.59 17.95 61.4 125.13 303.65 524 
IgE at 8 years (IU/ml) 6.38 7.78 11 96.2 169 695 921 
IgE at 11 years (IU/ml) 6 6 15.25 55 185.25 616.35 946 
 
Epigenome-wide assessments of statistical associations between log10 IgE and residuals of DNA 
methylation (DNA-M) in cord blood at 385,183 CpG sites were conducted in a longitudinal 
setting via linear mixed modeling.  This analysis was performed in two stages. In stage 1 we 
obtained the residuals of DNA-M by regressing DNA-M of each CpG (385,183) on cell 
proportions (CD4T, CD8T, NK, Mono, Bcell, Gran, Eos) and an indicator variables associated 
with different batches of DNA methylation data. In stage 2 we used residuals of DNA-M in cord 
blood to predict IgE at ages 5, 8, and 11 years using linear mixed models, adjusting for cord 
blood IgE, birth weight and gender of the child. In total, 458 CpG sites showed statistically 
significant associations with total IgE, after correcting for multiple testing by controlling FDR of 
0.05. Figure 3.1 shows the Manhattan plot of p-values for testing on the 385,183 CpG sites, with 
a red line indicating the p-value threshold corresponding to FDR of 0.05 [44]. Appendix Table 
A2.1 lists the 458 CpG sites with their regression coefficients along with p-values, chromosomes 






Figure 3.1 Manhattan plot for the longitudinal association of Genome-wide DNA methylation 
with log10 Immunoglobulin E (IgE). The horizontal dashed red line corresponds to the significance 
threshold p = 7.51E-05 (FDR Adjusted p-value <= 0.05). Blue and golden colors are used to 
differentiate the chromosomes. 
The resulting 458 CpG sites from our study were further tested in an independent cohort, the Isle 
of Wight (IoW) birth cohort. Of the 458 CpG sites 241 were available for analyses in IoW. The 
flow of this study is provided in Figure 3.2. We used linear mixed models to assess the 
longitudinal association between residuals of DNA-methylation of 241 CpG sites from Guthrie 
card blood samples with serum IgE of 30 children measured at ages 10 and 18 years as outcome. 
The analysis was performed in two stages similar to the main study and used the same additional 
covariates. At about 51% of the 241 CpG sites (124 CpGs), the longitudinal associations of 
Guthrie card blood DNA-methylation with IgE over time were consistent with those found in our 
study in terms of directions of regression coefficients, although none survived multiple testing.  
Majority of the 124 CpGs were located in body (~50%) and promoter regions (~48%) of the 
genes, Figure 3.3. In addition, 22 of these 124 CpGs were nominally significant with p-value 
<=0.05. Functional annotation analysis using DAVID of 84 genes corresponding to 124 CpG 




and functional categories: PI3K-Akt signaling pathway, pathways in cancer, metabolic pathways, 
polymorphism, alternative splicing, phosphoprotein, disease mutation, glycoprotein, protein 
transport, transcription regulation.  
 
Identify CpGs associated with prenatal 
total arsenic exposure (Taiwan cohort, 
385,183 CpGs from cord blood, and 
serum IgE from cord blood at age 5, 8 
and 11 years for 64 subjects) 
 





DAVID analysis for pathways (124 CpGs mapped 
to 84 genes) 
 
3 significant KEGG pathways and 7 functional 
categories identified at FDR=0.05 
Test the 458 CpGs in an independent 
cohort, IoW (241 CpGs are available 
from Guthrie card, with serum IgE 
from cord blood at age 10 and 18 years 
for 30 subjects) 
 
124 out of 241 (~51%) CpGs showed 
regression coefficients consistent with 
those in the Taiwan cohort.  
 
 
Intra-class correlation (ICC) coefficients calculated for 124 
CpG sites 
 
59 CpG sites have ICC value >=0.5 and p-value <=0.05 
Assess the Stability of DNA methylation at 124 






The stability of these 124 CpG sites were inferred via intra-class correlation (ICC) based on 
DNA methylation data in the IoW cohort. In particular, DNA methylation of these 124 CpG sites 
at birth from Guthrie cards, at age 10 and age 18 years for five subjects were included in this 
assessment. Among the 124 CpGs, DNA-M at 59 CpG sites had ICC at least 0.5 (p-value<=0.05) 
(Appendix Table T2.2).  
 
Figure 3.3 Longitudinal association of the residual of DNA methylation with log10 
Immunoglobulin E (IgE) of the 124 CpG sites mapped to 89 genes. Please refer to method 
section for the detail of analysis. Different colors indicate the location of the CpGs on a gene.  
 
3.5 Discussion 
The overall aim of this study was to identify CpG sites of which DNA methylation at birth 
measured in cord blood could potentially predict the level of IgE at later ages. We identified 458 
CpG sites (at FDR cutoff of 0.05) longitudinally associated with IgE in discovery cohort, 241 of 




CpG sites showed results consistent with those from the discovery cohort in terms of direction of 
association with IgE. These 124 CpGs were on 84 genes.  
 Functional analyses indicated that a number of genes associated with the 124 CpG sites 
were involved in biological processes related to IgE production. Phosphoinositide 3-kinase 
(PI3K) signaling is known to play a crucial role in IgE production, blockade of P13K enhances 
IgE levels [80]. IgE production is also known to be altered in cancer patients compare to control 
groups [81] and thus have been studied for their role in tumor surveillance and immunotherapy 
of cancer patients [82, 83]. Gene CD14, one of the 84 genes has been shown to elevate the IgE 
production [84]. Phosphodiesterase 11A (PDE11A) has been suggested for its role in asthma 
pathogenesis [85, 86], which indicates a potential role of this gene in IgE production.  
 Stability assessment of DNA methylation based on ICC at 124 CpG sites from birth to 
age 18 revealed that DNA methylation at 59 CpG sites is likely to be stable. SDA1 Domain 
Containing 1 (SDAD1) gene associated with one these 59 CpG sites has been known to 
contribute towards development of seasonal allergic rhinitis in Japanese population [87]. Fc 
Fragment Of IgG Binding Protein (FCGBP) another gene with CpG site having stable DNA 
methylation is known to share significant sequence homology with the carboxyl terminal of IgE 
binding protein [88]. Similarly, Immunoglobulin Superfamily Member 10 (IGSF10) and 
Butyrophilin Like 2 (BTNL2)  have been known to be associated with IgE [89] and they both 
have CpG sites with stable DNA methylation.  
 Combining this finding with their associations with IgE at different ages, these 59 CpG 







Genome wide longitudinal assessment of 385,183 CpG sites with IgE production led to 
identification of number CpG sites. Among the identified CpG sites, 124 were replicated in an 
independent cohort for their longitudinal association with IgE production at later ages. Genes 
associated with these CpG sites were enriched in DAVID pathways and categories known to 
influence the IgE production. Most importantly 59 of 124 CpG sites have stable DNA-
methylation across different time points. Thus, the identified CpG sites have the potential to 
serve as an epigenetic biomarker for IgE changes over time and can serve as candidates for 




















Whole blood is frequently utilized in genome-wide association studies of DNA methylation 
patterns in relation to environmental exposures or clinical outcomes. These associations can be 
confounded by the cellular heterogeneity. Several algorithms have been developed to measure or 
adjust for this heterogeneity. However, it is unknown whether these approaches are consistent 
and if not, which method(s) perform better.  
Results 
Methods: We compared eight cell-type correction methods including the method implemented in 
the minfi R package, the method by Houseman et al., the Removing unwanted variation (RUV) 
approach, the methods implemented in FaST-LMM-EWASher, ReFACTor, RefFreeEWAS, and 
RefFreeCellMix R programs, along with one approach utilizing surrogate variables (SVAs). In 
the first comparison, we evaluated the association of DNA methylation at each CpG across the 
whole genome with prenatal arsenic exposure levels and with cancer status, adjusted for 
estimated cell-type information obtained from different methods. We then compared CpGs 
showing statistical significance from different approaches. For the methods implemented in 
minfi and proposed by Houseman et al., we utilized homogeneous data with composition of 
some blood cells available and compared them with the estimated cell compositions. Finally, for 
methods not explicitly estimating cell compositions, we evaluated their performance using 
simulated DNA methylation data with a set of latent variables representing “cell types”.  
Results: Results from the SVA-based method overall showed the highest agreement with all 




better estimations on cell types compared to the originally proposed method by Houseman et al. 
Further simulation studies on methods free of reference data revealed that SVA provided good 
sensitivities and specificities, RefFreeCellMix in general produced high sensitivities but 
specificities tended to be low when confounding present, and FaST-LMM-EWASher gave the 
lowest sensitivity but highest specificity. 
Conclusions 
Results from real data and simulations indicated that SVA is recommended when the focus is on 
the identification of informative CpGs. When appropriate reference data are available, the 
method implemented in the minfi package is recommended. However, if no such reference data 
are available or if the focus is not on estimating cell proportions, the SVA method is suggested.  
4. 2 Background 
Whole blood is frequently utilized in genome-wide association studies of DNA methylation 
patterns in relation to environmental exposures or clinical outcomes. However, for DNA 
methylation assessed from whole blood, the association between DNA methylation and an 
exposure of interest could be confounded by cellular heterogeneity [90, 91]. In larger 
epidemiological studies, it is not feasible to isolate and profile every individual cell subset. Thus, 
several algorithms have been developed to measure and adjust for cellular heterogeneity in 
whole blood. 
 Houseman et al. proposed a method to infer the cell mixture proportions based on a 
regression calibration technique, which uses an external validation dataset to calibrate the model 
and correct for the bias [38]. Their approach was specifically designed for the Illumina 27k 
beadchip [92]. Jaffe and Irizarry [37] modified the Houseman et al.’s algorithm and tailored it to 




beadchip (450K array; Illumina, Inc., San Diego, CA, USA). This cell type correction method is 
implemented in Bioconductor [93] package minfi [94]. The above two approaches require 
external validation datasets and are designed to identify cell mixtures in tissues such as whole 
blood.  
 Apart from these two reference-based techniques, non-reference-based methods have also 
been developed. An advantage is that these non-reference based methods can also be applied to 
any other tissue in addition to blood. Zou et. al developed a non-reference-based method FaST-
LMM-EWASher. This method is built upon linear mixed models with top principal components 
as the covariates. RefFreeEWAS [95] and its recently improved  version (RefFreeCellMix)[96] 
are another two non-reference-based methods. They both utilize singular value decompositions 
(SVDs) and extract latent subject and cell-specific effects, but RefFreeCellMix incorporated 
additional constraints and utilities aiming to reduce the occurrence of false positives. Surrogate 
variable analysis (SVA) [97], based on SVDs of residuals in linear regressions, uses 
permutations to identify statistically significant eigen-vectors and consequently infer potential 
confounding factors (surrogate variables). A Bioconductor package is available to estimate 
surrogate variables using this approach [97]. ReFACTor [98]is another method that is free of 
reference database and it is based on principal component analyses on a set of potentially 
informative CpG sites.  
 Removing unwanted variation (RUV) is an approach designed to estimate cell type 
heterogeneity and built upon factor analyses. This approach utilizes reference CpGs inferred 
from reference database, based on which factor analyses are conducted. The factors are then 




reference database is needed, this method does not estimate cell type proportions as in the minfi 
package and in the Houseman et al. method. 
 Among all these methods (eight approaches in total), it was unknown whether the 
existing methods were comparable to one another, and if not, which method(s) might perform 
better. To this end, we applied each cell type correction method (Houseman et al., minfi, RUV, 
FaST-LMM-EWASher, ReFACTor, RefFreeEWAS, and RefFreeCellMix) as well as the 
surrogate variable analyses (SVA) to real data sets. We evaluated the association between 
genome-scale DNA methylation and a variable of interest adjusting for cell type compositions. 
Then we compared the methods with regard to agreement on the number of CpG sites identified 
as being statistically significant. In addition, for the methods implemented in the minfi package 
and proposed by Houseman et al., we utilized homogeneous data with some blood cells 
composition available and compared these with the estimated cell compositions. For methods 
free of reference groups (FaST-LMM-EWASher, RefFreeEWAS, RefFreeCellMix, ReFACTor, 
and SVA), we further utilized simulated data generated under different scenarios to compare 
different methods, which, combined with findings from the real data, enabled us to demonstrate 
the quality of each method.  
4.3 Method 
In this section we briefly describe the existing techniques for estimating cell proportions or 
inferring latent variables due to cell compositions, data sets (real and simulated) to assess these 
methods, and statistical methods used in the analyses. All the analyses were programmed in R 






Existing methods for cell compositions 
4.3.1 Reference-based methods 
Houseman et al. [38] developed a method for cell type correction that capitalizes on the idea that 
differentially methylated regions (DMRs) can serve as a signature for the distribution of different 
types of white blood cells. It uses these DMRs as a surrogate in a regression calibration based 
technique to identify the cell mixture distribution. Regression calibration technique can lead to 
bias estimate, thus external validation data is used to calibrate the model and to correct for the 
bias [99]. Their method was specifically for the Illumina 27k beadchip array.  
 The method by Jaffe and Irizarry [37] was adapted from the Houseman et al. [38] method 
and is tailored for Illumina450k along with 27k array. The algorithm in Houseman et al. 
identifies 500 CpG sites used to estimate cell mixture proportions from the Illumina 27k array. 
The modification of Jaffe and Irizarry was motivated because of the existence of probe SNPs in 
the 500 CpG sites and the inconsistency of CpG sites between the 27k and 450k arrays. In 
addition, the flow-sorted data of the six adult male subjects were used as references [35] .  
 The method of removing unwanted variation (RUV) uses information from reference 
database, but it does not estimate cell type proportions. Instead, this approach bases on the 
information of negative control probes and performs factor analysis on these probes to identify 
factors due to unmeasured confounders. These factors are then included in subsequent analyses 
to adjust for cell type effects. The negative control probes were chosen as top 500 CpG sites 







4.3.2 Reference-free methods 
In total, four commonly used or recently developed reference-free methods are implemented in 
our study, FaST-LMM-EWASher, RefFreeEWAS, RefFreeCellMix, and ReFACTor. These 
methods do not need any external validation datasets and have the potential to adjust for cell 
mixture arising from any other tissue in addition to blood. FaST-LMM-EWASher [101] applies 
the maximum likelihood (ML) approach in linear mixed models and optimize spectral 
decomposition to estimate cell types [102]. RefFreeEWAS utilizes singular value decomposition 
(SVD) to decompose the residuals of unadjusted linear model along with unadjusted linear 
coefficient estimates, and estimate latent subject and cell-specific effects. Bootstrap estimates for 
coefficient standard errors are used to account for the correlation in the error structure. 
 Surrogate variable analysis (SVA) estimates potential confounding factors from a 
singular value decomposition (SVD) of residuals and was initially applied to gene expression 
data  [103]. SVA utilizes the concept of expression heterogeneity while estimating surrogate 
variables. Expression heterogeneity (EH) refers to certain plausible biological profiles of the 
subject, which may not be captured by the covariates in study. Compared to the method in 
RefFreeEWAS, SVA decomposes the residual matrix and utilize permutations to identify 
statistically significant eigen-vectors which serve as a representative of EH (the so-called 
eigengenes), and then infer surrogate variables based on theses “eigengenes”.  Surrogate 
variables from SVA have the potential to cover information on cell types in DNA methylation 
from blood cells.  
 The method built in the R package RefFreeCellMix is improved from that in 
RefFreeEWAS. It uses a variant of non-negative matrix factorization to decompose the total 




and subject-specific cell-type distributions [96]. Another approach in the R package, ReFACTor, 
a variant form of principal component analysis (PCA) to adjust for the cell type effects. This 
method assumes that a small number of methylation sites are affected by underlying cell 
mixtures. It filters out CpGs if the variation is not large enough (the default cutoff is standard 
deviation=0.02). To avoid too many CpGs filtered out, in our analyses, we excluded CpGs such 
that their standard deviations were in the lower 5th percentile. By default this method searches for 
top 500 most informative methylation sites and performs PCA with a fixed number of 
components on these CpG sites to obtain the components. These ReFACTor components can be 
used as a covariate in epigenome wide association study or can be added one at time to remove 
the inflation due to cell type composition [98]. 
4.3.3 Three real data sets used to compare the approaches 
These three data sets include data on prenatal arsenic exposure and DNA methylation, an 
example data from FaST-LMM-EWASher, and data on breast cancer status and DNA 
methylation. The first two data sets were utilized to demonstrate each of the five methods for cell 
type compositions and their agreement in terms of identified CpGs potentially associated with a 
variable of interest. The third data set was used to assess the agreement between the estimated 
cell type proportions (using the Houseman et al. method and the method in minfi) and the 
physical counts of the cells. This data set served as a benchmark and was critical for the 
comparison between the Houseman et al. method and the method in minfi. The benchmark data 
used to compare reference-free methods were simulated data, as discussed in the next section.  
Prenatal arsenic exposure and DNA methylation data: The data were from a birth cohort study 
examining multiple prenatal and postnatal factors in relation to child health outcomes, part of the 




In total, 64 subjects with genome-scale DNA methylation and level of prenatal arsenic exposure 
were included in our study. DNA methylation data were pre-processed including quantile 
normalization, probe-type correction, and probe SNPs exclusion. After pre-processing, in total, 
385,183 CpG sites were included in the analyses. All the five methods were applied to this data 
set. This and the following example data set were used to compare the performance of the five 
methods.  
An example data from FaST-LMM-EWASher: This is an example data provided by the FaST-
LMM-EWASher package [104]. It was originally used to illustrate the method incorporated into 
FaST-LMM-EWASher. In total, 204 subjects with cancer status and DNA methylation from 
Illumina 27K array on 25,978 CpG sites are available.  
Breast cancer status and DNA methylation data: This data set has been previously described 
[105] and has genome-scale DNA methylation and breast cancer status available on 61 subjects 
at baseline and 39 subjects at six month follow-up along with complete blood counts. After pre-
processing, 484,489 CpG sites were included in the study. In this article, we focus on 
granulocytes, monocyte and lymphocytes cells since proportions of these cells can be estimated 
by use of the minfi package and the original Houseman et al. approach. In our study, proportions 
of these cells from the physical counts were compared to the cell proportions estimated by minfi 
and the Houseman et al. method. 
4.3.4 Simulated data sets to compare the methods 
To further evaluate the three reference-free methods (FaST-LMM-EWASher, RefFreeEWAS, 
RefFreeCellMix, ReFACTor, and SVA), we simulated DNA methylation data under different 




data for comparing reference-methods because the underlying truth was known. Two simulation 
scenarios were employed to evaluate the methods.   
 Scenario 1: We simulated DNA methylation data at 2,000 CpG sites across 600 samples, 
of which the first n CpG sites were associated with covariates of interest (e.g., level of arsenic 
exposure) and a set of latent variables, and the remaining CpG sites were only associated with 
the latent variables. The set of latent variables represent “cell types”.  One covariate of interest 
was considered and generated from a Normal distribution with mean 1 and variance 1 (N(0, 1)), 
The coefficients of this covariate was set at 0.3 and the intercept in the regressions was 0.5. Five 
“latent” variables were used and generated from five different Normal distributions: N(0,5), 
N(3,1), N(0,1), N(2,4), N(0,3), respectively. The association of DNA methylation and the latent 
variables was assumed linear and the coefficients were generated from N (0.5, 0.01). The 
distribution of random errors in the linear regressions was assumed to be Normal with mean 0 
and variance 1.2 for the n CpGs, mean 0 and variance of 1.2 for the next 100 CpGs, and mean 0 
and variance 2 for the remaining CpGs.  The last setting with larger variance in random errors 
was for situations that the influence of cell types on DNA methylation was weaker.  
 We took three values of n, n=50, 100, and 150, representing different sparsity levels 
(from high to low) of informative CpGs. In total, 100 data sets for each n were simulated. Note 
that under this scenario, the covariates and latent variables were generated separately and had no 
correlations.   
 Scenario 2: Latent variables generated under this scenario have potential confounding 
effects. The overall setting is the same as in Scenario 1, except that the covariate of interest and 




j|, i, j = 1, 2, 3, 4, 5, 6. For instance, the correlation of the continuous covariate with the first 
latent variable was 0.7, and with the second latent variable was 0.72=0.49.  
4.3.5 Statistical analyses 
Linear regression-based analyses were used to assess the associations of DNA methylation with 
variables of interest with cell type heterogeneity adjusted using eight different methods. In the 
analyses of the two real data sets (the arsenic and DNA methylation data, and the FasT-LMM-
EWASher example data), we recorded CpG sites showing statistically significant association 
with variables of interest (i.e., arsenic exposure and cancer) after implementing different cell 
type heterogeneity inference methods. We also inferred the number of statistically significant 
CpG sites without adjusting for cell type heterogeneity. To compare the eight cell type 
heterogeneity inference methods (Houseman et al., minfi, FaST-LMM-EWASher, 
RefFreeEWAS, RefFreeCellMix, ReFACTor, RUV, and SVA), we assessed the percentage of 
overlap between different methods in the number of identified CpG sites that showed statistical 
significance, and calculated a similarity index, Jaccard index (J-index) [106]. The percentage of 
overlap is calculated as the number of identified CpGs overlapped with that from SVA divided 
by the number of CpGs identified by SVA. We used Fisher exact test to assess the significance 
of overlap. Jaccard index measures the similarity between two finite sample sets. We used a 
Bioconductor package GeneOverlap to calculate this index. To assess whether the CpGs 
uniquely identified by the SVA approach are informative, we used the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [45, 46] to analyze the enrichment in Gene 
ontology (GO) [107] categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) [40, 




As for each simulated data set, we calculated sensitivity and specificity of the selected CpG sites 
for each cell type heterogeneity inference method. They were calculated by comparing the 
detected CpGs with the truly important CpGs. For each of the five methods, median of 
sensitivity and specificity along with 95% empirical intervals across 100 data sets were recorded 
for each setting under each simulation scenario.   
4.3 Results 
4.3.1 Findings from prenatal arsenic exposure and DNA-methylation data 
We used genome-scale DNA methylation data from a birth cohort study consisting of 64 cord 
blood samples examining multiple prenatal factors in relation to child health outcomes, pilot of 
the nationwide Taiwan Maternal and Infant Cohort Study [78, 79].  
 We assessed the association of DNA methylation at each CpG site across the whole 
genome with prenatal urinary arsenic exposure levels (a continuous measure), adjusting for cell-
type effects with cell type information inferred from one of the eight methods. For each method, 
the number of CpGs was recorded showing statistically significant associations with prenatal 
urinary arsenic exposure after adjusting for multiple testing by controlling false discovery rate 
(FDR) at 0.05. ReFACTor identified the largest number of CpGs (~60,000) and no CpGs were 
detected by FaST-LMM-EWASher (Table 4.1). RefFreeCellMix also identified a large number 
of CpGs (~3000). SVA and RefFreeEWAS detected more CpGs compared to the remaining 
methods. (Table 4.1). Next, we assessed the number of identified CpGs that overlap between 
different methods. The diagram in Figure 4.1 shows the overlap of CpG sites from four 
approaches (Houseman et al., minfi, RefFreeEWAS, and SVA) as well as the analyses without 
adjusting for cell types. Results from SVA showed the best agreement with findings from the 




common to all these five analytical methods labeled in Figure 4.1. Further comparisons indicated 
that CpG site cg10662395 was also identified by RefFreeCellMix and RUV, and this is the only 
CpG site overlapped among all the seven analyses (Houseman et al., minfi, RefFreeEWAS, 
SVA, RefFreeCellMix and RUV, as well as the analyses without adjusting for cell types). 
Although ReFACTor identified the largest number of CpGs, they did not overlap with the joint 
findings from the aforementioned seven analyses. Overall, CpGs identified via SVA overlapped 
with those from the Houseman et al. method, minfi and RefFreeEWAS (p-value<0.0001, Table 
4.1, Figure 4.1. The definition of percentage overlap is given in the Methods section). One of the 
two CpGs (cg06434480 and cg10662395), cg06434480 is located within 200 base pairs of 
transcription start site of gene HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) known to 
be associated with inorganic arsenic exposure [109]. While in a study conducted in humans 
Mono-methylated arsenic (MMA) it was found to downregulate the gene expression of HMGCR, 
a gene involved in cholesterol biosynthesis [110]. The other CpG cg10662395 is located in the 
body region of gene HCN2 (hyperpolarization activated cyclic nucleotide gated potassium 
channel 2). This gene was not found to be directly associated with arsenic exposure in the 
literature, but HCN2 has been known to regulate pacemaker activity in the heart and the brain of 
mouse and human [111, 112], and arsenic has been found to induce QT interval (i.e., time 
between initial deflection of QRS complex to the end of T wave) prolongation probably by 





Figure 4.1.  Venn diagram illustrating the overlap of identified CpG sites that are associated with 
prenatal arsenic exposure at FDR level of 0.05 after incorporating estimated cell type compositions 
by different methods for the association study of prenatal arsenic exposure with DNA-methylation. 












Figure 4.2.  Venn diagram illustrating the overlap of identified CpG sites that are associated with 
cancer status at FDR level of 0.05 after incorporating estimated cell type compositions by different 
methods for the association study of cancer status with DNA-methylation.  
 
The motivation of adjusting for cell types was due to the potential confounding effects of cell 
type compositions with respect to the association of arsenic exposure with DNA methylation, 
caused by the association of arsenic exposure with cell type compositions [114-117]. Our 
assessment on the correlations between total arsenic exposure and estimated cell type proportions 
also supported the potential confounding-role of cell types (Appendix Figure A4.1). To support 
the existence of such confounding effects, we assessed the associations with and without 
adjusting for cell type proportions at all CpG sites. We found that at more than 99% of all the 




10% from cell type unadjusted (the median of the coefficients was 2.32 with 5th percentile of 
0.40 and 95th percentile of 3.46) to cell types adjusted (the corresponding statistics were 0.080, 
0.0073 and 0.25), indicating a need of adjusting for cell types.  
 Overall, the analysis based on SVA identified CpG sites that had better overlap with the 
CpGs identified by other methods. To acquire the biological relevance of CpGs uniquely 
identified by use of SVA, we implemented DAVID to perform Gene Ontology (GO) analysis 
and to identify KEGG pathways. The 455 (out of 498) significant CpG identified uniquely by 
SVA were mapped to genes using Illumina annotation file for 450K DNA methylation array. Of 
great interest, GO categories related to transcription and regulation of RNA metabolic process 
were enriched after controlling  FDR at 0.05, as well as three KEGG pathways, endocytosis, 
cancer pathway and MAPK signaling pathway. A discussion on the connection of arsenic 
















Table 4.1. Number of significant CpG sites with and without cell type correction and overlap with 
the SVA method (data on prenatal arsenic exposure and DNA methylation). 
Method Identified CpGs (N)# Overlap with SVA (%)  p-value## 
Houseman et al. 10 1.20 <0.0001 
minfi 57 4..62 <0.0001 
SVA 498 --- --- 
RefFreeEWAS 133 6.01 <0.0001 
RefFreeCellMix 2,932 0.60 1.0 
ReFACTor 58,871 13.03 1.0 
EWASher* 0 0.0 --- 
RUV 356 0.20 1.0 
Unadjusted** 3 0.60 <0.0001 
* The FasT-LMM-EWASher method. 
** Unadjusted: cell type compositions were not included in the analyses. 
#The selection of CpG sites is based on FDR-adjusted p-values (FDR is controlled at 0.05). 
##P-value is based on Fishers exact test for overlap with results from SVA. The null hypothesis is 
that there is no overlap with the CpGs identified based on SVA. 
 
4.3.2 Findings from example data 
We repeated the same analysis on an example data set provided by the FasT-LMM-EWASher 
package. A tutorial website for applying all the cell type composition inference methods to this 
example data is available at https://akhilesh362.wordpress.com/. This data set includes DNA 
methylation from the Illumina 27K array and measures of a binary variable (cancer status) for 
204 subjects. In total, 7,648 CpGs were included in our study based on initial screening done by 
the FasT-LMM-EWASher package. In this example data, cell type proportions were likely to be 
different on average between subjects with cancer and those without cancer, based on two-
sample t-tests applied to logit-transformed sample proportions, explaining the potential need to 




methylation at a large number of CpG sites showed statistically significant associations with 
cancer status (Table 4.2). Some similar findings as in Table 4.1 were observed. ReFACTor 
identified a large number of CpGs, Fast-LMM-EWASher identified the least number of CpG 
sites, and SVA agreed nicely with minfi (Jaccard similarity index=0.4). A unique observation 
from this analysis is that RUV identified the largest number of CpGs (6,008 CpGs, close to the 
number of CpGs in the candidate pool, 7,648 CpGs). Since the original Houseman et al. method 
was designed specifically for Illumina 27K platform, it is reasonable that SVA also showed a 
large overlap with results from this approach (Jaccard similarity index=0.4). In total, 3 identified 
CpGs (cg22029275 located in the 1st Exon of FAM123A gene, cg07080358 located in 1st Exon of 
CNRIP1, and cg15202954 located within 200 base pair of transcription start site of NALCN 
gene) were common to all the eight cell correction methods as well as to the analyses without 
cell type composition adjusted. There is evidence that these three genes (FAM123A, CNRIP1 and 















Table 4.2. Number of significant CpG sites with and without cell-correction methods and overlap 
of CpG sites with those from the SVA method (example data from FasT-LMM-EWASher 
package).  
Method Identified CpGs 
(N)# 





Houseman et al. 1,835 54.71 <0.0001 0.40 
minfi 3,589 84.59 <0.0001 0.40 
SVA 1,888 --- --- ---  
RefFreeEWAS 788 30.51 <0.0001 0.30 
RefFreeCellMix 1,006 18.38 <0.0001 0.10 
ReFACTor 4,224 87.45 <0.0001 0.40 
EWASher* 3 0.16 <0.0001 0 
RUV 6,008 99.95 <0.0001 0.30 
Unadjusted** 3,768 82.89 <0.0001 0.40 
* The FasT-LMM-EWASher method.  
** Unadjusted: cell type compositions were not incorporated into the analyses. 
#The selection of CpG sites is based on FDR-adjusted p-values (FDR is controlled at 0.05). 
## P-value is based on Fishers exact test for overlap. The null hypothesis is that there is no overlap 
with the CpGs identified based on SVA. 
### J-index is Jaccard index. 
  
 DAVID analysis of genes associated with the significant CpGs identified uniquely by 
SVA led to the identification of three GO categories related to plasma membrane at FDR of 0.05 
(integral to plasma membrane, intrinsic to plasma membrane, and plasma membrane part), as 
well as KEGG pathways such as pathways in cancer and signaling pathways, which indicates 





4.3.3 Findings from breast cancer status and DNA-methylation data 
This analysis uses a data set discussed in Smith et al. [105]. Breast cancer status, DNA-
methylation, and cell counts for granulocytes, monocyte, and lymphocytes for 61 subjects at 
baseline and a subset of 39 subjects at six months follow up are implemented in the analyses. 
Among all the methods discussed, the method implemented in the minfi package and the original 
Houseman et al. method are able to estimate cell proportions.  We used minfi and the Houseman 
et al. approach to estimate the proportions of granulocyte, monocyte and lymphocyte cells. 
Lymphocytes proportion were derived by adding the proportions of B cell, T cell and Natural 
Killer (NK) cells. For the three cell types (granulocyte, monocyte and lymphocyte), Pearson 
correlations between estimated (minfi) and true cell proportions were 0.85, 0.79, 0.88 at baseline 
and 0.84, 0.78, 0.87 at the six month follow up, respectively. For the correlations based on the 
Houseman et al. method, they were 0.84, 0.78 and 0.88 at baseline and 0.78, 0.73 and 0.83 at the 
six month follow up, respectively. All the correlations showed statistically significant difference 
from zero (p-value<0.05). 
4.3.4 Findings from simulated data 
We simulated data applying two scenarios with the first scenario focusing on latent variable 
effects (comparable to effects of cell composition), and the second focusing on latent variable 
effects with confounding (comparable to effects of cell composition as well as confounding 
effects). In total, 100 data sets were simulated under each scenario. Details of the simulation 
scenarios are given in the Methods section.  The simulated data were used to evaluate the five 
methods that do not estimate cell proportions nor need reference databases, specifically, FaST-




 For data under all scenarios, we applied each of the five methods to each simulated data 
to draw information on cell compositions. We then incorporated the information to assess the 
associations of “DNA methylation” with the variable of interest at each pseudo CpG site, and 
compared each method by assessing the sensitivity and specificity of the selected CpG sites 
across all 100 data sets. Regardless of the number of important CpGs, FaST-LMM-EWASher 
resulted in the lowest sensitivity but the highest specificity for both scenarios, consistent with 
findings from real data (Table 4.3). Findings from RefFreeEWAS, RefFreeCellMix, ReFACTor, 
and SVA are, in general, comparable for data simulated under scenario 1, but SVA gives 
consistently higher sensitivity and specificity in all settings (Table 4.3). For data simulated under 
scenario 2 with high correlations (ρ=0.7), SVA outperformed FaST-LMM-EWASher, 
RefFreeEWAS, RefFreeCellMix and ReFACTor and had higher sensitivity and specificity. 
Compared with RefFreeEWAS, overall RefFreeCellMix outperformed RefFreeEWAS when 
confounding effects present, showing much higher sensitivities with relatively lower 
specificities. Results from ReFACTor indicated extremely low specificity under scenario 2, 
which is consistent with the rather large numbers of CpGs identified in real data. The 
performance of FaST-LMM-EWASher was similar between the two scenarios and was inferior 
to all other methods. On the other hand, the SVA method performed well under both scenarios, 
followed by RefFreeEWAS and RefFreeCellMix with RefFreeEWAS being weaker in capturing 
confounding effects. We also considered a situation with ρ=0.3, mimicking a situation of 
moderate confounding, and similar patterns observed as those from the relatively two extreme 
cases (ρ=0 and ρ=0.7).  
 In the above simulations, we fixed the regression coefficients of the important CpGs. To 




characteristic (ROC) plots. In total, 100 data sets were simulated under scenario 1 with 
regression coefficients for the variable of interest ranged from 0.01 to 0.3. For each data set, we 
calculated sensitivity and specificity of selected CpGs, based on which we estimated the ROC 
curves. Sensitivities from FaST-LMM-EWASher were substantially low and were not 
considered in this demonstration. The performance of RefFreeEWAS, RefFreeCellMix, and 
ReFACTor was comparable under scenario 1 (Table 4.3). We therefore only presented ROC 
curves for ReFreeEWAS and SVA for the purpose of comparison (Figure 4.2). The findings are 
consistent with what we observed from Table 4.3 for scenario 1, that is, SVA performed better 
than RefFreeEWAS. In addition, the results indicated that both SVA and RefFreeEWAS have 
high specificity regardless of the underlying regression coefficients, indicating the 













Table 4.3. Summary of sensitivity, specificity of FaST-LMM-EWASher, RefFreeEWAS, 
RefFreeCellMix, ReFACTor, and SVA for 100 simulated data across three settings. 
 Sensitivity (Median, 95% interval) Specificity (Median, 95% interval) 
 Number of Important CpGs =50 
 Scenario 1 (ρ = 
0) 
Scenario 2 (ρ = 
0.7) 
Scenario 1 (ρ = 0) Scenario 2 (ρ = 
0.7) 
Ewashera 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 
RefEWASRefb 1 (0.96, 1.00) 0.00 (0.00,0.49) 1.00 (0.99,1.00) 0.58 (0.06,1.00) 
CellMixc 1.00 (0.98, 1.00) 1.00 (1.00, 1.00) 1.00 (0.99, 1.00) 0.55 ( 0.20, 0.92) 
ReFACTor 1.00 (0.96, 1.00) 1.00 (1.00, 1.00) 1.00 (0.83, 1.00) 0 ( 0.00, 0.00) 
SVAd 1.00 (0.98, 1.00) 1.00 (0.96, 1.00) 1.00 (0.996, 1.00) 1.00 (0.996, 1.00) 
 Number of Important CpGs =100 
Ewashera 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 
RefbRefEWAS 1.00 (0.97,1.00) 0.00 (0.00,0.40) 1.00 (0.99, 1.00) 0.52 (0.01,1.00) 
CellMix 1.00 ( 0.98, 1.00) 1.00 ( 1.00, 1.00) 0.99 (0.97, 1.00) 0.21 (0.05, 0.53) 
ReFACTor 1.00 (0.97, 1.00) 1 (1.00, 1.00) 0.99 (0.81, 1.00) 0.00 (0.00, 0.00) 
SVAc 1.00 (0.99,1.00) 0.99 (0.97, 1.00) 1.00 (0.99, 1.00) 1.00 (0.99, 1.00) 
 Number of Important CpGs =150 
Ewasher 0.00 (0.00,0.00) 0.00 (0.00,0.00) 1.00 (1.00,1.00) 1.00 (1.00,1.00) 
RefRefEWAS 0.99 (0.97,1.00) 0.00 (0.00,0.29) 0.99 (0.99,1.00) 0.50 (0.01,1.00) 
CellMix 1.00 (0.98, 1.00)  1.00 ( 1.00, 1.00)  0.98 ( 0.93, 0.99) 0.10 ( 0.02, 0.29) 
ReFACTor 1.00 ( 0.98, 1.00) 1.00 ( 1.00, 1.00) 0.99 (0.79, 1.00) 0.00 (0.00, 0.00) 




Footnote: ρ = correlation between primary covariate and latent variables. ρ = 0 corresponds to 
data simulated from Scenario 1, while ρ=0.7 corresponds to data simulated from Scenario 2. 





We compared eight cell-type correction methods using real and simulated data. Based on DNA 
methylation in a cohort study, the methods in ReFACTor identified the largest number of CpGs 
(~60K CpGs), none of which overlapped with the common CpGs detected by other methods 
including the analysis without adjusting for cell type compositions (but excluding the method in 
FaST-LMM-EWASher). The method in FaST-LMM-EWASher did not identify any CpG sites. 
Except for ReFACTor and FaST-LMM-EWASher, at least one detected CpG was shared 
between all the other methods. More than 50% of CpGs identified by the Houseman et al. 
method and by the approach implemented in minfi were also detected by the SVA method; The 
overlap in CpGs was much less between these two methods and the remaining methods. The 
genes associated with CpGs uniquely identified by using SVA with prenatal urinary arsenic as 
primary exposure led to the enrichment of GO categories and KEGG pathways that were 
consistent with our understanding with respect to the effect of arsenic on DNA methylation. 
Arsenic exposure leads to generation of reactive oxygen species (ROS) which induces DNA 
damage [121]. This reactive oxygen species play a crucial role in signal transduction pathways, 
transcription factor regulation [122], and mitogen activated protein kinases (MAPKs) signal 
transduction pathway is one such pathway that is affected by ROS [123]. DAVID analysis of 
genes associated with the CpGs uniquely identified by SVA for FaST-LMM-EWASher example 




identified by using SVA are potentially informative. Using the example dataset provided by 
FasT-LMM-EWASher method, we found that all methods except for FasT-LMM-EWASher 
identified a large number of CpG sites. This was likely due to the platform used to measure DNA 
methylation levels (Illumina 27K), which is centered more on cancer genes. However, CpGs 
identified based on ReFACTor and RUV were close to the number of CpGs in the pool of 
candidate CpGs, indicating possible inflations. On the other hand, results from minfi showed the 
greatest overlap with the SVA method (Table 4.2). Based on these two real data sets, results 
from the method in the minfi package and those from SVA were most agreeable. However, for 
real data, the underlying truth was unknown, which was the motivation of incorporating a data 
set with cell counts known and the use of a series of simulation studies. Findings from these data 
were further discussed in this section.  
 Using the available cell counts in the cancer status and DNA methylation dataset we 
observed agreements between cell types estimated by Houseman et al. and minfi, but minfi 
showed a better agreement. The Houseman et al. approach was designed for the Illumina 27K 
beadchip array, which may not fit the 450K array as noted in the literature [37]. The modification 
of the Houseman et al. approach implemented in the minfi package, on the other hand, is suitable 
for both 27K and 450K array. The reference data were from six adult white European males. It 
has been shown that DNA methylation patterns vary by sex, age and ancestry [124-128]. 
Generalizing the cell mixtures estimated by minfi to studies with both genders and non-
Europeans of different age groups may potentially introduce bias.   
 Further simulations investigating reference-free methods supported the findings from real 
data. Regardless of the number of important CpGs, FaST-LMM-EWASher showed the lowest 




for cell type compositions. ReFACTor produced lowest specificity when confounding effects 
were present, supporting the rather low overlapping with findings from other methods. On the 
other hand, findings from ReFACTor, RefFreeEWAS, RefFreeCellMix and SVA were in general 
comparable for data simulated under scenario 1 (no-confounding effects), but SVA gave 
consistently higher sensitivity and specificity when cofounding effects present.  
 The SVA approach does not provide estimates on cell type compositions; however, our 
ultimate goal was not to estimate cell counts. The goal was to identify an approach that best 
assesses DNA methylation differentiation due to exposure or diseases, corrected for a potential 
cell type bias. From this viewpoint and the findings from real data and the high sensitivities and 
specificities from simulations (under both scenarios, confounding and no confounding), using 
SVA to adjust for cell type compositions seems to be an appropriate method and may perform 
better than the existing methods. It is worth noting that information included in the surrogate 
variables produced by the SVA method may also include other information in addition to cell 
type compositions. There is a potential of over-adjustment by use of this approach. Furthermore, 
we would like to point out that all these reference-free methods can be directly applied to 
genome-wide bisulfite sequencing data and we expect similar findings in terms of their ability in 
inferring cell type compositions.  
Conclusion 
When appropriate reference data are available and if inferences on cell type compositions are 
needed, the method implemented in the minfi package is recommended. However, if no such 
reference data are available or if the focus is not on estimating cell proportions, the SVA method 






The work presented in this dissertation is distributed in the ongoing project related to epigenome 
wide association studies. The epigenetic markers identified in this study will benefit researchers 
in epigenetic studies in that they will help elucidate the pathophysiology of disease associated 
with in utero arsenic exposure, and provide insight into the production of immunoglobulin E. 
The replications of identified CpG sites in independent cohorts strengthen the validity of the 
findings. I summarize the highlights of the work as follows: 
1. The 252 CpG sites identified and replicated in an independent cohort can serve as an 
epigenetic marker for the adverse health effect of in utero arsenic exposure on the newborn 
subjects. 
2. Of the 252 CpG sites, 5 CpG sites were found to be longitudinally associated with low density 
lipoprotein measures of the subjects at ages 2, 5, 8, 11 and 14. The genes corresponding to these 
five CpGs (cg25189764, cg04986899, cg04903360, cg08198265 and cg10473311) also had 
literature support for their association with cardiovascular disease or diabetes. The DNA 
methylation measurements at the identified five CpG sites are known to be stable across different 
age group. Thus, these five CpG sites have the potential to serve as an epigenetic marker for the 
adverse effect of in-utero arsenic exposure and its association with LDL measures at later ages. 
3. The 124 CpG sites longitudinally associated with IgE in the main cohort and replicated in an 
independent cohort can serve as an epigenetic marker predicting the production of IgE. Of 124 
the DNA methylation measures at 59 CpG sites were found to be stable at birth, age 10 and age 
18 in IoW cohort. Thus, these 59 CpG sites are more reliable to serve as an epigenetic marker 
explaining the production of IgE and could eventually help in revealing the pathophysiology of 




4. In the assessment of the methods for cell type adjustment we found that Houseman’s 
algorithm implemented in Bioconductor package “minfi” is the best choice if reference dataset is 
available. Although R package “sva” performed best compared to other methods in most of the 
situations, but given the possibility of over fit it is recommended in the situation where reference 
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Name Coef (CI) P-value Coef (CI) P-value Gene MAPINFOCHR Relation to CpG Islands Name
cg19407236 -0.66 (-0.84, -0.49) 1.44E-09 0 -0.07(-0.33,0.2) 6.13E-01 0.992 RPSAP58 23946205 19 S_Shore chr19:23945713-23946128
cg17923401 -0.84 (-1.07, -0.62) 1.62E-09 0 -0.16(-0.46,0.13) 2.78E-01 0.967 SIGLEC7;SIGLEC7 51644168 19
cg06515634 -0.54 (-0.68, -0.39) 2.04E-09 0 -0.04(-0.14,0.06) 4.57E-01 0.988 1.51E+08 1 Island chr1:151445871-151446142
cg03403996 1.55 (1.12, 1.97) 3.14E-09 0 0.66(-0.42,1.74) 2.30E-01 0.967 TRIM31 30074162 6 S_Shelf chr6:30071225-30071428
cg07600884 -0.55 (-0.71, -0.4) 5.75E-09 0 0.02(-0.16,0.2) 8.16E-01 0.992 LRRC8D;LRRC8D 90286190 1 Island chr1:90286189-90287222
cg26241877 0.54 (0.38, 0.69) 8.78E-09 0.001 0.13(-0.04,0.29) 1.39E-01 0.967 52630003 18 S_Shelf chr18:52626517-52626849
cg16587616 -0.52 (-0.68, -0.37) 1.81E-08 0.001 -0.07(-0.3,0.15) 5.25E-01 0.989 KHDRBS2;KHDRBS2 62996022 6 Island chr6:62995855-62996228
cg10197432 -0.55 (-0.71, -0.39) 1.86E-08 0.001 0.16(0,0.31) 4.66E-02 0.776 C6orf103 1.47E+08 6 Island chr6:146920034-146920245
cg03462714 0.7 (0.49, 0.91) 2.65E-08 0.001 . ADARB2 1547894 10
cg06889951 0.34 (0.23, 0.44) 5.43E-08 0.002 0(-0.15,0.15) 9.87E-01 0.997 FGF3 69625218 11 Island chr11:69625108-69625473
cg26284982 -0.58 (-0.77, -0.4) 6.13E-08 0.002 0(-0.1,0.1) 9.89E-01 0.997 C17orf57 45401312 17 Island chr17:45400874-45401440
cg27256528 -0.4 (-0.52, -0.27) 9.62E-08 0.003 0.1(-0.04,0.24) 1.49E-01 0.967 A2BP1;A2BP1 6533667 16 Island chr16:6533019-6533983
cg25249539 -0.59 (-0.77, -0.4) 1.07E-07 0.003 -0.06(-0.41,0.28) 7.14E-01 0.992 56803358 20 Island chr20:56803282-56804112
cg27367142 -0.6 (-0.8, -0.41) 1.13E-07 0.003 -0.03(-0.31,0.25) 8.12E-01 0.992 77127199 10
cg13011003 1.26 (0.85, 1.67) 1.63E-07 0.004 -0.83(-1.36,-0.29) 2.67E-03 0.493 1.26E+08 12
cg20677901 -0.64 (-0.85, -0.43) 1.91E-07 0.004 0.19(0.02,0.36) 3.13E-02 0.719 TP73 3568210 1 Island chr1:3566445-3569636
cg11801110 0.38 (0.26, 0.51) 1.96E-07 0.004 -0.01(-0.1,0.08) 8.38E-01 0.992 PIM3 50356763 22 Island chr22:50353596-50357215
cg14232870 0.61 (0.4, 0.81) 2.90E-07 0.006 0.05(-0.1,0.2) 5.16E-01 0.989 SHANK2;SHANK2 70458782 11
cg00345443 -0.45 (-0.6, -0.3) 3.09E-07 0.006 0.15(-0.09,0.4) 2.23E-01 0.967 54121778 3 Island chr3:54121624-54122147
cg01615818 -1.27 (-1.69, -0.84) 3.19E-07 0.006 0.02(-0.51,0.55) 9.38E-01 0.992 ZNF681 23941438 19 Island chr19:23941240-23941538
cg03865648 -0.46 (-0.61, -0.3) 4.07E-07 0.007 . 1.73E+08 3 N_Shore chr3:173115404-173115775
cg00768741 0.37 (0.24, 0.49) 4.46E-07 0.008 -0.02(-0.13,0.1) 7.77E-01 0.992 HSPG2 22210791 1 N_Shore chr1:22210992-22211318
cg26278987 0.78 (0.52, 1.05) 4.56E-07 0.008 -0.03(-0.81,0.75) 9.40E-01 0.992 C4orf50 5960351 4
cg19846314 -0.56 (-0.76, -0.37) 4.84E-07 0.008 0.16(-0.15,0.47) 3.13E-01 0.967 GAD1;GAD1 1.72E+08 2 Island chr2:171678546-171680358
cg00630892 0.74 (0.49, 1) 5.08E-07 0.008 -0.07(-0.17,0.04) 2.18E-01 0.967 NRBP2 1.45E+08 8 Island chr8:144921644-144921914
cg13496244 0.38 (0.25, 0.51) 6.43E-07 0.009 0.1(-0.1,0.3) 3.14E-01 0.967 4925830 7 S_Shelf chr7:4922707-4923576
cg00947796 0.36 (0.23, 0.48) 6.63E-07 0.009 -0.02(-0.17,0.12) 7.55E-01 0.992 1316185 16
cg06946213 0.32 (0.2, 0.43) 6.95E-07 0.01 0.02(-0.12,0.16) 7.74E-01 0.992 1.03E+08 6
cg08522676 -0.32 (-0.43, -0.21) 7.31E-07 0.01 0.08(-0.03,0.2) 1.69E-01 0.967 54343702 12 Island chr12:54343622-54343848
cg07583091 -0.48 (-0.65, -0.31) 7.83E-07 0.01 0.04(-0.08,0.17) 5.00E-01 0.989 GTF2H1;HPS5;HPS5;GT 18343626 11 Island chr11:18343625-18344238
cg25137787 0.73 (0.47, 0.99) 8.05E-07 0.01 -0.03(-0.3,0.25) 8.52E-01 0.992 2863815 1
cg13718729 -0.53 (-0.72, -0.34) 8.85E-07 0.01 0.12(-0.16,0.39) 4.03E-01 0.968 GRIN1;GRIN1;GRIN1 1.40E+08 9 Island chr9:140056283-140057837
cg06526522 0.43 (0.28, 0.58) 9.01E-07 0.01 0.01(-0.09,0.12) 8.36E-01 0.992 PRDM16;PRDM16 3129005 1
cg09419102 0.35 (0.22, 0.47) 9.01E-07 0.01 0.04(-0.02,0.1) 2.41E-01 0.967 65550444 11 S_Shore chr11:65547499-65549261
cg11569407 0.37 (0.24, 0.5) 9.12E-07 0.01 . 1.30E+08 10 Island chr10:130008558-130009620
cg06458094 0.32 (0.2, 0.43) 9.39E-07 0.01 0.03(-0.09,0.16) 5.83E-01 0.992 20448558 17
cg04069951 -0.37 (-0.5, -0.24) 9.46E-07 0.01 -0.17(-0.44,0.11) 2.28E-01 0.967 CD81 2398336 11 Island chr11:2398223-2399598
cg07969609 0.44 (0.29, 0.6) 9.58E-07 0.01 . 98438319 8
cg20646995 -0.39 (-0.53, -0.25) 1.03E-06 0.01 0.01(-0.19,0.22) 9.01E-01 0.992 LRWD1;ALKBH4 1.02E+08 7 Island chr7:102105123-102105782
cg17032590 0.49 (0.31, 0.66) 1.09E-06 0.011 0.12(-0.03,0.27) 1.04E-01 0.967 SLC2A7 9074847 1
cg06043190 0.52 (0.33, 0.71) 1.14E-06 0.011 -0.01(-0.12,0.1) 8.84E-01 0.992 EML4;EML4 42396882 2 Island chr2:42396301-42396933
cg20263686 0.32 (0.21, 0.44) 1.21E-06 0.011 -0.03(-0.13,0.08) 6.12E-01 0.992 ANK1;ANK1;ANK1;ANK41643429 8
cg03430846 -0.43 (-0.59, -0.28) 1.28E-06 0.011 . NRG1 31497082 8 Island chr8:31496525-31498346
cg13324337 -0.55 (-0.75, -0.35) 1.30E-06 0.011 -0.01(-0.15,0.13) 8.85E-01 0.992 1.00E+08 15
cg04986899* -0.42 (-0.58, -0.27) 1.37E-06 0.011 -0.02(-0.15,0.12) 8.22E-01 0.992 XYLT1 17553784 16
cg15530351 0.77 (0.49, 1.06) 1.40E-06 0.011 -0.07(-0.23,0.09) 3.83E-01 0.968 ANGPT2;ANGPT2;ANG 6407676 8
cg18226049 0.38 (0.24, 0.52) 1.41E-06 0.011 -0.03(-0.15,0.1) 6.96E-01 0.992 TSSC4 2424791 11 S_Shelf chr11:2421040-2422474
cg21696208 -0.48 (-0.65, -0.3) 1.44E-06 0.011 -0.03(-0.22,0.17) 7.97E-01 0.992 MTFR1;MTFR1 66556075 8 N_Shore chr8:66556764-66557513
cg24288527 -0.45 (-0.62, -0.29) 1.44E-06 0.011 0.06(-0.06,0.18) 3.54E-01 0.968 PPP1R3C 93390347 10 N_Shelf chr10:93392667-93393147
cg20063462 -0.61 (-0.84, -0.39) 1.49E-06 0.011 0.02(-0.16,0.21) 8.03E-01 0.992 TMEM87B 1.13E+08 2 N_Shore chr2:112812827-112813614
cg04293085 -0.37 (-0.5, -0.23) 1.56E-06 0.012 0.12(0,0.24) 5.98E-02 0.843 ADRA1D 4202378 20 Island chr20:4202148-4202765
cg14449633 0.71 (0.45, 0.97) 1.58E-06 0.012 0.1(-0.12,0.31) 3.68E-01 0.968 51532432 10
cg17841267 0.36 (0.23, 0.5) 1.63E-06 0.012 -0.08(-0.24,0.07) 2.92E-01 0.967 1.12E+08 10
cg01238672 0.4 (0.25, 0.54) 1.65E-06 0.012 0.09(-0.06,0.25) 2.41E-01 0.967 1.70E+08 6
cg04438098 0.81 (0.51, 1.11) 1.70E-06 0.012 0.58(0.22,0.95) 1.79E-03 0.493 1.12E+08 13 S_Shore chr13:112212062-112212297
cg12439423 0.34 (0.21, 0.46) 1.77E-06 0.012 0.04(-0.06,0.15) 4.19E-01 0.968 ANK1;ANK1;ANK1;ANK41522721 8
cg07243405 0.35 (0.22, 0.47) 1.81E-06 0.012 0.07(-0.05,0.19) 2.52E-01 0.967 C7orf20 915203 7 N_Shore chr7:915753-916644
cg23217126 -0.49 (-0.67, -0.31) 1.90E-06 0.013 0.16(0.01,0.31) 3.77E-02 0.719 DOK6 67068268 18 Island chr18:67067509-67069168
cg21515956 0.45 (0.28, 0.61) 1.93E-06 0.013 0.03(-0.06,0.12) 5.26E-01 0.989 KIF26A 1.05E+08 14 S_Shelf chr14:104601959-104605672
cg17696468 -0.35 (-0.48, -0.22) 1.95E-06 0.013 -0.1(-0.23,0.03) 1.19E-01 0.967 ELP4 31742528 11
cg06970076 0.5 (0.32, 0.69) 2.03E-06 0.013 -0.07(-0.32,0.17) 5.55E-01 0.99 IFT140 1560791 16 S_Shore chr16:1559965-1560194
cg15268244 0.34 (0.21, 0.46) 2.15E-06 0.013 0.19(0.04,0.34) 1.26E-02 0.719 77196840 15 N_Shore chr15:77197258-77197895
cg15311933 -0.62 (-0.85, -0.39) 2.24E-06 0.014 -0.01(-0.17,0.14) 8.62E-01 0.992 PQLC2;AKR7A2;PQLC2 19638897 1 Island chr1:19638207-19639309
cg06419180* -0.39 (-0.54, -0.25) 2.29E-06 0.014 -0.06(-0.15,0.04) 2.38E-01 0.967 CSGALNACT1;CSGALN19262414 8
cg26297950 -0.35 (-0.47, -0.22) 2.39E-06 0.014 0.03(-0.07,0.13) 6.20E-01 0.992 FLCN;FLCN 17124828 17 Island chr17:17124698-17124931
cg09115646 -0.76 (-1.04, -0.47) 2.43E-06 0.014 -0.11(-0.26,0.05) 1.84E-01 0.967 2978687 10
cg26789064 0.52 (0.32, 0.71) 2.43E-06 0.014 0.1(-0.09,0.28) 2.93E-01 0.967 4866130 4 N_Shore chr4:4866438-4866813
cg20074159 0.59 (0.37, 0.81) 2.45E-06 0.014 0.16(-0.07,0.4) 1.69E-01 0.967 1.10E+08 3
cg06962275 -0.49 (-0.68, -0.31) 2.52E-06 0.014 0.01(-0.11,0.12) 9.09E-01 0.992 NCRNA00171 30010203 6
cg01616682 -0.41 (-0.56, -0.26) 2.55E-06 0.014 0.13(-0.09,0.34) 2.39E-01 0.967 CALCB 15095017 11 Island chr11:15094957-15095872
cg12266551 0.46 (0.28, 0.63) 2.77E-06 0.015 -0.04(-0.15,0.08) 5.25E-01 0.989 TOMM40;TOMM40;TOM45394624 19 Island chr19:45393833-45394992
cg12417362 -0.48 (-0.66, -0.3) 2.77E-06 0.015 0.1(-0.04,0.25) 1.55E-01 0.967 NAV1 2.02E+08 1 Island chr1:201617041-201619788
cg23127291 0.46 (0.29, 0.64) 2.83E-06 0.015 -0.08(-0.24,0.08) 3.04E-01 0.967 CCDC102A 57563324 16 Island chr16:57562451-57563325
cg18403361 -0.42 (-0.58, -0.26) 2.89E-06 0.015 0.04(-0.11,0.2) 5.94E-01 0.992 CLEC14A 38725750 14 S_Shore chr14:38724254-38725537
cg21216268 0.32 (0.2, 0.44) 2.95E-06 0.015 -0.02(-0.1,0.06) 5.91E-01 0.992 PHC3 1.70E+08 3
cg18875631 0.38 (0.23, 0.52) 2.99E-06 0.015 -0.05(-0.16,0.07) 4.22E-01 0.968 MIR543 1.01E+08 14
cg07965335 0.44 (0.27, 0.61) 3.07E-06 0.015 -0.01(-0.11,0.09) 8.51E-01 0.992 SORBS2;SORBS2;SORB 1.87E+08 4
cg05638165 0.45 (0.28, 0.62) 3.08E-06 0.015 0(-0.12,0.12) 9.40E-01 0.992 KIAA1614 1.81E+08 1
cg04521224 0.5 (0.31, 0.68) 3.10E-06 0.015 0.03(-0.09,0.15) 6.22E-01 0.992 37332584 2
cg22119716 -0.58 (-0.8, -0.36) 3.17E-06 0.015 . 3497214 2
cg01078197 -0.47 (-0.65, -0.29) 3.34E-06 0.016 0.06(-0.18,0.31) 6.12E-01 0.992 MSL3L2 2.35E+08 2 Island chr2:234776882-234777098
cg16993936 0.41 (0.25, 0.57) 3.43E-06 0.016 0(-0.17,0.18) 9.65E-01 0.994 OPTN;OPTN;OPTN;OPT13146903 10
cg03351580 0.36 (0.22, 0.5) 3.46E-06 0.016 -0.02(-0.16,0.13) 8.27E-01 0.992 1.67E+08 6 N_Shore chr6:166666837-166667541
cg21814615 0.25 (0.16, 0.35) 3.53E-06 0.016 -0.03(-0.13,0.08) 6.12E-01 0.992 KNTC1 1.23E+08 12
cg23928234 0.43 (0.26, 0.59) 3.62E-06 0.016 0(-0.12,0.12) 9.71E-01 0.995 WWC2 1.84E+08 4
cg22470309 -0.36 (-0.49, -0.22) 3.80E-06 0.017 0.07(-0.04,0.18) 2.25E-01 0.967 RGL3;RGL3 11529252 19 Island chr19:11529213-11529588
cg27079740 0.45 (0.28, 0.62) 3.89E-06 0.017 0.09(-0.06,0.25) 2.35E-01 0.967 GPM6A;GPM6A;GPM6A1.77E+08 4
cg08529049 -0.34 (-0.47, -0.21) 3.94E-06 0.017 0.25(0.02,0.47) 3.38E-02 0.719 CWH43 48988038 4 Island chr4:48987790-48988808
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Table A1.1
Name Coef (CI) P-value Coef (CI) P-value Gene MAPINFOCHR Relation to CpG Islands Name
cg23767840 1.61 (0.99, 2.24) 3.99E-06 0.017 -0.12(-0.31,0.07) 2.23E-01 0.967 EPN2;EPN2;EPN2 19174122 17
cg10363926 0.38 (0.24, 0.53) 4.04E-06 0.017 -0.01(-0.11,0.08) 7.67E-01 0.992 SH3RF3 1.10E+08 2
cg12497914 -0.51 (-0.71, -0.32) 4.12E-06 0.017 0.08(-0.06,0.22) 2.83E-01 0.967 EBF4 2674285 20 Island chr20:2672904-2674698
cg25408698 0.36 (0.22, 0.49) 4.15E-06 0.017 0.01(-0.14,0.15) 8.99E-01 0.992 HRNBP3 77099293 17 N_Shore chr17:77099995-77100203
cg11170796 0.37 (0.23, 0.51) 4.29E-06 0.018 0(-0.09,0.08) 9.15E-01 0.992 TCF3;TCF3 1650224 19 S_Shelf chr19:1646117-1646713
cg12635602 0.5 (0.31, 0.7) 4.35E-06 0.018 -0.01(-0.22,0.19) 9.04E-01 0.992 58731357 11 Island chr11:58731311-58731535
cg05494740 0.36 (0.22, 0.5) 4.45E-06 0.018 -0.03(-0.11,0.04) 4.09E-01 0.968 C16orf7 89775683 16 N_Shore chr16:89777018-89778789
cg03709938 -0.3 (-0.42, -0.19) 4.50E-06 0.018 0.03(-0.07,0.13) 5.42E-01 0.99 MMEL1 2560950 1 Island chr1:2559892-2561055
cg04705068 0.3 (0.18, 0.42) 4.58E-06 0.018 0.05(-0.11,0.21) 5.12E-01 0.989 FAM20B 1.79E+08 1
cg14199148 -0.61 (-0.85, -0.37) 4.59E-06 0.018 0.06(-0.07,0.2) 3.75E-01 0.968 WDFY2;WDFY2 52158669 13 Island chr13:52158056-52159235
cg15028160 -0.66 (-0.92, -0.41) 4.62E-06 0.018 -0.23(-0.59,0.13) 2.08E-01 0.967 PPFIA3;C19orf73;PPFIA 49622717 19 Island chr19:49622023-49623635
cg15152301 0.39 (0.24, 0.54) 4.74E-06 0.018 0(-0.13,0.13) 9.79E-01 0.997 CACNA2D2;CACNA2D 50425602 3
cg05876635 -0.42 (-0.59, -0.26) 4.83E-06 0.018 0.07(-0.06,0.2) 2.99E-01 0.967 55955383 7 Island chr7:55954935-55955387
cg10985810* 0.36 (0.22, 0.5) 4.95E-06 0.018 0.02(-0.07,0.11) 6.61E-01 0.992 PTPRN2;PTPRN2;PTPR 1.58E+08 7 Island chr7:158282214-158283382
cg22311507 -0.58 (-0.81, -0.35) 5.00E-06 0.018 -0.02(-0.15,0.1) 7.06E-01 0.992 MYCN 16079921 2 Island chr2:16079801-16083032
cg17652792 0.26 (0.16, 0.37) 5.03E-06 0.018 -0.05(-0.22,0.12) 5.68E-01 0.991 PCDHB16;PCDHB16 1.41E+08 5 N_Shore chr5:140563510-140564361
cg17416383 0.5 (0.31, 0.7) 5.06E-06 0.018 0(-0.13,0.12) 9.50E-01 0.993 HEXIM2 43247150 17 Island chr17:43246839-43247167
cg10250651 -0.38 (-0.53, -0.23) 5.07E-06 0.018 0.03(-0.09,0.15) 6.10E-01 0.992 PNN 39644019 14 N_Shore chr14:39644344-39645022
cg23052757 -0.45 (-0.63, -0.27) 5.12E-06 0.018 0.02(-0.13,0.17) 7.75E-01 0.992 C4orf17 1.00E+08 4
cg02959759 -0.77 (-1.06, -0.47) 5.20E-06 0.019 . CACNA1C;CACNA1C;C 2801584 12 S_Shore chr12:2800139-2801062
cg00530298 0.67 (0.41, 0.93) 5.25E-06 0.019 0.09(-0.07,0.25) 2.62E-01 0.967 POLS 6749408 5
cg25282083 0.43 (0.26, 0.6) 5.35E-06 0.019 0.04(-0.07,0.14) 5.04E-01 0.989 BAZ2A 56992955 12
cg16906204 -0.37 (-0.51, -0.22) 5.61E-06 0.019 0.04(-0.09,0.17) 5.58E-01 0.99 HNRNPM;HNRNPM 8509784 19 Island chr19:8509635-8510765
cg13688262 0.34 (0.21, 0.48) 5.62E-06 0.019 0.01(-0.13,0.15) 9.15E-01 0.992 TESK1 35609485 9 S_Shelf chr9:35603968-35605991
cg23824713 0.49 (0.3, 0.68) 5.79E-06 0.02 -0.06(-0.26,0.15) 5.86E-01 0.992 SERPINB5 61157738 18
cg11696986 -0.39 (-0.54, -0.23) 5.89E-06 0.02 0.08(-0.03,0.19) 1.72E-01 0.967 20837778 7 Island chr7:20837551-20838369
cg08210297 0.35 (0.21, 0.49) 5.91E-06 0.02 0.08(-0.02,0.17) 1.18E-01 0.967 ALPI;ALPI 2.33E+08 2 N_Shelf chr2:233323380-233323936
cg26974035 -0.51 (-0.71, -0.31) 6.37E-06 0.021 0.01(-0.1,0.12) 8.52E-01 0.992 LOC727677 1.28E+08 8
cg25550629 0.35 (0.21, 0.48) 6.46E-06 0.021 0.04(-0.06,0.14) 4.52E-01 0.988 53546895 12
cg13656504* 0.29 (0.17, 0.4) 6.50E-06 0.021 0.04(-0.08,0.17) 4.77E-01 0.988 TNXB 32030160 6
cg18581445 -0.33 (-0.46, -0.2) 6.52E-06 0.021 0.04(-0.04,0.13) 3.07E-01 0.967 SHD;SHD 4280054 19 S_Shore chr19:4279042-4279809
cg26618039 0.34 (0.2, 0.47) 6.53E-06 0.021 -0.05(-0.14,0.04) 2.68E-01 0.967 CPNE7;CPNE7 89650531 16 Island chr16:89650417-89650697
cg21364719 0.29 (0.18, 0.41) 6.78E-06 0.021 0.02(-0.13,0.17) 8.12E-01 0.992 ZADH2 72919061 18 N_Shore chr18:72919914-72921785
cg18207109 -0.41 (-0.58, -0.25) 6.81E-06 0.021 -0.06(-0.27,0.14) 5.44E-01 0.99 AIFM2 71889019 10 N_Shelf chr10:71892092-71892802
cg01755562 -0.43 (-0.6, -0.26) 6.84E-06 0.021 0.05(-0.07,0.16) 3.98E-01 0.968 CLSTN2 1.40E+08 3 Island chr3:139653430-139655115
cg13313430* -0.61 (-0.85, -0.37) 6.84E-06 0.021 -0.04(-0.17,0.1) 5.74E-01 0.992 ICA1;ICA1;ICA1 8157910 7
cg12522049 -0.51 (-0.72, -0.31) 6.94E-06 0.021 -0.04(-0.15,0.08) 5.39E-01 0.99 85798898 15 Island chr15:85798738-85798964
cg17884327 -0.39 (-0.54, -0.23) 7.23E-06 0.022 -0.08(-0.34,0.18) 5.44E-01 0.99 1.98E+08 3 Island chr3:197840490-197840783
cg18812904 0.45 (0.27, 0.63) 7.35E-06 0.022 -0.05(-0.16,0.05) 2.97E-01 0.967 77609087 18 Island chr18:77608383-77609118
cg14221748 0.42 (0.25, 0.58) 7.36E-06 0.022 0.07(-0.06,0.21) 2.62E-01 0.967 BAT2L1 1.34E+08 9
cg13365436* -0.39 (-0.55, -0.24) 7.39E-06 0.022 -0.14(-0.33,0.05) 1.37E-01 0.967 AP2A2 968650 11
cg19512961 0.31 (0.19, 0.43) 7.49E-06 0.022 -0.05(-0.16,0.05) 3.30E-01 0.967 GOLGA3 1.33E+08 12 Island chr12:133363184-133363403
cg13853761 0.45 (0.27, 0.63) 7.51E-06 0.022 0(-0.17,0.16) 9.95E-01 0.997 C11orf2 64863232 11 N_Shore chr11:64863698-64863980
cg25291978 0.46 (0.28, 0.64) 7.65E-06 0.022 0.03(-0.06,0.12) 5.19E-01 0.989 PLAGL1;PLAGL1 1.44E+08 6 S_Shore chr6:144384894-144385888
cg05350411 -0.41 (-0.58, -0.25) 7.84E-06 0.023 0.06(-0.05,0.18) 2.78E-01 0.967 569174 4 Island chr4:568513-570488
cg01994750 0.54 (0.33, 0.76) 8.02E-06 0.023 . 95500778 11
cg05282260 0.62 (0.37, 0.87) 8.02E-06 0.023 -0.01(-0.28,0.26) 9.24E-01 0.992 1.57E+08 6
ch.10.756792F -0.51 (-0.72, -0.31) 8.05E-06 0.023 . 29649153 10
cg25910443 -0.51 (-0.71, -0.31) 8.09E-06 0.023 0.04(-0.07,0.16) 4.40E-01 0.983 C9orf3 97488953 9 Island chr9:97488818-97489172
cg08724753 0.36 (0.22, 0.51) 8.16E-06 0.023 -0.02(-0.15,0.1) 7.38E-01 0.992 C6orf103 1.47E+08 6
cg22806341 -0.3 (-0.42, -0.18) 8.23E-06 0.023 0.07(-0.1,0.24) 4.41E-01 0.983 1.30E+08 10 N_Shore chr10:130339526-130339777
cg24615831 -0.33 (-0.46, -0.2) 8.24E-06 0.023 0.12(0,0.24) 5.93E-02 0.843 PTS 1.12E+08 11 Island chr11:112097022-112097547
cg15553408 0.39 (0.23, 0.55) 8.38E-06 0.023 0.07(-0.08,0.21) 3.70E-01 0.968 LTB;LTB 31549010 6 Island chr6:31548436-31549277
cg08214267 0.48 (0.29, 0.67) 8.43E-06 0.023 -0.12(-0.23,-0.01) 3.09E-02 0.719 GPR77 47843887 19
cg05026840 0.72 (0.43, 1.01) 8.46E-06 0.023 -0.07(-0.17,0.03) 1.46E-01 0.967 SCARF1;SCARF1;SCAR 1538656 17 Island chr17:1538415-1538851
cg15998406* -0.55 (-0.78, -0.33) 8.62E-06 0.023 -0.01(-0.29,0.27) 9.42E-01 0.992 EFNA2 1287832 19 Island chr19:1287416-1287885
cg05028274 0.34 (0.2, 0.48) 8.63E-06 0.023 -0.09(-0.2,0.02) 1.08E-01 0.967 71755733 16 N_Shore chr16:71756949-71758166
cg17210546 0.3 (0.18, 0.43) 8.79E-06 0.023 0.06(-0.04,0.16) 2.33E-01 0.967 3122422 19 Island chr19:3122333-3122716
cg12818596 -0.28 (-0.39, -0.17) 8.87E-06 0.023 0.17(0,0.34) 4.77E-02 0.776 61119419 14 S_Shelf chr14:61114102-61116552
cg15863322 0.44 (0.26, 0.62) 8.88E-06 0.023 -0.06(-0.18,0.05) 2.81E-01 0.967 MTUS2 29599410 13
cg07473454 0.3 (0.18, 0.43) 8.93E-06 0.023 0.04(-0.04,0.11) 3.20E-01 0.967 PRAM1 8555526 19 Island chr19:8555436-8555650
cg07826246 0.29 (0.17, 0.4) 9.05E-06 0.023 0.03(-0.06,0.12) 5.03E-01 0.989 1717111 7
cg19594433 0.46 (0.27, 0.65) 9.16E-06 0.023 0.1(-0.02,0.22) 9.85E-02 0.967 SCAMP2 75147064 15
cg05089296 -0.4 (-0.56, -0.24) 9.56E-06 0.024 0.03(-0.11,0.16) 7.11E-01 0.992 81636615 14
cg19973338 0.35 (0.21, 0.49) 9.57E-06 0.024 0.01(-0.07,0.09) 7.30E-01 0.992 C17orf99 76141249 17
cg15940508 -0.37 (-0.52, -0.22) 9.58E-06 0.024 0.14(-0.11,0.39) 2.70E-01 0.967 1.57E+08 6
cg07105117 0.31 (0.18, 0.43) 9.87E-06 0.024 -0.03(-0.17,0.12) 7.07E-01 0.992 UGT1A10;UGT1A6;UGT2.35E+08 2 Island chr2:234652246-234652720
cg24056567 -0.27 (-0.38, -0.16) 9.91E-06 0.024 0.09(-0.05,0.22) 1.92E-01 0.967 PSD3 18871909 8 Island chr8:18871072-18872046
cg12413918* 0.41 (0.24, 0.58) 9.97E-06 0.024 0.07(-0.15,0.29) 5.19E-01 0.989 ERBB2;ERBB2 37855819 17 N_Shore chr17:37856448-37856891
cg12879143 0.39 (0.23, 0.55) 1.00E-05 0.024 0.14(-0.06,0.34) 1.62E-01 0.967 1.39E+08 3 Island chr3:138679244-138679579
cg00725356 -0.33 (-0.46, -0.2) 1.02E-05 0.025 0.17(0.03,0.31) 1.90E-02 0.719 KLF15 1.26E+08 3 Island chr3:126074783-126076865
cg02580045 0.39 (0.23, 0.54) 1.02E-05 0.025 -0.01(-0.12,0.09) 7.85E-01 0.992 ANKRD13A 1.10E+08 12
cg04136781 -0.31 (-0.44, -0.19) 1.04E-05 0.025 0.01(-0.11,0.13) 8.72E-01 0.992 PPT2;PPT2 32129786 6
cg13968717 0.43 (0.26, 0.61) 1.04E-05 0.025 -0.04(-0.14,0.06) 4.46E-01 0.987 CDYL;CDYL;CDYL;CD 4954232 6
cg21424664 0.38 (0.23, 0.54) 1.05E-05 0.025 0.01(-0.1,0.11) 9.00E-01 0.992 CHCHD2 56174299 7 Island chr7:56173912-56174398
cg24138528 -0.48 (-0.67, -0.28) 1.07E-05 0.025 -0.02(-0.17,0.13) 8.13E-01 0.992 1.42E+08 6
cg00782839 -0.5 (-0.7, -0.29) 1.08E-05 0.025 0.02(-0.17,0.22) 8.27E-01 0.992 8816130 2 N_Shore chr2:8816314-8817264
cg05948856 0.42 (0.25, 0.59) 1.08E-05 0.025 -0.08(-0.24,0.07) 2.95E-01 0.967 EEF2;SNORD37 3982825 19 Island chr19:3982824-3983190
cg14181982 -0.89 (-1.25, -0.52) 1.08E-05 0.025 0(-0.14,0.14) 9.84E-01 0.997 KLRAQ1;KLRAQ1;KLR 48668251 2 Island chr2:48667559-48668355
cg09896346 -0.37 (-0.53, -0.22) 1.12E-05 0.026 0.14(-0.01,0.29) 6.71E-02 0.893 TCEA3;TCEA3 23751195 1 Island chr1:23750508-23751663
cg16435686 1.72 (1.01, 2.42) 1.14E-05 0.026 0.05(-1.03,1.14) 9.21E-01 0.992 47964834 10 N_Shelf chr10:47967314-47967636
cg18033436 -0.56 (-0.79, -0.33) 1.14E-05 0.026 -0.05(-0.17,0.08) 4.76E-01 0.988 1.03E+08 10 Island chr10:102982302-102983600
cg26139606 0.32 (0.19, 0.45) 1.14E-05 0.026 -0.12(-0.25,0) 5.89E-02 0.843 44990002 13
cg18793198 -0.41 (-0.58, -0.24) 1.15E-05 0.026 0.05(-0.07,0.18) 4.11E-01 0.968 1.31E+08 12 S_Shore chr12:131389263-131389783
cg04881214* -0.57 (-0.81, -0.34) 1.16E-05 0.026 -0.03(-0.18,0.11) 6.47E-01 0.992 PPM1B;PPM1B;PPM1B; 44395864 2 Island chr2:44394983-44396629
cg19768241 -0.34 (-0.47, -0.2) 1.17E-05 0.026 0.05(-0.12,0.23) 5.58E-01 0.99 CALCB 15095070 11 Island chr11:15094957-15095872
cg09343421 0.3 (0.17, 0.42) 1.20E-05 0.026 0.03(-0.05,0.1) 4.77E-01 0.988 SRRT;SRRT;SRRT;SRR 1.00E+08 7 N_Shore chr7:100484425-100484651
cg15355967 0.29 (0.17, 0.41) 1.21E-05 0.026 0(-0.08,0.08) 9.47E-01 0.993 3697542 2 N_Shore chr2:3698659-3698875
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cg17048169* 0.39 (0.23, 0.54) 1.21E-05 0.026 0.13(0,0.26) 5.31E-02 0.815 NGEF;NGEF 2.34E+08 2 S_Shelf chr2:233740668-233741879
cg25793785 0.27 (0.16, 0.38) 1.21E-05 0.026 0.16(-0.08,0.41) 1.93E-01 0.967 38281423 19 Island chr19:38281090-38281424
cg09239064 0.31 (0.19, 0.44) 1.22E-05 0.026 -0.09(-0.24,0.05) 1.93E-01 0.967 C16orf81 89229439 16 N_Shelf chr16:89232410-89232683
cg14700965 0.55 (0.33, 0.78) 1.24E-05 0.026 . 1.09E+08 8 N_Shelf chr8:109455600-109456263
cg13024668 0.4 (0.23, 0.56) 1.25E-05 0.026 0.01(-0.11,0.13) 8.76E-01 0.992 1.89E+08 2
cg15136797 -0.41 (-0.57, -0.24) 1.25E-05 0.026 0.06(-0.08,0.19) 4.14E-01 0.968 RNF103 86851071 2 Island chr2:86850042-86851178
cg15179472 0.32 (0.19, 0.46) 1.25E-05 0.026 0.09(-0.04,0.21) 1.66E-01 0.967 70736858 15
cg27183188 0.54 (0.32, 0.76) 1.25E-05 0.026 0.06(-0.06,0.18) 3.53E-01 0.968 ALDOC 26904121 17
cg06167730 -0.37 (-0.52, -0.22) 1.26E-05 0.026 -0.08(-0.24,0.08) 3.11E-01 0.967 991533 8 Island chr8:991532-991862
cg20995172 0.31 (0.18, 0.43) 1.26E-05 0.026 -0.04(-0.13,0.05) 3.67E-01 0.968 C6orf47 31627225 6 N_Shore chr6:31628338-31628658
cg08582720 0.31 (0.19, 0.44) 1.27E-05 0.026 0.1(0,0.2) 5.11E-02 0.808 PLTP;PLTP 44538611 20 N_Shore chr20:44539729-44540099
cg20548564 0.47 (0.28, 0.67) 1.30E-05 0.026 -0.04(-0.2,0.12) 6.50E-01 0.992 POLR1D 28240073 13
cg25463742 0.51 (0.3, 0.73) 1.30E-05 0.026 0.01(-0.12,0.14) 8.54E-01 0.992 CASZ1;CASZ1 10839574 1
cg22938488 0.33 (0.19, 0.46) 1.31E-05 0.026 -0.01(-0.11,0.08) 7.73E-01 0.992 LPCAT1 1501670 5
cg24120847 -0.44 (-0.62, -0.26) 1.31E-05 0.026 0.07(-0.05,0.19) 2.49E-01 0.967 DERL3;DERL3;DERL3 24181562 22 Island chr22:24180491-24181666
cg27150870 0.38 (0.23, 0.54) 1.31E-05 0.026 -0.09(-0.29,0.11) 3.72E-01 0.968 ANKRD11 89390609 16
cg14894369 0.3 (0.18, 0.43) 1.32E-05 0.026 0.01(-0.19,0.2) 9.55E-01 0.993 DIABLO;DIABLO;DIAB 1.23E+08 12 N_Shore chr12:122710054-122711371
cg14933246 -0.43 (-0.61, -0.25) 1.33E-05 0.026 0(-0.14,0.14) 9.89E-01 0.997 PHF11;PHF11 50091767 13
cg21218636 -0.37 (-0.52, -0.22) 1.33E-05 0.026 0.07(-0.08,0.22) 3.41E-01 0.967 PCTP;PCTP;PCTP 53828515 17 Island chr17:53828422-53828738
cg10439725 0.34 (0.2, 0.48) 1.35E-05 0.026 0.09(0,0.17) 3.91E-02 0.72 ZDHHC1 67431954 16 N_Shore chr16:67433128-67433554
cg04086977 0.34 (0.2, 0.48) 1.36E-05 0.027 0.02(-0.09,0.12) 7.53E-01 0.992 1.35E+08 10 N_Shore chr10:134830984-134832209
cg13713537* -0.44 (-0.62, -0.26) 1.36E-05 0.027 -0.07(-0.19,0.06) 2.79E-01 0.967 NOS1 1.18E+08 12
cg07283896 -0.41 (-0.57, -0.24) 1.37E-05 0.027 -0.06(-0.26,0.14) 5.28E-01 0.989 11855283 6
cg21959334 0.37 (0.21, 0.52) 1.39E-05 0.027 -0.06(-0.17,0.04) 2.50E-01 0.967 2.29E+08 1 N_Shelf chr1:228582428-228582894
cg10847390 0.34 (0.2, 0.48) 1.41E-05 0.027 -0.01(-0.1,0.09) 9.09E-01 0.992 1.35E+08 10
cg05701403 -0.37 (-0.52, -0.22) 1.44E-05 0.027 0.11(-0.1,0.31) 3.15E-01 0.967 PLEKHA7 16947551 11 S_Shore chr11:16946392-16947398
cg08943361 0.48 (0.28, 0.67) 1.44E-05 0.027 0.02(-0.11,0.16) 7.66E-01 0.992 56462172 16 S_Shelf chr16:56458735-56459748
cg24120960 0.44 (0.26, 0.62) 1.48E-05 0.028 . STAG1 1.36E+08 3
cg13078140* -0.48 (-0.68, -0.28) 1.49E-05 0.028 -0.07(-0.2,0.06) 3.19E-01 0.967 SLIT2 20255082 4 Island chr4:20253276-20256868
cg13467672 -0.36 (-0.51, -0.21) 1.49E-05 0.028 0.09(-0.03,0.2) 1.26E-01 0.967 40464625 17 Island chr17:40464293-40464947
cg25692835 0.49 (0.28, 0.69) 1.52E-05 0.028 0.1(-0.01,0.22) 7.21E-02 0.893 C2orf64;UNC50;C2orf64 99224894 2 Island chr2:99224681-99225322
cg27023871 0.7 (0.41, 0.99) 1.55E-05 0.029 -0.02(-0.19,0.15) 8.13E-01 0.992 TBCD 80848259 17
cg04446345 -0.32 (-0.45, -0.19) 1.56E-05 0.029 0.05(-0.06,0.16) 3.52E-01 0.968 UPK3A;UPK3A 45680844 22 Island chr22:45680644-45681016
cg17619347 0.47 (0.27, 0.66) 1.56E-05 0.029 -0.01(-0.11,0.08) 7.95E-01 0.992 SRRT;SRRT;SRRT;SRR 1.00E+08 7
cg04903360* -0.35 (-0.49, -0.2) 1.58E-05 0.029 -0.04(-0.18,0.09) 5.17E-01 0.989 PARD3 35103065 10 N_Shore chr10:35103124-35105243
cg18514573 -0.47 (-0.67, -0.27) 1.58E-05 0.029 0.1(-0.11,0.31) 3.54E-01 0.968 21610423 6
cg21412973 -0.26 (-0.36, -0.15) 1.58E-05 0.029 0.04(-0.12,0.21) 6.03E-01 0.992 1408557 4 Island chr4:1408521-1409224
cg11852843 0.29 (0.17, 0.4) 1.59E-05 0.029 0(-0.12,0.12) 9.63E-01 0.993 OBSCN;OBSCN 2.28E+08 1 N_Shore chr1:228473835-228474043
cg14582248 0.39 (0.23, 0.56) 1.59E-05 0.029 0(-0.1,0.1) 9.71E-01 0.995 5066984 6
cg21801445 -0.35 (-0.49, -0.2) 1.62E-05 0.029 -0.09(-0.19,0.02) 9.84E-02 0.967 13213606 18 N_Shelf chr18:13217073-13219044
cg05658707 0.44 (0.25, 0.62) 1.63E-05 0.029 0.03(-0.18,0.23) 7.97E-01 0.992 VGLL4 11722129 3
cg09230014 0.39 (0.23, 0.55) 1.65E-05 0.029 -0.01(-0.18,0.16) 8.97E-01 0.992 PTPRN2;PTPRN2;PTPR 1.58E+08 7
cg19774624 -0.67 (-0.95, -0.39) 1.66E-05 0.029 . HDAC5;HDAC5 42201019 17 Island chr17:42200521-42201543
cg22510637 0.36 (0.21, 0.51) 1.66E-05 0.029 -0.02(-0.13,0.09) 7.02E-01 0.992 R3HCC1 23147025 8 S_Shore chr8:23145528-23146006
cg02503850 -0.26 (-0.37, -0.15) 1.67E-05 0.029 0.13(-0.02,0.27) 9.15E-02 0.967 ADAMTS14;ADAMTS1 72432552 10 Island chr10:72432242-72432738
cg15192041 0.33 (0.19, 0.47) 1.69E-05 0.029 -0.02(-0.16,0.11) 7.27E-01 0.992 69414923 11
cg01538575 0.29 (0.17, 0.41) 1.71E-05 0.029 0(-0.08,0.09) 9.16E-01 0.992 RFX2;RFX2 6039991 19 Island chr19:6039990-6040228
cg00961792 0.26 (0.15, 0.37) 1.72E-05 0.029 0.01(-0.05,0.07) 7.62E-01 0.992 PIGR 2.07E+08 1
cg02808220 0.41 (0.24, 0.58) 1.72E-05 0.029 -0.03(-0.14,0.08) 5.94E-01 0.992 MIR483;INS-IGF2;IGF2 2156282 11 S_Shore chr11:2154033-2154387
cg07247103 0.31 (0.18, 0.44) 1.72E-05 0.029 0.04(-0.05,0.12) 4.06E-01 0.968 BANP;BANP 88059817 16 N_Shore chr16:88061122-88061595
cg10473311* -0.64 (-0.91, -0.37) 1.72E-05 0.029 -0.34(-0.6,-0.08) 1.19E-02 0.719 PTPRN2;PTPRN2;PTPR 1.58E+08 7
cg16256065 0.35 (0.2, 0.5) 1.72E-05 0.029 0(-0.11,0.11) 9.99E-01 0.999 LRP5 68216328 11 Island chr11:68216289-68216547
cg01563959 0.4 (0.23, 0.57) 1.73E-05 0.029 -0.03(-0.14,0.08) 5.91E-01 0.992 CYTSB;CYTSB 20014025 17
cg01791874 -0.58 (-0.82, -0.33) 1.74E-05 0.029 -0.02(-0.11,0.07) 6.88E-01 0.992 11-Mar 16180055 5 Island chr5:16179064-16180420
cg25941154 0.33 (0.19, 0.47) 1.74E-05 0.029 0(-0.14,0.14) 9.95E-01 0.997 JAZF1 28208557 7
cg01646289 0.43 (0.25, 0.61) 1.76E-05 0.029 0.06(-0.06,0.18) 3.35E-01 0.967 1.35E+08 10 Island chr10:134732601-134733777
cg14757492 0.29 (0.17, 0.41) 1.76E-05 0.029 -0.05(-0.15,0.05) 3.19E-01 0.967 COPE;DDX49;COPE;CO19029194 19 N_Shore chr19:19029924-19030653
cg20897072 0.54 (0.32, 0.77) 1.76E-05 0.029 0.1(-0.05,0.24) 1.88E-01 0.967 1495082 6
cg14256983 0.38 (0.22, 0.53) 1.77E-05 0.029 0(-0.17,0.16) 9.59E-01 0.993 C9orf102 98639872 9 S_Shore chr9:98637245-98638445
cg24309215 0.31 (0.18, 0.45) 1.77E-05 0.029 0.04(-0.14,0.21) 6.83E-01 0.992 1.21E+08 12 N_Shore chr12:121022419-121022704
cg26286098 0.56 (0.32, 0.8) 1.77E-05 0.029 . B3GALTL 31905755 13
cg16750440 -0.58 (-0.82, -0.33) 1.80E-05 0.029 0.06(-0.14,0.26) 5.68E-01 0.991 C10orf79 1.06E+08 10 S_Shore chr10:105991899-105992248
cg26876637 0.35 (0.2, 0.5) 1.82E-05 0.029 -0.14(-0.25,-0.02) 2.13E-02 0.719 HRNR 1.52E+08 1
cg02607130* 0.47 (0.27, 0.67) 1.83E-05 0.029 0.05(-0.1,0.21) 5.02E-01 0.989 GRIN3B 1008643 19 Island chr19:1007551-1012222
cg04756597 0.31 (0.18, 0.44) 1.84E-05 0.029 0.04(-0.05,0.14) 3.67E-01 0.968 44730607 22 S_Shelf chr22:44726724-44727590
cg23911291* 0.31 (0.18, 0.45) 1.87E-05 0.03 0.05(-0.07,0.18) 3.85E-01 0.968 DAXX;DAXX;DAXX;D 33288572 6 N_Shore chr6:33288733-33289008
cg26266708 -0.57 (-0.81, -0.33) 1.89E-05 0.03 . ISL2 76630962 15 Island chr15:76630029-76630970
cg05567435 0.37 (0.21, 0.53) 1.92E-05 0.03 -0.02(-0.18,0.13) 7.75E-01 0.992 METTL7B 56074329 12
cg18594551 0.31 (0.18, 0.44) 1.95E-05 0.031 0.06(-0.03,0.15) 2.11E-01 0.967 KRTAP23-1 31720835 21
cg12384572 0.4 (0.23, 0.57) 1.98E-05 0.031 0.03(-0.08,0.14) 5.61E-01 0.99 USP4;USP4 49377951 3 S_Shore chr3:49377340-49377854
cg13116816 0.41 (0.24, 0.59) 2.00E-05 0.031 0.13(-0.25,0.51) 4.88E-01 0.988 C7orf23 86839071 7
cg02305765 -0.6 (-0.85, -0.35) 2.01E-05 0.031 -0.05(-0.24,0.13) 5.59E-01 0.99 53107910 12 N_Shore chr12:53107912-53108471
cg25994616 -0.54 (-0.76, -0.31) 2.01E-05 0.031 -0.03(-0.15,0.09) 6.18E-01 0.992 NOTCH4 32166739 6 S_Shelf chr6:32163292-32164383
cg18523886 0.31 (0.18, 0.45) 2.02E-05 0.031 -0.09(-0.26,0.08) 3.02E-01 0.967 39126551 20
cg02399294 0.28 (0.16, 0.4) 2.03E-05 0.031 0.01(-0.14,0.15) 8.98E-01 0.992 CCDC40 78063763 17
cg04432454 -0.45 (-0.64, -0.26) 2.03E-05 0.031 -0.05(-0.19,0.09) 5.00E-01 0.989 LMF1 949229 16 N_Shore chr16:949658-949960
cg26721877 -0.35 (-0.49, -0.2) 2.03E-05 0.031 0.06(-0.11,0.22) 5.09E-01 0.989 STC2 1.73E+08 5 Island chr5:172754056-172757098
cg04299274 0.35 (0.2, 0.5) 2.05E-05 0.031 0.01(-0.07,0.1) 7.36E-01 0.992 KSR1 25798741 17
cg08854799 0.33 (0.19, 0.47) 2.08E-05 0.031 0.02(-0.11,0.15) 7.54E-01 0.992 FAM83E 49107139 19 Island chr19:49106882-49107178
cg06505394 -0.72 (-1.02, -0.41) 2.09E-05 0.031 -0.04(-0.26,0.18) 7.04E-01 0.992 HNRNPUL1;HNRNPUL 41771095 19 Island chr19:41770013-41771113
cg09244071 0.32 (0.18, 0.46) 2.10E-05 0.031 0.05(-0.05,0.15) 2.96E-01 0.967 CUX1;CUX1;CUX1 1.02E+08 7
cg23077029 -0.23 (-0.32, -0.13) 2.11E-05 0.031 0.09(-0.01,0.19) 7.75E-02 0.893 1.08E+08 6 N_Shore chr6:107810066-107812733
cg12640770 0.42 (0.24, 0.6) 2.13E-05 0.031 0.13(-0.04,0.29) 1.46E-01 0.967 IRAK1BP1 79577691 6 Island chr6:79577158-79577756
cg06988897 -0.57 (-0.81, -0.33) 2.14E-05 0.031 -0.06(-0.44,0.32) 7.39E-01 0.992 FAM38A 88803803 16 Island chr16:88803802-88804112
cg07281948 0.47 (0.27, 0.67) 2.14E-05 0.031 -0.08(-0.21,0.05) 2.14E-01 0.967 LRP1 57601935 12
cg10905310 -0.52 (-0.74, -0.3) 2.14E-05 0.031 0.03(-0.09,0.15) 6.15E-01 0.992 GDPD5 75236908 11 Island chr11:75236189-75237781
cg00513411 -0.5 (-0.72, -0.29) 2.17E-05 0.032 0.01(-0.09,0.11) 8.21E-01 0.992 21586262 6 N_Shore chr6:21587421-21589175
cg08495545 0.36 (0.21, 0.51) 2.18E-05 0.032 -0.01(-0.11,0.08) 7.69E-01 0.992 76965309 17
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cg16034168 -0.62 (-0.88, -0.35) 2.18E-05 0.032 0.06(-0.07,0.19) 3.82E-01 0.968 ACOT7;ACOT7;ACOT7 6336711 1 N_Shelf chr1:6339948-6340268
cg13437525 -0.5 (-0.71, -0.29) 2.20E-05 0.032 0.21(0.08,0.35) 2.47E-03 0.493 METTL7A 51318487 12
cg04635504 0.26 (0.15, 0.37) 2.21E-05 0.032 0.05(-0.08,0.19) 4.21E-01 0.968 KCNQ1;KCNQ1 2829241 11 S_Shore chr11:2828445-2828884
cg15202954 -0.39 (-0.56, -0.23) 2.21E-05 0.032 . NALCN 1.02E+08 13 Island chr13:102068116-102069258
cg05533124 -0.5 (-0.71, -0.28) 2.22E-05 0.032 0.03(-0.13,0.2) 6.90E-01 0.992 AQP4;AQP4 24443298 18 Island chr18:24443200-24443458
cg24194674 0.89 (0.51, 1.27) 2.22E-05 0.032 -0.04(-0.22,0.14) 6.63E-01 0.992 ADAM12;ADAM12 1.28E+08 10
cg08839808 0.77 (0.44, 1.1) 2.25E-05 0.032 -0.08(-0.43,0.26) 6.28E-01 0.992 1.57E+08 6
cg14948795 0.3 (0.17, 0.43) 2.25E-05 0.032 -0.12(-0.21,-0.02) 1.41E-02 0.719 CDK2AP1 1.24E+08 12 S_Shore chr12:123755246-123756408
cg05655247 0.41 (0.24, 0.59) 2.26E-05 0.032 0.01(-0.1,0.12) 8.72E-01 0.992 1065028 1
cg14641600 0.27 (0.16, 0.39) 2.26E-05 0.032 -0.04(-0.14,0.05) 3.72E-01 0.968 TCF7;TCF7;TCF7;TCF7 1.33E+08 5
cg26773771 -0.72 (-1.03, -0.41) 2.26E-05 0.032 -0.01(-0.14,0.12) 9.16E-01 0.992 21830857 17
cg07138793 0.52 (0.3, 0.75) 2.28E-05 0.032 -0.12(-0.34,0.11) 2.99E-01 0.967 OCA2 28148330 15 Island chr15:28147925-28148465
cg11841231 0.35 (0.2, 0.5) 2.29E-05 0.032 -0.2(-0.39,-0.01) 3.67E-02 0.719 PARD3B;PARD3B;PARD2.06E+08 2
cg26577201 -0.43 (-0.61, -0.25) 2.29E-05 0.032 -0.01(-0.15,0.14) 9.24E-01 0.992 CRYBA2;CRYBA2;CRY 2.20E+08 2 Island chr2:219857682-219858917
cg10729426 -0.57 (-0.81, -0.33) 2.37E-05 0.033 -0.14(-0.3,0.02) 7.75E-02 0.893 ZNF549 58038585 19 Island chr19:58038572-58039208
cg18527919 0.42 (0.24, 0.61) 2.37E-05 0.033 0.05(-0.12,0.22) 5.63E-01 0.99 C2orf84 24398170 2 Island chr2:24397645-24398194
cg15334916 0.38 (0.22, 0.54) 2.40E-05 0.033 0.06(-0.09,0.2) 4.35E-01 0.982 COL13A1;COL13A1;CO 71563776 10 S_Shore chr10:71561302-71562876
cg27583604 0.32 (0.19, 0.46) 2.41E-05 0.033 0.07(-0.03,0.17) 1.58E-01 0.967 PLK3 45267345 1 S_Shore chr1:45265534-45266783
cg15191798 -0.59 (-0.85, -0.34) 2.42E-05 0.033 -0.01(-0.22,0.19) 8.88E-01 0.992 LRRC49;THAP10;THAP 71184618 15 Island chr15:71184276-71184689
cg15979150 -0.37 (-0.52, -0.21) 2.43E-05 0.033 . FAM164C;FAM164C 75535757 14 N_Shore chr14:75535825-75536376
cg07894883 0.3 (0.17, 0.43) 2.44E-05 0.033 0.1(-0.03,0.22) 1.30E-01 0.967 ZCCHC24 81146877 10 S_Shore chr10:81145958-81146197
cg22551163 0.54 (0.31, 0.77) 2.45E-05 0.033 -0.01(-0.17,0.15) 9.12E-01 0.992 SFRS8 1.32E+08 12
cg05071046 -0.3 (-0.43, -0.17) 2.46E-05 0.033 0.08(-0.01,0.18) 8.95E-02 0.967 54325583 16 Island chr16:54325040-54325703
cg21849812 0.34 (0.19, 0.49) 2.48E-05 0.033 -0.05(-0.18,0.08) 4.43E-01 0.984 17848522 1
cg05890620 -0.43 (-0.61, -0.24) 2.49E-05 0.033 0.04(-0.06,0.14) 4.14E-01 0.968 ICAM4;ICAM4;ICAM4 10397612 19 Island chr19:10397603-10398703
cg10255761 0.35 (0.2, 0.5) 2.49E-05 0.033 -0.03(-0.15,0.08) 5.39E-01 0.99 KLHDC8B 49210029 3 S_Shore chr3:49208629-49209196
cg06962768 0.37 (0.21, 0.52) 2.51E-05 0.033 0.12(-0.02,0.27) 1.03E-01 0.967 EPDR1 37959782 7 N_Shore chr7:37960316-37961046
cg17702455 1.22 (0.69, 1.74) 2.53E-05 0.033 -0.04(-0.23,0.15) 6.73E-01 0.992 JAZF1 28058989 7
cg11160944 -0.67 (-0.95, -0.38) 2.54E-05 0.033 0.14(0.02,0.26) 2.05E-02 0.719 45570048 17 Island chr17:45569833-45570134
cg12424468 0.39 (0.22, 0.56) 2.55E-05 0.033 -0.05(-0.19,0.09) 4.66E-01 0.988 C11orf2 64863373 11 N_Shore chr11:64863698-64863980
cg10419849 -0.35 (-0.5, -0.2) 2.57E-05 0.033 0.04(-0.08,0.17) 4.81E-01 0.988 TNKS 9537322 8
cg21578322 -0.52 (-0.75, -0.3) 2.57E-05 0.033 0.03(-0.08,0.14) 5.55E-01 0.99 TTLL9;DUSP15;DUSP1 30458044 20 Island chr20:30457907-30458712
cg21211873* 0.35 (0.2, 0.5) 2.58E-05 0.033 0.03(-0.06,0.13) 4.87E-01 0.988 CYFIP1;CYFIP1 22960638 15
cg25373579 0.27 (0.15, 0.38) 2.58E-05 0.033 -0.01(-0.08,0.06) 8.10E-01 0.992 VEGFA;VEGFA;VEGFA43752302 6
cg07015927 0.3 (0.17, 0.42) 2.59E-05 0.033 0.01(-0.14,0.17) 8.57E-01 0.992 DSCR8;DSCR8;DSCR8;D39493537 21
cg19490868 -0.28 (-0.4, -0.16) 2.59E-05 0.033 0.05(-0.09,0.2) 4.86E-01 0.988 RTN1;RTN1;RTN1 60097124 14 N_Shore chr14:60097208-60097553
cg05422836 -0.42 (-0.61, -0.24) 2.61E-05 0.033 0.06(-0.14,0.26) 5.48E-01 0.99 81806286 8 Island chr8:81805955-81806327
cg09544549* 0.32 (0.18, 0.45) 2.63E-05 0.033 0.07(-0.05,0.2) 2.31E-01 0.967 MYH9 36697013 22
cg10927727 0.34 (0.19, 0.48) 2.63E-05 0.033 0.03(-0.1,0.16) 6.06E-01 0.992 1.31E+08 2 Island chr2:130986131-130987183
cg17542795 -0.53 (-0.75, -0.3) 2.65E-05 0.034 . 1.79E+08 4
cg07329149 -0.55 (-0.78, -0.31) 2.69E-05 0.034 0.04(-0.06,0.15) 4.31E-01 0.98 NDUFB3;FAM126B 2.02E+08 2 Island chr2:201936024-201936376
cg22488462 0.3 (0.17, 0.42) 2.70E-05 0.034 -0.11(-0.27,0.05) 1.85E-01 0.967 CARS2 1.11E+08 13
cg14106345 0.43 (0.24, 0.61) 2.71E-05 0.034 0.07(-0.07,0.2) 3.24E-01 0.967 RNF112 19317240 17
cg04496485 -0.37 (-0.53, -0.21) 2.74E-05 0.034 -0.05(-0.21,0.12) 5.64E-01 0.99 714565 1 S_Shore chr1:713984-714547
cg16184346 0.35 (0.2, 0.5) 2.74E-05 0.034 -0.08(-0.26,0.1) 3.95E-01 0.968 PLEKHB1;PLEKHB1;PL 73367968 11 N_Shelf chr11:73371800-73372632
cg08458852 0.63 (0.36, 0.9) 2.79E-05 0.035 0.11(-0.05,0.26) 1.68E-01 0.967 PARN;PARN 14529837 16
cg00280177 0.45 (0.26, 0.65) 2.81E-05 0.035 . 24799870 8 Island chr8:24799703-24800147
cg06700226 0.36 (0.21, 0.52) 2.81E-05 0.035 -0.02(-0.13,0.09) 7.55E-01 0.992 5198019 12
cg14295458 0.39 (0.22, 0.55) 2.81E-05 0.035 0.08(-0.09,0.25) 3.38E-01 0.967 OSBPL7 45891164 17 Island chr17:45890956-45891165
cg26748794 -1 (-1.43, -0.57) 2.83E-05 0.035 -0.4(-1.34,0.53) 3.97E-01 0.968 FAM38A 88804051 16 Island chr16:88803802-88804112
cg05055490 0.37 (0.21, 0.53) 2.85E-05 0.035 -0.02(-0.16,0.12) 7.45E-01 0.992 26284602 7
cg06219206 -0.46 (-0.66, -0.26) 2.86E-05 0.035 0.05(-0.06,0.16) 3.99E-01 0.968 SOX5 24383177 12
cg19149031 0.51 (0.29, 0.73) 2.86E-05 0.035 -0.15(-0.51,0.21) 4.02E-01 0.968 SLC22A3 1.61E+08 6 Island chr6:160783666-160784135
cg20908131 -0.6 (-0.87, -0.34) 2.86E-05 0.035 0.08(-0.07,0.24) 2.79E-01 0.967 C14orf64 98419775 14
cg24994360 0.3 (0.17, 0.44) 2.90E-05 0.035 0.01(-0.11,0.14) 8.06E-01 0.992 2.42E+08 2
cg21391023 0.48 (0.27, 0.69) 2.91E-05 0.035 0.11(-0.05,0.28) 1.68E-01 0.967 BTBD8 92545580 1 N_Shore chr1:92545819-92546480
cg08800878 -0.28 (-0.41, -0.16) 2.92E-05 0.035 0.01(-0.12,0.15) 8.76E-01 0.992 EMX1 73152809 2 S_Shore chr2:73151200-73152060
cg24724630 -0.32 (-0.45, -0.18) 2.92E-05 0.035 0.01(-0.11,0.14) 8.33E-01 0.992 NRG2;NRG2;NRG2;NRG1.39E+08 5
cg09173861 0.35 (0.2, 0.5) 2.93E-05 0.035 0.01(-0.12,0.14) 8.65E-01 0.992 SYT17 19180212 16 Island chr16:19179002-19180217
cg18333694 0.27 (0.15, 0.39) 2.95E-05 0.035 -0.02(-0.1,0.05) 5.39E-01 0.99 357882 11 S_Shore chr11:355947-356447
cg06187356 -0.37 (-0.53, -0.21) 2.96E-05 0.035 0(-0.13,0.12) 9.59E-01 0.993 NPBWR2 62738210 20 S_Shore chr20:62737382-62738071
cg08845333 -0.3 (-0.43, -0.17) 2.96E-05 0.035 0.09(-0.02,0.19) 1.08E-01 0.967 ICAM5 10403403 19 Island chr19:10399844-10405375
cg11058229 0.32 (0.18, 0.45) 3.00E-05 0.035 -0.01(-0.08,0.07) 8.63E-01 0.992 97089082 14
cg21514227 -0.33 (-0.47, -0.18) 3.00E-05 0.035 0.04(-0.11,0.19) 5.94E-01 0.992 NOTCH3 15288315 19 Island chr19:15288314-15288911
cg24206697 -0.49 (-0.71, -0.28) 3.00E-05 0.035 0.01(-0.09,0.1) 8.96E-01 0.992 ZNF514 95822125 2 N_Shelf chr2:95824802-95825721
cg05041061 0.5 (0.28, 0.72) 3.04E-05 0.035 -0.02(-0.23,0.19) 8.70E-01 0.992 BAHCC1 79426049 17 Island chr17:79425847-79426169
cg13045351 0.69 (0.39, 0.99) 3.05E-05 0.035 . ZSCAN16 28092048 6
cg16120811 -0.28 (-0.4, -0.16) 3.07E-05 0.036 0.05(-0.11,0.22) 5.31E-01 0.989 WEE1 9594484 11 Island chr11:9594346-9596536
cg04594483 0.35 (0.2, 0.51) 3.10E-05 0.036 0.05(-0.09,0.2) 4.52E-01 0.988 RADIL 4862020 7
cg21885134 0.3 (0.17, 0.43) 3.10E-05 0.036 -0.06(-0.15,0.04) 2.22E-01 0.967 1794994 5
cg26076233 2.71 (1.53, 3.9) 3.12E-05 0.036 . DYNLL1 1.21E+08 12 N_Shelf chr12:120933649-120934713
cg14431547 0.32 (0.18, 0.46) 3.14E-05 0.036 0.11(-0.1,0.32) 2.89E-01 0.967 MELK 36572421 9 N_Shore chr9:36572703-36573073
cg07759052 -0.54 (-0.77, -0.3) 3.16E-05 0.036 -0.02(-0.16,0.13) 8.37E-01 0.992 HMBOX1;HMBOX1 28752150 8 S_Shelf chr8:28748070-28748431
cg05229340 0.38 (0.22, 0.55) 3.21E-05 0.037 . CCDC46 63833529 17
cg13923018 -0.33 (-0.48, -0.19) 3.22E-05 0.037 0.09(-0.03,0.21) 1.24E-01 0.967 PDZD2 31855380 5 Island chr5:31855003-31855426
cg22454769 -0.41 (-0.59, -0.23) 3.24E-05 0.037 -0.18(-0.37,0.01) 6.10E-02 0.843 FHL2;FHL2;FHL2;FHL2 1.06E+08 2 Island chr2:106014878-106015884
cg22647900 0.36 (0.2, 0.51) 3.24E-05 0.037 -0.06(-0.18,0.05) 2.68E-01 0.967 EIF3M 32604844 11 N_Shore chr11:32605183-32605729
cg14122138 -0.58 (-0.83, -0.33) 3.25E-05 0.037 0(-0.16,0.16) 9.80E-01 0.997 SRCIN1 36719737 17 Island chr17:36719544-36719938
cg03097134 0.33 (0.18, 0.47) 3.26E-05 0.037 -0.08(-0.18,0.03) 1.47E-01 0.967 37598264 6
cg01602153 0.53 (0.3, 0.77) 3.27E-05 0.037 0.11(-0.04,0.26) 1.55E-01 0.967 FAM110B 59058660 8 Island chr8:59058167-59059414
cg12837905 0.36 (0.2, 0.52) 3.32E-05 0.037 -0.03(-0.15,0.09) 5.84E-01 0.992 1.32E+08 10 N_Shore chr10:131813042-131813277
cg21204804 -0.41 (-0.59, -0.23) 3.32E-05 0.037 0.15(0.03,0.28) 1.92E-02 0.719 8290321 11 Island chr11:8289532-8290322
cg17377797 0.35 (0.2, 0.51) 3.33E-05 0.037 0.09(-0.1,0.27) 3.42E-01 0.967 OR6C1 55714289 12
cg06954677 -0.37 (-0.53, -0.21) 3.35E-05 0.037 -0.03(-0.15,0.1) 6.74E-01 0.992 IDO2 39873708 8
cg06467181 -0.42 (-0.6, -0.23) 3.37E-05 0.037 0.03(-0.12,0.17) 7.00E-01 0.992 ZCCHC2 60191671 18 Island chr18:60189509-60192109
cg11860412 -0.25 (-0.36, -0.14) 3.37E-05 0.037 0.02(-0.09,0.14) 6.77E-01 0.992 ONECUT3 1753217 19 Island chr19:1753216-1755606
cg24592500 0.72 (0.4, 1.04) 3.39E-05 0.037 0.02(-0.13,0.17) 7.88E-01 0.992 2863801 1
cg25142228 0.22 (0.12, 0.31) 3.42E-05 0.037 -0.04(-0.12,0.05) 3.85E-01 0.968 SETD1B 1.22E+08 12 N_Shore chr12:122247781-122248424
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cg09822423 -0.42 (-0.61, -0.24) 3.43E-05 0.037 . 1.93E+08 1
cg24349819 -0.34 (-0.49, -0.19) 3.43E-05 0.037 -0.05(-0.19,0.09) 4.73E-01 0.988 ARHGAP27;ARHGAP27 43476547 17 S_Shelf chr17:43472527-43474343
cg20989855 -0.37 (-0.53, -0.21) 3.45E-05 0.037 -0.09(-0.31,0.12) 3.86E-01 0.968 KCNIP4;KCNIP4;KCNIP20985927 4
cg11776115* 0.32 (0.18, 0.46) 3.47E-05 0.037 0.04(-0.05,0.14) 3.36E-01 0.967 DOT1L 2189267 19 N_Shore chr19:2190989-2191262
cg05479662 0.35 (0.19, 0.5) 3.48E-05 0.037 0.05(-0.08,0.18) 4.39E-01 0.983 47347811 8
cg05502283 0.32 (0.18, 0.46) 3.48E-05 0.037 -0.06(-0.14,0.03) 1.77E-01 0.967 NFIX 13203715 19 N_Shelf chr19:13207375-13207621
cg16325482 0.36 (0.2, 0.52) 3.48E-05 0.037 0(-0.11,0.11) 9.39E-01 0.992 CANT1;CANT1;CANT1 76989499 17 N_Shore chr17:76989642-76990039
cg07152869 0.42 (0.23, 0.6) 3.51E-05 0.038 -0.25(-0.76,0.26) 3.38E-01 0.967 KIAA0556 27741555 16
cg05590569 0.34 (0.19, 0.49) 3.52E-05 0.038 0.03(-0.13,0.18) 7.38E-01 0.992 10144009 2
cg10140240 -0.37 (-0.54, -0.21) 3.53E-05 0.038 0.01(-0.09,0.11) 7.97E-01 0.992 BIRC5;BIRC5;BIRC5;EP 76220672 17
cg01841415 0.33 (0.18, 0.47) 3.56E-05 0.038 0.03(-0.09,0.15) 6.15E-01 0.992 KCNT1 1.39E+08 9 N_Shore chr9:138680881-138681159
cg18372548 0.35 (0.19, 0.5) 3.57E-05 0.038 0(-0.11,0.12) 9.36E-01 0.992 STIM2;STIM2;STIM2 26913852 4
cg00766914 -0.33 (-0.47, -0.18) 3.60E-05 0.038 0.02(-0.1,0.14) 7.43E-01 0.992 PDSS2 1.08E+08 6 Island chr6:107780774-107781409
cg20491488 0.34 (0.19, 0.49) 3.62E-05 0.038 0.04(-0.12,0.19) 6.48E-01 0.992 ITPRIP 1.06E+08 10 Island chr10:106074965-106075368
cg22343181 0.41 (0.23, 0.59) 3.64E-05 0.038 -0.06(-0.15,0.04) 2.45E-01 0.967 NOC4L 1.33E+08 12 N_Shore chr12:132633217-132635301
cg07058086 -0.56 (-0.8, -0.31) 3.65E-05 0.038 0.03(-0.09,0.15) 6.74E-01 0.992 KIF13B 29120186 8 Island chr8:29119957-29120787
cg14646974 -1.1 (-1.58, -0.61) 3.66E-05 0.038 0.06(-0.53,0.65) 8.42E-01 0.992 HSD17B7P2 38645378 10 Island chr10:38645112-38645513
cg11556164 -0.3 (-0.43, -0.17) 3.69E-05 0.038 -0.11(-0.25,0.03) 1.17E-01 0.967 LRRN3;IMMP2L;LRRN31.11E+08 7
cg04025701 -0.4 (-0.58, -0.23) 3.70E-05 0.038 0.04(-0.09,0.17) 5.31E-01 0.989 RPS14;RPS14;RPS14;RP 1.50E+08 5 Island chr5:149828881-149829631
cg16725642 0.29 (0.16, 0.41) 3.70E-05 0.038 -0.02(-0.12,0.09) 7.37E-01 0.992 EPHB4 1.00E+08 7 Island chr7:100421295-100421515
cg15959529 0.38 (0.21, 0.55) 3.71E-05 0.038 0.04(-0.09,0.16) 5.55E-01 0.99 TRIM39;TRIM39 30309908 6 N_Shelf chr6:30312837-30313419
cg00888154 0.36 (0.2, 0.51) 3.74E-05 0.038 0.07(-0.02,0.16) 1.35E-01 0.967 PIGG;PIGG 503399 4
cg14422315 0.25 (0.14, 0.35) 3.74E-05 0.038 0.02(-0.06,0.1) 6.42E-01 0.992 CRTAC1 99664004 10
cg16237262 0.41 (0.23, 0.59) 3.74E-05 0.038 0.07(-0.06,0.2) 2.71E-01 0.967 SLC9A4 1.03E+08 2
cg03971344 0.31 (0.17, 0.44) 3.77E-05 0.038 -0.11(-0.21,-0.01) 3.32E-02 0.719 ANKRD11 89349124 16 S_Shore chr16:89345463-89348521
cg20335293 -0.33 (-0.48, -0.19) 3.77E-05 0.038 0(-0.16,0.15) 9.76E-01 0.996 1.57E+08 2
cg25599950 -0.41 (-0.6, -0.23) 3.77E-05 0.038 -0.02(-0.18,0.15) 8.43E-01 0.992 COBL 51259763 7
cg00137629 0.27 (0.15, 0.39) 3.81E-05 0.039 0.02(-0.06,0.1) 6.65E-01 0.992 GUSB 65445384 7 N_Shore chr7:65446771-65447340
cg01619490 0.46 (0.26, 0.67) 3.82E-05 0.039 0.03(-0.14,0.21) 7.03E-01 0.992 40724242 21 S_Shelf chr21:40720185-40721625
cg17170190 0.29 (0.16, 0.42) 3.87E-05 0.039 0.01(-0.07,0.09) 8.56E-01 0.992 B4GALT2;B4GALT2 44445979 1 S_Shore chr1:44444635-44445622
cg26011692 0.36 (0.2, 0.52) 3.87E-05 0.039 0.12(-0.03,0.27) 1.16E-01 0.967 LTBP2 75052601 14 Island chr14:75052567-75052820
cg25527494 -0.38 (-0.55, -0.21) 3.88E-05 0.039 0.02(-0.14,0.18) 8.11E-01 0.992 1.01E+08 13 N_Shore chr13:100641334-100642188
cg15504662 -0.44 (-0.64, -0.25) 3.90E-05 0.039 0.15(0.01,0.29) 3.76E-02 0.719 LIMK2;LIMK2;LIMK2 31644160 22
cg18454685 -0.35 (-0.5, -0.19) 3.91E-05 0.039 0.13(0.02,0.24) 2.28E-02 0.719 CACNA1G;CACNA1G;C48639239 17 Island chr17:48636103-48639279
cg07147863 -0.31 (-0.44, -0.17) 3.95E-05 0.039 0.07(-0.08,0.21) 3.68E-01 0.968 FBXL18 5534548 7 Island chr7:5534384-5534766
cg02823625 0.37 (0.21, 0.53) 3.96E-05 0.039 -0.03(-0.52,0.46) 9.08E-01 0.992 KLHL30 2.39E+08 2 N_Shore chr2:239048071-239048454
cg14002714 0.37 (0.21, 0.53) 3.97E-05 0.039 0.03(-0.12,0.18) 6.75E-01 0.992 KTN1;KTN1;KTN1;KTN56095810 14
cg02369024 0.3 (0.17, 0.44) 4.06E-05 0.04 0.06(-0.02,0.13) 1.53E-01 0.967 63204500 7
cg24892571 0.36 (0.2, 0.51) 4.06E-05 0.04 0.01(-0.06,0.09) 7.02E-01 0.992 HMGA2;HMGA2 66284828 12
cg06980341 0.32 (0.18, 0.46) 4.07E-05 0.04 0.04(-0.08,0.17) 4.92E-01 0.989 ARHGEF10L 17874602 1
cg21442876 0.47 (0.26, 0.68) 4.09E-05 0.04 0.02(-0.12,0.17) 7.51E-01 0.992 PET112L 1.53E+08 4
cg05394800 -0.31 (-0.44, -0.17) 4.10E-05 0.04 -0.01(-0.2,0.18) 9.55E-01 0.993 50707050 13 N_Shore chr13:50707585-50708019
cg13897122 0.41 (0.23, 0.6) 4.14E-05 0.04 0.02(-0.13,0.16) 8.12E-01 0.992 IL18RAP 1.03E+08 2
cg07643314 -0.28 (-0.41, -0.16) 4.15E-05 0.04 0.06(-0.06,0.18) 3.00E-01 0.967 DAZL 16647343 3 S_Shore chr3:16645948-16646259
cg02849103 -0.35 (-0.5, -0.19) 4.16E-05 0.04 0.05(-0.07,0.17) 4.14E-01 0.968 10350874 16
cg11860777 -0.42 (-0.61, -0.23) 4.16E-05 0.04 -0.06(-0.17,0.05) 2.58E-01 0.967 IGFBP4 38609504 17
cg16426715* 0.23 (0.13, 0.34) 4.19E-05 0.04 0.06(-0.02,0.14) 1.58E-01 0.967 GRK6;GRK6;GRK6 1.77E+08 5
cg17240454 0.32 (0.18, 0.46) 4.21E-05 0.04 -0.06(-0.2,0.08) 4.02E-01 0.968 SPDEF 34524278 6
cg13053653 -0.32 (-0.47, -0.18) 4.22E-05 0.04 0.03(-0.09,0.16) 6.10E-01 0.992 HOXD3 1.77E+08 2 N_Shore chr2:177039551-177039951
ch.4.104561249F 0.31 (0.17, 0.45) 4.22E-05 0.04 -0.02(-0.14,0.1) 7.73E-01 0.992 1.04E+08 4
cg23119977 0.39 (0.22, 0.57) 4.23E-05 0.04 0(-0.09,0.09) 9.72E-01 0.995 FRMD5 44213307 15
cg06049367 0.38 (0.21, 0.55) 4.31E-05 0.041 -0.07(-0.22,0.09) 3.95E-01 0.968 INSC;INSC 15139573 11 S_Shelf chr11:15136058-15136545
cg07059167 -0.46 (-0.67, -0.26) 4.33E-05 0.041 0.02(-0.1,0.14) 7.64E-01 0.992 PTOV1 50354224 19 Island chr19:50353790-50355483
cg11696388 0.31 (0.17, 0.45) 4.33E-05 0.041 0(-0.08,0.08) 9.41E-01 0.992 ANK1;ANK1;ANK1;ANK41557540 8 N_Shore chr8:41559255-41559609
cg07808859 -0.44 (-0.64, -0.24) 4.35E-05 0.041 . 1.35E+08 5
cg02493644 -0.44 (-0.64, -0.24) 4.36E-05 0.041 0.06(-0.06,0.18) 3.32E-01 0.967 84816314 7 S_Shore chr7:84814839-84816242
cg25971741 0.82 (0.45, 1.18) 4.36E-05 0.041 -0.03(-0.16,0.1) 6.06E-01 0.992 JARID2 15343116 6
cg16121206 -0.51 (-0.74, -0.28) 4.38E-05 0.041 -0.12(-0.46,0.22) 4.82E-01 0.988 APOL2;APOL2 36636055 22
cg04946387 0.91 (0.5, 1.31) 4.40E-05 0.041 -0.14(-0.52,0.24) 4.78E-01 0.988 B3GAT1;B3GAT1 1.34E+08 11 Island chr11:134253449-134254151
cg07862554 -0.32 (-0.46, -0.18) 4.42E-05 0.041 0(-0.13,0.12) 9.39E-01 0.992 MME;MME;MME;MME 1.55E+08 3 N_Shore chr3:154797398-154797988
cg27301231 -0.28 (-0.41, -0.16) 4.44E-05 0.041 0.02(-0.15,0.19) 7.95E-01 0.992 C3orf59 1.93E+08 3
cg26222498 0.38 (0.21, 0.55) 4.47E-05 0.042 0.06(-0.06,0.18) 2.94E-01 0.967 INPP5A 1.34E+08 10 S_Shelf chr10:134460274-134460479
cg04986304 0.35 (0.2, 0.51) 4.48E-05 0.042 -0.04(-0.15,0.06) 4.16E-01 0.968 54590530 1 S_Shelf chr1:54587364-54587578
cg06810011 -0.3 (-0.44, -0.17) 4.51E-05 0.042 0.01(-0.15,0.16) 9.24E-01 0.992 IMMP2L 1.11E+08 7
cg06884262 -0.25 (-0.36, -0.14) 4.54E-05 0.042 0.05(-0.09,0.19) 4.88E-01 0.988 KHSRP 6425638 19 Island chr19:6425485-6425843
cg12612213* 0.28 (0.16, 0.41) 4.54E-05 0.042 0.1(-0.03,0.23) 1.22E-01 0.967 EPHB3 1.84E+08 3 N_Shore chr3:184286935-184287329
cg02048317 0.29 (0.16, 0.42) 4.55E-05 0.042 -0.04(-0.21,0.13) 6.63E-01 0.992 80004967 17 N_Shelf chr17:80008514-80010567
cg25463779 0.27 (0.15, 0.4) 4.55E-05 0.042 -0.01(-0.13,0.11) 8.98E-01 0.992 FAM101A 1.25E+08 12
cg00378730 -0.27 (-0.4, -0.15) 4.57E-05 0.042 0.04(-0.08,0.16) 4.85E-01 0.988 CHAT;CHAT;CHAT;CH 50822650 10 Island chr10:50822350-50822666
cg13357821 0.4 (0.22, 0.58) 4.58E-05 0.042 -0.11(-0.21,-0.02) 2.20E-02 0.719 CUX1;CUX1;CUX1 1.02E+08 7
cg04641165 0.38 (0.21, 0.55) 4.62E-05 0.042 0.02(-0.1,0.14) 7.60E-01 0.992 MYLIP 16139117 6
cg03490881 0.33 (0.18, 0.47) 4.63E-05 0.042 0.11(0,0.22) 4.28E-02 0.763 GIMAP6;GIMAP6;GIMA1.50E+08 7
cg06214983 0.31 (0.17, 0.44) 4.63E-05 0.042 0.08(-0.04,0.2) 1.74E-01 0.967 MANEAL;MANEAL 38259501 1 Island chr1:38259095-38260427
cg13556548 -0.34 (-0.5, -0.19) 4.63E-05 0.042 0.09(-0.03,0.22) 1.39E-01 0.967 C1orf55 2.26E+08 1 S_Shore chr1:226186803-226187336
cg19752565 0.27 (0.15, 0.39) 4.63E-05 0.042 0(-0.09,0.1) 9.38E-01 0.992 SCN7A 1.67E+08 2
cg25760416 0.35 (0.19, 0.51) 4.63E-05 0.042 0.01(-0.15,0.17) 9.14E-01 0.992 HFM1 91871748 1 S_Shore chr1:91869876-91870390
cg25226092 0.32 (0.18, 0.46) 4.67E-05 0.042 0.01(-0.12,0.13) 9.18E-01 0.992 MOBP;MOBP 39508863 3
cg16196384 -0.31 (-0.45, -0.17) 4.69E-05 0.042 0.07(-0.05,0.19) 2.38E-01 0.967 PMPCB 1.03E+08 7 Island chr7:102937857-102938141
cg09929564 -0.52 (-0.75, -0.29) 4.72E-05 0.042 0.19(0.02,0.36) 2.85E-02 0.719 ILF2 1.54E+08 1 S_Shore chr1:153643318-153643529
cg27366964 -0.52 (-0.75, -0.29) 4.74E-05 0.042 . C10orf11 77946906 10
cg21509457 0.32 (0.18, 0.46) 4.75E-05 0.042 -0.01(-0.19,0.18) 9.40E-01 0.992 UBE3C 1.57E+08 7
cg27431596 -0.45 (-0.66, -0.25) 4.76E-05 0.042 0.05(-0.06,0.16) 4.17E-01 0.968 ZNF697 1.20E+08 1 Island chr1:120190377-120191251
cg02697721 0.33 (0.18, 0.48) 4.78E-05 0.042 -0.12(-0.3,0.06) 2.04E-01 0.967 FAM110A;FAM110A 819800 20 N_Shore chr20:821674-822500
cg22795239* 0.38 (0.21, 0.55) 4.81E-05 0.043 0.01(-0.15,0.16) 9.25E-01 0.992 WNT16 1.21E+08 7
cg16403344 -0.33 (-0.48, -0.18) 4.83E-05 0.043 0.07(-0.06,0.21) 2.87E-01 0.967 RPH3A;RPH3A 1.13E+08 12
cg14510947 -0.47 (-0.68, -0.26) 4.87E-05 0.043 0.09(-0.04,0.22) 1.60E-01 0.967 SNORA76 62223546 17 Island chr17:62223224-62224124
cg05624577 0.73 (0.4, 1.06) 4.91E-05 0.043 -0.23(-0.65,0.18) 2.73E-01 0.967 81411055 15 Island chr15:81410715-81411067
cg07058988 0.37 (0.21, 0.54) 4.98E-05 0.043 0.02(-0.1,0.15) 7.24E-01 0.992 80297159 17
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Name Coef (CI) P-value Coef (CI) P-value Gene MAPINFOCHR Relation to CpG Islands Name
cg23637124 -0.32 (-0.47, -0.18) 4.98E-05 0.043 0.16(0.04,0.27) 8.42E-03 0.719 SHC4;SHC4 49255455 15 Island chr15:49254984-49255564
cg10105110 0.32 (0.18, 0.47) 5.00E-05 0.043 0.02(-0.1,0.13) 7.94E-01 0.992 C10orf99 85940649 10
cg15674514 0.33 (0.18, 0.48) 5.00E-05 0.043 -0.18(-0.35,-0.02) 3.21E-02 0.719 76674273 18 Island chr18:76674209-76674797
cg19750824 2.45 (1.35, 3.56) 5.03E-05 0.044 -0.8(-1.98,0.39) 1.84E-01 0.967 1.79E+08 1
cg25189764* 0.48 (0.26, 0.69) 5.04E-05 0.044 0.01(-0.11,0.13) 8.81E-01 0.992 FYN;FYN 1.12E+08 6
cg11233468 0.28 (0.15, 0.41) 5.11E-05 0.044 -0.05(-0.15,0.05) 3.40E-01 0.967 FUT6;FUT6 5831171 19 N_Shore chr19:5831595-5832297
cg13716760 0.31 (0.17, 0.45) 5.11E-05 0.044 0.01(-0.1,0.11) 9.08E-01 0.992 15371248 9
cg26655764 0.33 (0.18, 0.47) 5.11E-05 0.044 -0.02(-0.17,0.12) 7.48E-01 0.992 CPNE7;CPNE7 89657805 16 N_Shelf chr16:89661799-89662043
cg09681360 0.43 (0.23, 0.62) 5.14E-05 0.044 0.09(-0.06,0.24) 2.20E-01 0.967 PHC3 1.70E+08 3 N_Shore chr3:169898946-169899626
cg15297799 -0.23 (-0.33, -0.13) 5.16E-05 0.044 0.02(-0.12,0.16) 8.09E-01 0.992 C18orf22 77794239 18 N_Shore chr18:77794360-77794761
cg10210510 -0.44 (-0.63, -0.24) 5.19E-05 0.044 0(-0.13,0.13) 9.62E-01 0.993 COL9A2 40771135 1 S_Shore chr1:40769186-40769871
cg15474407 -0.42 (-0.61, -0.23) 5.19E-05 0.044 0.07(-0.08,0.21) 3.57E-01 0.968 ARNTL2 27500572 12
cg16047663 -0.39 (-0.56, -0.21) 5.21E-05 0.044 -0.08(-0.2,0.05) 2.17E-01 0.967 RNPEP 2.02E+08 1
cg05137466 -0.48 (-0.7, -0.27) 5.22E-05 0.044 0.15(-0.01,0.31) 7.21E-02 0.893 34809811 9 Island chr9:34809590-34810229
cg02478369 1.72 (0.95, 2.5) 5.23E-05 0.044 0.06(-0.07,0.19) 3.55E-01 0.968 15083645 17
cg07523741 0.35 (0.19, 0.51) 5.24E-05 0.044 -0.09(-0.29,0.11) 3.90E-01 0.968 PKD2L2 1.37E+08 5 Island chr5:137224986-137225477
cg23261846 -0.53 (-0.77, -0.29) 5.24E-05 0.044 0.02(-0.1,0.14) 7.53E-01 0.992 30591384 12
cg09676630 0.4 (0.22, 0.58) 5.25E-05 0.044 0.02(-0.06,0.09) 6.61E-01 0.992 FBRSL1 1.33E+08 12 N_Shore chr12:133102168-133102604
cg22285621 -0.28 (-0.4, -0.15) 5.25E-05 0.044 0.02(-0.14,0.18) 8.08E-01 0.992 SSH3 67071322 11 Island chr11:67070807-67071801
cg26330076 0.32 (0.18, 0.47) 5.25E-05 0.044 -0.11(-0.28,0.05) 1.70E-01 0.967 FICD 1.09E+08 12 S_Shelf chr12:108908702-108909475
cg10991454 0.29 (0.16, 0.42) 5.30E-05 0.044 -0.03(-0.11,0.05) 4.34E-01 0.982 LCLAT1;LCLAT1 30834674 2
cg05155965 -0.35 (-0.5, -0.19) 5.32E-05 0.044 0.07(-0.04,0.19) 2.08E-01 0.967 NR2F2;NR2F2 96873885 15 Island chr15:96873408-96877721
cg24863642* 0.31 (0.17, 0.45) 5.38E-05 0.045 0.1(-0.06,0.25) 2.25E-01 0.967 NDUFS2;NDUFS2 1.61E+08 1 Island chr1:161171809-161172256
cg24870483 0.35 (0.19, 0.51) 5.41E-05 0.045 -0.01(-0.11,0.09) 8.47E-01 0.992 2.43E+08 2 N_Shore chr2:242805752-242806034
cg26965718* 0.59 (0.32, 0.86) 5.41E-05 0.045 0.12(-0.03,0.27) 1.12E-01 0.967 HGS 79658957 17 N_Shelf chr17:79662850-79663055
cg03655389 0.31 (0.17, 0.44) 5.43E-05 0.045 -0.02(-0.13,0.09) 7.30E-01 0.992 TPPP 665188 5 Island chr5:665187-665401
cg21169267 0.37 (0.21, 0.54) 5.44E-05 0.045 -0.01(-0.18,0.16) 9.25E-01 0.992 FAM129B;FAM129B 1.30E+08 9
cg05940691 -0.4 (-0.58, -0.22) 5.46E-05 0.045 0.07(-0.06,0.21) 2.64E-01 0.967 WDR64 2.42E+08 1
cg24354818 0.81 (0.44, 1.17) 5.47E-05 0.045 0.57(0.11,1.03) 1.61E-02 0.719 TNFRSF6B;TNFRSF6B; 62328094 20 Island chr20:62328013-62328558
cg21610090 -0.26 (-0.37, -0.14) 5.52E-05 0.045 0(-0.13,0.13) 9.92E-01 0.997 CDKL4 39455859 2
cg01501009 -0.41 (-0.6, -0.23) 5.53E-05 0.045 0.01(-0.13,0.15) 8.44E-01 0.992 ZNF835 57183268 19 Island chr19:57182887-57183375
cg00451102 -0.46 (-0.66, -0.25) 5.56E-05 0.045 -0.08(-0.22,0.05) 2.32E-01 0.967 21679284 10
cg24158553 -0.38 (-0.55, -0.21) 5.57E-05 0.045 -0.03(-0.18,0.11) 6.46E-01 0.992 GABPB1;GABPB1;FLJ1 50647608 15 Island chr15:50646437-50647742
cg10929866 0.59 (0.32, 0.85) 5.58E-05 0.045 -0.02(-0.29,0.26) 9.13E-01 0.992 SNX9 1.58E+08 6
cg12354377 -0.29 (-0.42, -0.16) 5.59E-05 0.045 -0.07(-0.22,0.08) 3.82E-01 0.968 ANK3 62149557 10
cg22175345 0.41 (0.22, 0.59) 5.59E-05 0.045 -0.05(-0.26,0.15) 6.26E-01 0.992 17194180 4
cg07830254 0.28 (0.15, 0.4) 5.60E-05 0.045 -0.14(-0.26,-0.02) 2.31E-02 0.719 C7orf34 1.43E+08 7
cg16379910 -0.32 (-0.47, -0.18) 5.64E-05 0.045 0.08(-0.05,0.21) 2.39E-01 0.967 78636730 14
cg02342415* 0.34 (0.19, 0.5) 5.68E-05 0.046 0.07(-0.15,0.3) 5.21E-01 0.989 IQSEC1;IQSEC1 12940876 3 Island chr3:12940753-12941134
cg00976381 0.42 (0.23, 0.6) 5.69E-05 0.046 0.11(-0.07,0.28) 2.27E-01 0.967 SLC23A1;SLC23A1 1.39E+08 5 Island chr5:138713814-138714340
cg02348830 0.39 (0.21, 0.56) 5.71E-05 0.046 0.06(-0.05,0.16) 3.02E-01 0.967 TREX1;ATRIP;ATRIP;T 48506168 3
cg07592519 -0.58 (-0.84, -0.32) 5.74E-05 0.046 0.08(-0.05,0.21) 2.14E-01 0.967 KCNQ1;KCNQ1 2735101 11
cg16453617 0.37 (0.2, 0.54) 5.76E-05 0.046 -0.02(-0.13,0.08) 6.48E-01 0.992 CACNA1H;CACNA1H 1257884 16 S_Shelf chr16:1254108-1254375
cg19547200 -0.71 (-1.03, -0.39) 5.76E-05 0.046 -0.02(-0.14,0.11) 7.96E-01 0.992 SERHL 42896249 22 N_Shore chr22:42896636-42897041
cg19307180 -0.43 (-0.62, -0.23) 5.77E-05 0.046 -0.09(-0.23,0.06) 2.45E-01 0.967 DGKH;DGKH 42803600 13
cg07296387 0.5 (0.27, 0.72) 5.78E-05 0.046 -0.14(-0.33,0.05) 1.48E-01 0.967 CDH22 44838981 20 Island chr20:44838887-44839204
cg26530061 -0.33 (-0.47, -0.18) 5.79E-05 0.046 0.12(-0.01,0.24) 7.56E-02 0.893 27265522 7 S_Shore chr7:27265158-27265493
cg08744727 0.41 (0.22, 0.59) 5.80E-05 0.046 -0.01(-0.19,0.17) 9.11E-01 0.992 ZNF876P 206112 4 N_Shore chr4:206377-206892
cg12083893 0.37 (0.2, 0.54) 5.81E-05 0.046 0(-0.09,0.1) 9.76E-01 0.996 91111929 10
cg00965154 0.42 (0.23, 0.62) 5.82E-05 0.046 -0.01(-0.17,0.15) 9.07E-01 0.992 SMTN;SMTN;SMTN 31485117 22 S_Shelf chr22:31480774-31481373
cg12072690 0.39 (0.21, 0.56) 5.82E-05 0.046 -0.06(-0.2,0.08) 4.10E-01 0.968 MCF2L;MCF2L 1.14E+08 13 Island chr13:113750486-113751565
cg08490349 0.26 (0.14, 0.38) 5.83E-05 0.046 0.03(-0.07,0.13) 5.18E-01 0.989 MPRIP;MPRIP 17086207 17
cg16912910 0.32 (0.18, 0.47) 5.83E-05 0.046 0.01(-0.16,0.18) 8.94E-01 0.992 29497165 6
cg02082252* 0.41 (0.22, 0.6) 5.85E-05 0.046 0.06(-0.06,0.19) 3.30E-01 0.967 EHMT2;EHMT2 31866286 6 N_Shore chr6:31867691-31867957
cg23806084 0.51 (0.28, 0.74) 5.86E-05 0.046 0.04(-0.05,0.14) 3.75E-01 0.968 PSMB9;TAP1;PSMB9;T 32821605 6 Island chr6:32820849-32822370
cg12084011 0.46 (0.25, 0.66) 5.89E-05 0.046 0.03(-0.08,0.13) 6.10E-01 0.992 BCAP29;BCAP29;BCAP 1.07E+08 7 Island chr7:107220344-107221075
cg20802509 0.35 (0.19, 0.5) 5.91E-05 0.046 -0.02(-0.12,0.08) 6.81E-01 0.992 URB2 2.30E+08 1 S_Shelf chr1:229761128-229762299
cg15513163 -0.29 (-0.42, -0.16) 5.95E-05 0.046 0.18(0.04,0.32) 1.40E-02 0.719 70034139 1 Island chr1:70032967-70034495
cg06624525 0.29 (0.16, 0.42) 5.96E-05 0.046 -0.06(-0.18,0.05) 2.72E-01 0.967 35001084 15
cg08615818 0.37 (0.2, 0.54) 5.96E-05 0.046 -0.01(-0.23,0.22) 9.54E-01 0.993 HCCA2 1531515 11
cg08166750 -0.35 (-0.52, -0.19) 5.99E-05 0.046 -0.05(-0.2,0.09) 4.64E-01 0.988 EPS8L1;EPS8L1 55598443 19 Island chr19:55597977-55598887
cg09962824 0.33 (0.18, 0.48) 5.99E-05 0.046 0.02(-0.06,0.11) 5.54E-01 0.99 CBS 44479417 21 N_Shore chr21:44480559-44480772
cg05908587 -0.31 (-0.46, -0.17) 6.00E-05 0.046 0.02(-0.11,0.15) 7.47E-01 0.992 GALNTL1;GALNTL1 69726251 14 Island chr14:69726250-69728393
cg10706989 -0.44 (-0.65, -0.24) 6.01E-05 0.046 0.12(-0.01,0.25) 7.26E-02 0.893 C13orf34;C13orf37;C13o 73302078 13 Island chr13:73301230-73302154
cg12613382 0.31 (0.17, 0.45) 6.03E-05 0.046 0.01(-0.07,0.09) 8.28E-01 0.992 1.33E+08 12 S_Shore chr12:132663322-132663748
cg23947450 0.28 (0.15, 0.41) 6.03E-05 0.046 -0.03(-0.15,0.1) 6.67E-01 0.992 UNC84A;UNC84A 900037 7
cg05055326 -0.36 (-0.53, -0.2) 6.11E-05 0.046 0(-0.13,0.14) 9.53E-01 0.993 HCG9 29945080 6 Island chr6:29944402-29945169
cg26990023 0.4 (0.22, 0.58) 6.13E-05 0.046 0.02(-0.13,0.17) 8.03E-01 0.992 SMOC2;SMOC2 1.69E+08 6 N_Shore chr6:168972516-168974109
cg14526039 0.34 (0.18, 0.49) 6.17E-05 0.047 0.01(-0.09,0.1) 8.97E-01 0.992 KLHDC8B 49210221 3 S_Shore chr3:49208629-49209196
cg21495568 0.37 (0.2, 0.54) 6.19E-05 0.047 -0.03(-0.16,0.1) 6.64E-01 0.992 SAP18 21715145 13 S_Shore chr13:21714289-21715115
cg01707127 0.37 (0.2, 0.54) 6.22E-05 0.047 0(-0.12,0.11) 9.56E-01 0.993 LMF1 947051 16 S_Shore chr16:945437-946420
cg12934466 -0.31 (-0.45, -0.17) 6.24E-05 0.047 -0.02(-0.16,0.12) 7.45E-01 0.992 ZNF397;ZNF397 32820979 18 Island chr18:32820785-32821203
cg23155333 0.37 (0.2, 0.54) 6.24E-05 0.047 -0.09(-0.19,0.01) 7.41E-02 0.893 35323673 19 Island chr19:35323531-35323952
cg03914237 0.38 (0.21, 0.56) 6.25E-05 0.047 0.07(-0.07,0.22) 3.29E-01 0.967 THSD7A 11558886 7
cg08180572 -0.51 (-0.74, -0.28) 6.29E-05 0.047 0.04(-0.17,0.26) 6.94E-01 0.992 SPNS1;SPNS1;SPNS1;SP28985143 16 N_Shore chr16:28985881-28986661
cg12384932 0.22 (0.12, 0.33) 6.31E-05 0.047 -0.01(-0.16,0.14) 9.30E-01 0.992 NALCN 1.02E+08 13
cg07008591 0.39 (0.21, 0.56) 6.34E-05 0.047 0.01(-0.11,0.13) 8.75E-01 0.992 TEAD1 12809661 11
cg07818422 -0.3 (-0.43, -0.16) 6.40E-05 0.048 -0.02(-0.12,0.09) 7.44E-01 0.992 WDFY2 52301946 13
cg26272907 0.71 (0.38, 1.03) 6.43E-05 0.048 0.17(-0.06,0.41) 1.50E-01 0.967 TUBGCP3 1.13E+08 13 N_Shelf chr13:113201706-113201927
cg16041798 0.34 (0.19, 0.5) 6.44E-05 0.048 0.12(-0.03,0.28) 1.25E-01 0.967 MTHFD1 64905375 14
cg05946856 -0.31 (-0.45, -0.17) 6.48E-05 0.048 0.1(-0.13,0.33) 3.82E-01 0.968 1.57E+08 6
cg07042546 0.28 (0.15, 0.41) 6.50E-05 0.048 -0.05(-0.15,0.05) 3.43E-01 0.967 RNF214;RNF214 1.17E+08 11 S_Shore chr11:117102742-117103452
cg03955354 0.35 (0.19, 0.51) 6.51E-05 0.048 0.08(-0.04,0.2) 1.98E-01 0.967 2925039 16
cg03904876 -0.25 (-0.37, -0.14) 6.63E-05 0.049 0.08(-0.03,0.19) 1.44E-01 0.967 54322092 12 S_Shore chr12:54321301-54321721
ch.7.109930408F -0.33 (-0.49, -0.18) 6.64E-05 0.049 -0.04(-0.27,0.19) 7.42E-01 0.992 1.10E+08 7
cg05341199 0.34 (0.18, 0.49) 6.67E-05 0.049 0.05(-0.09,0.19) 4.81E-01 0.988 GPR133 1.32E+08 12 N_Shelf chr12:131605558-131605767
cg02286715 -0.24 (-0.35, -0.13) 6.69E-05 0.049 0.04(-0.08,0.16) 4.75E-01 0.988 PPP2R2C 6473881 4 Island chr4:6472175-6474534
cg00791851 -0.31 (-0.45, -0.16) 6.71E-05 0.049 0(-0.46,0.46) 9.95E-01 0.997 76518896 1
TAIWAN COHORT NHBCS CpG Information
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Name Coef (CI) P-value Coef (CI) P-value Gene MAPINFOCHR Relation to CpG Islands Name
cg08198265* 0.57 (0.31, 0.83) 6.77E-05 0.049 0.01(-0.09,0.15) 8.75E-01 0.992 BST1 15708451 4 S_Shelf chr4:15704640-15705000
cg19850333 -0.36 (-0.53, -0.2) 6.77E-05 0.049 0.04(-0.06,0.15) 4.28E-01 0.977 CCRL2;CCRL2 46448579 3
cg00049047 -0.37 (-0.54, -0.2) 6.78E-05 0.049 0.06(-0.06,0.19) 3.34E-01 0.967 GDNF 37838425 5 Island chr5:37836747-37840726
cg25588480 0.41 (0.22, 0.6) 6.78E-05 0.049 -0.05(-0.19,0.09) 4.82E-01 0.988 MINK1;MINK1;MINK1; 4763240 17
cg18132007 -0.21 (-0.3, -0.11) 6.79E-05 0.049 0.11(0.01,0.2) 2.86E-02 0.719 TP53I11;TP53I11 44972684 11 Island chr11:44971048-44972685
cg16364152 -0.43 (-0.63, -0.23) 6.80E-05 0.049 -0.01(-0.13,0.1) 8.27E-01 0.992 RP5-1022P6.2 5591818 20 Island chr20:5591490-5591875
cg14794023 0.27 (0.15, 0.4) 6.81E-05 0.049 0.1(-0.03,0.23) 1.18E-01 0.967 POM121L12 53103576 7 Island chr7:53103275-53103801
cg21678813 -0.32 (-0.47, -0.17) 6.81E-05 0.049 0.13(0.02,0.24) 2.64E-02 0.719 20229879 11
cg23319696 0.45 (0.24, 0.65) 6.82E-05 0.049 0.09(-0.1,0.27) 3.46E-01 0.968 2111870 5 Island chr5:2111836-2112484
cg06935052 0.29 (0.16, 0.42) 6.84E-05 0.049 -0.04(-0.15,0.07) 4.74E-01 0.988 SMARCB1;SMARCB1 24176449 22
cg19254118 0.44 (0.24, 0.64) 6.85E-05 0.049 -0.01(-0.15,0.14) 9.26E-01 0.992 ADAT3;SCAMP4 1907972 19 N_Shore chr19:1908118-1908509
cg19724043 0.27 (0.14, 0.39) 6.86E-05 0.049 0.02(-0.12,0.17) 7.39E-01 0.992 15380395 21 N_Shelf chr21:15383530-15383813
cg27640763 0.46 (0.25, 0.68) 6.89E-05 0.049 0.17(-0.02,0.37) 7.92E-02 0.893 LUM 91503109 12
cg00217795 0.3 (0.16, 0.44) 6.90E-05 0.049 -0.03(-0.18,0.11) 6.47E-01 0.992 DIO2;DIO2;DIO2 80677688 14
cg09568216 -0.52 (-0.76, -0.28) 6.90E-05 0.049 -0.04(-0.13,0.06) 4.48E-01 0.988 NPR3 32779925 5
cg12523924 -0.33 (-0.49, -0.18) 6.90E-05 0.049 0.13(0.01,0.25) 3.39E-02 0.719 63255359 5 Island chr5:63255044-63255407
cg12241963 0.27 (0.14, 0.39) 6.91E-05 0.049 0.02(-0.14,0.17) 8.19E-01 0.992 33807279 6
cg16275882 -0.26 (-0.38, -0.14) 6.91E-05 0.049 0.13(0.02,0.24) 1.69E-02 0.719 1288184 7 S_Shore chr7:1286022-1287658
cg16703934 0.3 (0.16, 0.44) 6.91E-05 0.049 -0.07(-0.2,0.06) 2.71E-01 0.967 TSPAN33 1.29E+08 7 S_Shore chr7:128784695-128785096
cg08622675 0.43 (0.23, 0.63) 6.92E-05 0.049 0.02(-0.11,0.16) 7.36E-01 0.992 KDELR2;KDELR2 6524998 7 S_Shore chr7:6523064-6523897
cg07990873 0.27 (0.15, 0.4) 6.93E-05 0.049 -0.03(-0.14,0.08) 6.11E-01 0.992 ZNF671 58235167 19 N_Shelf chr19:58238585-58239028
cg02816732 0.38 (0.2, 0.55) 6.94E-05 0.049 -0.12(-0.27,0.03) 1.13E-01 0.967 TNS3 47384337 7
cg02333281 0.46 (0.25, 0.67) 6.96E-05 0.049 -0.06(-0.27,0.15) 5.93E-01 0.992 6636970 10
cg26581228 0.51 (0.27, 0.74) 6.98E-05 0.049 -0.03(-0.13,0.06) 5.19E-01 0.989 TRERF1 42326264 6
cg05310249 -0.43 (-0.62, -0.23) 6.99E-05 0.049 -0.02(-0.12,0.09) 7.34E-01 0.992 NKX2-6 23560590 8 Island chr8:23559838-23560591
cg07158747 -0.4 (-0.58, -0.21) 6.99E-05 0.049 . 91196488 1 S_Shelf chr1:91190489-91192804
cg02487202 0.31 (0.17, 0.45) 7.02E-05 0.049 -0.04(-0.12,0.05) 4.02E-01 0.968 ANKRD11 89358232 16
cg06896857 0.34 (0.18, 0.5) 7.03E-05 0.049 0.04(-0.07,0.15) 4.74E-01 0.988 PPP1R15A;PPP1R15A 49375797 19 Island chr19:49375484-49375928
cg00079219 -0.29 (-0.43, -0.16) 7.04E-05 0.049 0.08(-0.05,0.22) 2.03E-01 0.967 HOTAIR 54360131 12 N_Shore chr12:54360374-54360660
cg08391419 0.31 (0.17, 0.46) 7.04E-05 0.049 0.01(-0.09,0.1) 9.14E-01 0.992 STK32C 1.34E+08 10 S_Shelf chr10:134071971-134072193
cg05819837 0.35 (0.19, 0.5) 7.07E-05 0.049 0.07(-0.01,0.14) 8.29E-02 0.917 CUX1;CUX1;CUX1 1.02E+08 7
cg09187936 0.23 (0.12, 0.33) 7.07E-05 0.049 -0.02(-0.12,0.09) 7.54E-01 0.992 SETD1B 1.22E+08 12 S_Shelf chr12:122265374-122265954
cg04406115 0.32 (0.17, 0.46) 7.09E-05 0.049 -0.02(-0.16,0.13) 8.28E-01 0.992 KDM4B 5065640 19 Island chr19:5065639-5065919
cg11175091 0.45 (0.24, 0.65) 7.09E-05 0.049 -0.02(-0.18,0.15) 8.47E-01 0.992 MIR1243;ANK2;ANK2;A1.14E+08 4
cg15266969 0.29 (0.16, 0.42) 7.10E-05 0.049 0.07(-0.05,0.2) 2.23E-01 0.967 SLC22A12;SLC22A12 64369352 11
cg00704664 1.15 (0.62, 1.68) 7.13E-05 0.049 1.21(0.02,2.4) 4.55E-02 0.776 CDH4 60500578 20 N_Shore chr20:60501966-60502173
cg00269725 0.73 (0.39, 1.07) 7.23E-05 0.049 -0.03(-0.22,0.16) 7.31E-01 0.992 1.57E+08 6
cg20918219 -0.22 (-0.32, -0.12) 7.23E-05 0.049 0.06(-0.02,0.15) 1.55E-01 0.967 SCARA3;SCARA3 27493854 8 S_Shelf chr8:27490959-27491775
cg08557393 0.33 (0.18, 0.48) 7.24E-05 0.049 -0.06(-0.19,0.07) 3.31E-01 0.967 DOK4 57521521 16
cg25338036 0.47 (0.26, 0.69) 7.24E-05 0.049 -0.02(-0.15,0.1) 6.93E-01 0.992 CSMD1 3047536 8
cg03131730 0.27 (0.14, 0.39) 7.29E-05 0.049 0.06(-0.03,0.15) 2.01E-01 0.967 CCDC42;CCDC42 8638810 17
cg05129295 0.39 (0.21, 0.56) 7.29E-05 0.049 0.02(-0.1,0.13) 7.87E-01 0.992 1316294 8
cg01592801 -0.34 (-0.5, -0.18) 7.30E-05 0.049 -0.14(-0.37,0.1) 2.55E-01 0.967 KCNS2 99438942 8 Island chr8:99438692-99440425
cg10130718 0.54 (0.29, 0.79) 7.35E-05 0.049 0.08(-0.34,0.5) 7.00E-01 0.992 DMRTB1 53925368 1 Island chr1:53925191-53926228
cg03897139 0.31 (0.17, 0.45) 7.39E-05 0.05 0.03(-0.08,0.14) 5.50E-01 0.99 DPYSL4 1.34E+08 10 N_Shore chr10:134019500-134019776
cg05965745 -0.41 (-0.59, -0.22) 7.39E-05 0.05 -0.05(-0.3,0.21) 7.18E-01 0.992 PRDM16;PRDM16 3077798 1 N_Shelf chr1:3080934-3081292
cg13205528 -0.49 (-0.72, -0.26) 7.44E-05 0.05 -0.03(-0.25,0.19) 7.70E-01 0.992 2705849 1 N_Shore chr1:2706025-2706961
cg10221365 0.28 (0.15, 0.4) 7.45E-05 0.05 0.06(-0.11,0.22) 5.02E-01 0.989 JMJD5;JMJD5 27214422 16 N_Shore chr16:27214772-27215678
cg02493798 1.11 (0.6, 1.63) 7.50E-05 0.05 0.19(-0.37,0.76) 5.01E-01 0.989 ALOX12 6899577 17 Island chr17:6898820-6900427
cg12401679 0.27 (0.14, 0.39) 7.51E-05 0.05 0.01(-0.15,0.17) 9.08E-01 0.992 LOC619207 1.35E+08 10 N_Shore chr10:135270783-135271061
cg17943647 -0.55 (-0.81, -0.3) 7.51E-05 0.05 0.05(-0.09,0.18) 5.04E-01 0.989 TRIM2;TRIM2 1.54E+08 4
TAIWAN COHORT NHBCS CpG Information
FDR P-value FDR P-value
Footnote: This results were obtained by fitting Robust regression with the M-values of DNA-methylation as response and log10 of maternal urinary arsenic level adjusting for Urinary 
creatinine, child’s gender, batch effect, mother’s age, mother’s pre-pregnancy body mass index (BMI), mother’s education level, and cell proportions of 6 cell types. M-values are logit of 
DNA methylation, defined as log2 [β/(1-β)]. CpG sites in bold showed consistent association with Total urinary arsenic level of mother in NHBCS, and CpGs marked with "*" are the 
CpGs such that their corresponding genes are in the identified KEGG pathways.
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Subject CD8T CD4T NK Bcell Mono Gran
1 0.086339 0.161789 0.03705 0.125422 0.108936 0.535165
2 0.071657 0.128531 0.025776 0.120749 0.130483 0.579767
3 0.055667 0.117509 0.112656 0.106542 0.120631 0.523271
4 0.094488 0.105196 0.035431 0.098882 0.114146 0.585546
5 0.127137 0.144023 0.0091 0.077574 0.080921 0.568545
6 0.114757 0.171282 0 0.243679 0.127776 0.405114
7 0.221126 0.353146 0 0.191755 0.044692 0.219486
8 0.106903 0.159796 0.021962 0.125591 0.098902 0.526875
9 0.141326 0.176845 0.044873 0.108733 0.126921 0.440781
10 0.110878 0.195382 0 0.23698 0.128623 0.343273
11 0.113305 0.185754 0 0.207857 0.103421 0.4232
12 0.103108 0.306985 1.07E-19 0.046686 0 0.558618
13 0.056519 0.128894 0.064005 0.071728 0.109834 0.58592
14 0.039974 0.109659 0.130263 0.117196 0.080217 0.583316
15 0.131113 0.11647 0.020356 0.058528 0.07092 0.625321
16 0.093583 0.165071 0 0.093822 0.087372 0.581508
17 0.143037 0.104781 0 0.243772 0.1317 0.4711
18 0.091523 0.278061 0.116745 0.146964 0.100536 0.276378
19 0.10395 0.219228 0.014414 0.130644 0.104624 0.467834
20 0.042257 0.123753 0.082375 0.133762 0.142382 0.499199
21 0.124195 0.157698 0 0.131555 0.086831 0.531584
22 0.090689 0.155113 0.12881 0.177518 0.087908 0.419279
23 0.034937 0.096715 0.043709 0.124229 0.1107 0.63069
24 0.070149 0.180137 0.077627 0.126873 0.139379 0.410679
25 0.034482 0.135348 0.060564 0.141314 0.123158 0.560727
26 0.064729 0.038857 0.0107 0.061138 0.110737 0.73377
27 0.030939 0.145214 0.042139 0.103386 0.075217 0.63486
28 0.069561 0.176162 0.012068 0.261309 0.129053 0.39821
29 0.077367 0.200833 0 0.153033 0.084993 0.516621
30 0.046674 0.074382 0.060829 0.086505 0.098737 0.669492
31 0.061626 0.061423 0.024778 0.126057 0.113859 0.648363
32 0.124063 0.137529 0.070476 0.151346 0.218414 0.361695
33 0.115761 0.206974 0 0.178757 0.111402 0.453671
34 0.138564 0.128998 0.031599 0.140466 0.092372 0.519693
35 0.100378 0.128192 0.015141 0.175882 0.154002 0.461204
36 0.083233 0.119729 0.021163 0.19733 0.104917 0.531799
37 0.092963 0.07327 0.058152 0.058765 0.081584 0.686868
38 0.166116 0.326477 -1.39E-17 0.143829 0.073455 0.324551
39 0.11892 0.153317 0 0.254617 0.08274 0.421659
40 0.02767 0.085303 0.082031 0.08386 0.155102 0.5797
41 0.070268 0.05107 0.026707 0.08257 0.106381 0.70062
42 0.072235 0.153685 0.063122 0.143498 0.130354 0.495626
43 0.020794 0.118555 0.159978 0.148758 0.17757 0.401548
44 0.07095 0.161602 0 0.086025 0.115794 0.590266




Subject CD8T CD4T NK Bcell Mono Gran
46 0.131383 0.22382 -6.94E-18 0.154252 0.121875 0.404513
47 0.02962 0.021543 0.020384 0.069937 0.104432 0.771136
48 0.155763 0.175066 0.117977 0.173808 0.076379 0.394373
49 0.090426 0.190173 0.057454 0.152837 0.073335 0.508091
50 0.048113 0.115364 0.029918 0.118548 0.17001 0.538238
51 0.120098 0.269878 0.018139 0.141287 0.126483 0.349225
52 0.057611 0.18277 0.101527 0.152387 0.11435 0.423623
53 0.120721 0.165444 0.042014 0.135022 0.11225 0.471869
54 0.103501 0.131154 0.053606 0.115437 0.14038 0.519567
55 0.075224 0.153331 3.47E-18 0.095834 0.111252 0.587624
56 0.068445 0.11561 0.123447 0.144862 0.208628 0.377559
57 0.086244 0.326938 0 0.168179 0.051681 0.393962
58 0.042673 0.091076 0.033382 0.097413 0.115793 0.641253
59 0.045027 0.060593 0.032034 0.087649 0.096683 0.711222
60 0.034927 0.03991 0.022319 0.105901 0.128001 0.696177
61 0.066205 0.124148 0 0.129001 0.169022 0.53968
62 0.091891 0.139212 0.011755 0.147737 0.129403 0.536163
63 0.087555 0.099459 0.099699 0.18809 0.108163 0.507678
64 0 0.121129 0.212002 0.121968 0.083253 0.507372
Lymphocytes Myeloid Cells
Footnote: Cell proportions for 6 cell types, calculated using estimatecellcounts  in 
R-package minfi using the DNA methylation dataset for 64 subjects in this study
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CpG Estimate StdErr RAW_P ahoc_p Estimate StdErr RAW_P ahoc_p UCSC_Re UCSC_Re CHR UCSC_CpG_Islands_Name Relation_to_UCSC_CpG_Island
cg05712903 -2.3861 0.3144 3.63E-07 0.000117 1.2484 0.2754 0.000258 0.044319 RUFY1 TSS200 5 chr5:178977298-178978291 Island
cg07523741 -2.1622 0.4112 4.49E-05 0.014399 1.9706 0.4511 0.00037 0.063655 PKD2L2 Body 5 chr5:137224986-137225477 Island
cg26624744* -2.65 0.5523 0.000125 0.040107 -2.179 0.5091 0.000451 0.077528 CYFIP2;C TSS1500;T 5 chr5:156692812-156693749 N_Shore
cg08392484* -2.5938 0.455 1.70E-05 0.005467 -1.4976 0.3767 0.000887 0.152492 ELL2 Body 5
cg13984351* -1.4511 0.2642 2.68E-05 0.008604 -1.6858 0.4342 0.00109 0.187548 BMI1 TSS200 10
cg07945323 -2.143 0.4003 3.64E-05 0.011671 1.7933 0.4647 0.001149 0.197644 KRTAP6-2TSS1500;T 21
cg17207545* -1.8271 0.3376 3.19E-05 0.010242 -0.7231 0.191 0.001351 0.232393 7 chr7:102134871-102135575 N_Shore
cg26015416* 1.2691 0.2662 0.000134 0.042938 0.5849 0.158 0.001629 0.280265 NTNG1;N 3'UTR;3'U 1 chr1:108023232-108023442 S_Shore
cg13593553 -1.362 0.2633 5.43E-05 0.017415 1.6389 0.4717 0.002706 0.465396 LOC28331TSS200;B 12
cg25316853 -1.0846 0.2134 6.62E-05 0.021241 0.8909 0.2578 0.002822 0.485306 SLC1A3;S TSS200;T 5
cg04521724* -2.4301 0.4792 6.78E-05 0.021754 -1.1768 0.3431 0.002987 0.513709 2
cg08535184 -4.0804 0.8616 0.000144 0.046143 0.9926 0.3033 0.004233 0.72815 ZDHHC18TSS1500 1 chr1:27153033-27153243 N_Shore
cg13778815 -2.1845 0.4165 4.61E-05 0.014811 0.9933 0.3263 0.006983 0.996133 FRG2 TSS1500 4
cg22017777 -2.0933 0.386 3.12E-05 0.010023 1.1193 0.3766 0.008159 0.996133 EPB41L4ABody 5
cg26785949 -1.433 0.3041 0.000152 0.04876 1.0951 0.3799 0.009909 0.996133 CTU1 TSS1500 19 chr19:51611423-51612176 S_Shore
cg09856295 -3.48 0.6146 1.85E-05 0.005943 0.6376 0.2217 0.010065 0.996133 VPS39 TSS1500 15 chr15:42500160-42500561 S_Shore
cg16658180* -1.9881 0.4214 0.00015 0.048141 -1.8384 0.6561 0.011787 0.996133 1
cg16119772* -2.3622 0.4373 3.26E-05 0.010475 -0.9321 0.3327 0.011793 0.996133 5
cg14820221 -1.1354 0.22 5.57E-05 0.017878 0.1101 0.03958 0.012323 0.996133 SAFB2 Body 19 chr19:5593709-5594194 Island
cg24349819 0.996 0.1852 3.44E-05 0.011029 -0.7218 0.2614 0.012844 0.996133 ARHGAP2Body;Body 17 chr17:43472527-43474343 S_Shelf
cg17818792 -1.6083 0.3368 0.000131 0.042189 0.9657 0.3555 0.014142 0.996133 17
cg01750170* -1.6064 0.2863 2.07E-05 0.006632 -0.5702 0.2123 0.015091 0.996133 7 chr7:155595692-155599414 N_Shore
cg02830936* -1.621 0.299 3.13E-05 0.010053 -0.5639 0.211 0.015533 0.996133 MTMR9L TSS1500 1 chr1:32705524-32707141 S_Shore
cg25471923* -2.0163 0.3834 4.47E-05 0.014358 -1.2814 0.4809 0.015796 0.996133 7 chr7:27238690-27240311 S_Shore
cg11506157* -2.3942 0.4878 9.76E-05 0.031315 -1.2242 0.4613 0.016153 0.996133 5
cg00565679 -1.9808 0.3723 3.91E-05 0.012541 0.8423 0.3183 0.01642 0.996133 12
cg22590761* -2.1274 0.427 8.28E-05 0.026565 -0.5393 0.2048 0.01686 0.996133 LOXL1;LO5'UTR;1stE 15 chr15:74218696-74220373 Island
cg05671241 -1.8796 0.391 0.000123 0.039343 1.3449 0.5119 0.017081 0.996133 3 chr3:126373571-126374142 Island
cg07708818* -1.1902 0.2364 7.34E-05 0.023565 -1.1338 0.4412 0.019272 0.996133 GALNS Body 16 chr16:88884168-88884523 N_Shore
cg01394833 -1.4305 0.3015 0.000141 0.045312 0.8815 0.3451 0.019916 0.996133 3 chr3:193587352-193587889 N_Shelf
ch_7_73585 -0.4311 0.08591 7.64E-05 0.024538 0.4027 0.1586 0.020539 0.996133
cg08935238 -1.5733 0.2975 4.20E-05 0.013478 0.9927 0.4023 0.023858 0.996133 PCDHGA4; Body;Body 5 chr5:140798757-140799359 N_Shore
cg04596842 -1.8717 0.3865 0.000113 0.036286 0.6421 0.2608 0.024126 0.996133 14 chr14:19685063-19687329 Island
cg10343024* -1.5232 0.2483 6.74E-06 0.002164 -1.4319 0.587 0.02529 0.996133 PJA2 5'UTR 5 chr5:108744926-108745640 Island
cg26931526* -2.2768 0.4607 9.06E-05 0.029069 -1.1845 0.4972 0.028445 0.996133 1 chr1:8277195-8277822 N_Shore
cg20411075* 1.2781 0.2118 8.33E-06 0.002673 0.6121 0.2603 0.030282 0.996133 13 chr13:21678416-21678648 N_Shore
cg17535691 1.2657 0.2645 0.000129 0.041364 -0.4991 0.213 0.030805 0.996133 TLX1NB 5'UTR 10 chr10:102882977-102883551 N_Shore
cg01443832* -1.2298 0.2321 4.09E-05 0.013142 -0.429 0.1865 0.033596 0.996133 LOC646762TSS1500 7 chr7:29724188-29725436 Island
cg05132568* -1.6437 0.3166 5.19E-05 0.016651 -1.037 0.4517 0.033898 0.996133 KIAA2013 Body 1 chr1:11985643-11986634 N_Shelf
cg05955566* -2.1435 0.4098 4.76E-05 0.015267 -1.3319 0.618 0.044932 0.996133 IKBIP;APAFBody;TSS1 12 chr12:99038272-99039483 Island
cg00787013 -2.852 0.5844 0.000104 0.033345 1.0435 0.4845 0.045054 0.996133 10
cg04614823* -1.4216 0.286 8.50E-05 0.027299 -0.674 0.3136 0.045457 0.996133 TMEM5 Body 12 chr12:64173448-64174238 Island
cg26305042 2.158 0.3664 1.13E-05 0.00364 -0.4515 0.2114 0.046646 0.996133 WNT7B Body 22 chr22:46326912-46327254 Island
cg04293526* 2.1306 0.4499 0.000144 0.046141 0.6957 0.3308 0.049815 0.996133 ITM2C;ITMBody;Body 2 chr2:231729631-231730821 Island
cg07723251 -2.0924 0.4095 6.22E-05 0.019962 1.2251 0.5841 0.050357 0.996133 CA10;CA10TSS1500;T 17 chr17:50235175-50236466 S_Shore
cg04385523 -1.8465 0.3875 0.000135 0.043253 -1.0475 0.4999 0.050565 0.996133 C3orf23;C35'UTR;5'UT 3 chr3:44379532-44380310 S_Shore
cg26268565 -2.5699 0.4517 1.75E-05 0.005602 0.5693 0.2751 0.053189 0.996133 LHFPL3 Body 7
cg15367212 -2.3685 0.432 2.74E-05 0.008781 -0.9944 0.4863 0.055789 0.996133 3
cg07805777 0.9145 0.1541 1.04E-05 0.003327 0.4737 0.233 0.057081 0.996133 11 chr11:15962882-15963223 Island
cg06976485 -2.7173 0.5396 7.34E-05 0.023571 1.562 0.7792 0.060274 0.996133 ATF6B;ATF Body;Body 6
cg15323840 -1.5241 0.3184 0.000128 0.041122 -0.663 0.3335 0.062219 0.996133 SYNJ2 Body 6 chr6:158402072-158403444 S_Shore
cg06499213 -1.5944 0.3379 0.00015 0.048024 -0.7132 0.3638 0.065631 0.996133 TRAF3IP2;TBody;Body 6
cg26875958 -1.3584 0.276 9.46E-05 0.030368 -0.9417 0.4917 0.071513 0.996133 GRM1;GRM3'UTR;Bod 6 chr6:146755475-146755901 N_Shelf
cg06998210 -1.3859 0.2941 0.000152 0.048759 -0.8177 0.4374 0.077927 0.996133 CA7;CA7 Body;TSS1 16 chr16:66878172-66879072 Island
ch_6_27918 -0.9032 0.1883 0.000126 0.040329 0.7404 0.3961 0.077959 0.996133
cg24699146 -1.1967 0.2224 3.43E-05 0.010996 -0.6063 0.3255 0.078871 0.996133 HMGCL;HMTSS1500;T 1
cg03239925 -2.9066 0.6006 0.000114 0.036566 -0.5395 0.2905 0.079702 0.996133 NFATC1;NFBody;Body 18 chr18:77230597-77230803 Island
cg08234372 -2.6627 0.4634 1.55E-05 0.004967 1.0774 0.5837 0.081428 0.996133 16
cg09803177 -1.7389 0.2868 7.85E-06 0.00252 0.7065 0.3892 0.086183 0.996133 CPPED1;CPTSS1500;T 16 chr16:12897365-12897889 S_Shore
cg23631062 -1.437 0.2579 2.26E-05 0.00724 0.4461 0.2468 0.087433 0.996133 OLFM3 TSS200 1
cg11380128 -2.4902 0.5146 0.000114 0.036598 -1.0204 0.5684 0.089442 0.996133 PRLH TSS1500 2
cg03869928 -1.6397 0.3372 0.000108 0.034664 -1.1262 0.6403 0.095581 0.996133 2 chr2:8818292-8818503 N_Shore
cg01055579 -2.0959 0.3085 1.74E-06 0.000558 0.6608 0.3796 0.098781 0.996133 NLE1;NLE1TSS200;TSS 17 chr17:33468896-33469418 S_Shore
cg17746819 -1.1603 0.2237 5.24E-05 0.016818 0.4266 0.2458 0.099661 0.996133 DBT TSS200 1
cg13054881 -2.0628 0.4171 8.97E-05 0.028807 0.4601 0.2672 0.102171 0.996133 ADAM6 TSS1500 14
cg25911551 -1.2727 0.2406 4.19E-05 0.013434 0.3079 0.1802 0.104618 0.996133 GAB1;GAB Body;Body 4
cg18194535 -2.6931 0.5629 0.000129 0.041384 1.0325 0.6071 0.106188 0.996133 LOC154822TSS1500 7 chr7:158798591-158799434 S_Shore
cg05110962 -2.0719 0.4229 9.96E-05 0.031981 -0.7926 0.4933 0.12552 0.996133 15
cg19787366 1.0729 0.2281 0.000155 0.049684 0.4598 0.2876 0.127305 0.996133 MPPE1 TSS1500 18 chr18:11908222-11909082 Island
cg23660197 -1.6824 0.3376 8.24E-05 0.02645 0.5687 0.357 0.128574 0.996133 MICB 3'UTR 6
cg25637226 -2.2269 0.468 0.000137 0.043842 -1.5932 1.0008 0.128825 0.996133 CARS2 Body 13 chr13:111358080-111358894 N_Shelf
cg11970982 -2.2887 0.4768 0.000125 0.03998 0.8203 0.5209 0.132716 0.996133 2
cg14788673 -2.2645 0.4731 0.000128 0.041176 0.8678 0.5581 0.137334 0.996133 FGGY;FGGYBody;Body 1
cg15820400 -1.431 0.2634 3.05E-05 0.009787 0.5797 0.3755 0.139967 0.996133 FBXL17 Body 5
cg02023402 -1.6257 0.2742 1.05E-05 0.00336 0.5494 0.3576 0.141925 0.996133 7
cg13284152 -1.465 0.2962 8.98E-05 0.028841 0.7203 0.4694 0.142304 0.996133 6
cg06218627 -1.2444 0.2592 0.000124 0.039812 0.6186 0.4062 0.145204 0.996133 LOC402377TSS200;5'U 9 chr9:123555399-123555899 Island
cg00206271 -1.4157 0.2774 6.30E-05 0.020239 0.49 0.3259 0.149923 0.996133 SNTG2 Body 2 chr2:1163016-1163820 S_Shelf
cg23858558 -1.4833 0.2282 3.16E-06 0.001013 0.5074 0.3391 0.151883 0.996133 SDC2 TSS1500 8 chr8:97505747-97507607 N_Shore
cg14191955 -2.1271 0.4453 0.000131 0.042053 -0.5142 0.3451 0.153551 0.996133 17
cg00883210 -2.1253 0.4121 5.61E-05 0.017999 0.8141 0.5479 0.154658 0.996133 4 chr4:3565311-3567185 Island
cg01880149 -2.8 0.5426 5.57E-05 0.017867 1.0764 0.7245 0.154663 0.996133 FLG Body 1
cg13951490 -1.7984 0.3559 7.06E-05 0.022649 0.7221 0.4954 0.162236 0.996133 PCDHGA4; Body;Body 5 chr5:140798757-140799359 Island
cg25488567 -1.1795 0.2446 0.000119 0.038053 -0.6895 0.475 0.163767 0.996133 FAM26F TSS1500 6 chr6:116783067-116783678 N_Shore
cg22673380 -0.8 0.1422 2.00E-05 0.006435 0.5949 0.4192 0.17289 0.996133 SLC12A7 Body 5 chr5:1054619-1054880 Island
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Table A2.1
CpG Estimate StdErr RAW_P ahoc_p Estimate StdErr RAW_P ahoc_p UCSC_Re UCSC_Re CHR UCSC_CpG_Islands_Name Relation_to_UCSC_CpG_Island
cg00573504 -2.088 0.3525 1.06E-05 0.003396 -0.6346 0.4581 0.18287 0.996133 5
cg10144474 -1.9852 0.412 0.00012 0.038364 -0.4391 0.319 0.185514 0.996133 15
cg12143439 -1.304 0.2774 0.000156 0.049966 -0.3307 0.2409 0.186656 0.996133 CD14;CD141stExon;5' 5 chr5:140011482-140012739 Island
cg13313214 -2.1982 0.4173 4.38E-05 0.014074 0.5719 0.422 0.192142 0.996133 STK31;STK 1stExon;5' 7
cg02448934 0.4537 0.07789 1.31E-05 0.00419 0.3459 0.2675 0.21243 0.996133 BTNL2 Body 6
cg00795205 -0.9408 0.1735 3.13E-05 0.010048 0.2277 0.1764 0.213052 0.996133 PRKCB;PRKBody;Body 16
cg07467338 -1.9048 0.3933 0.000113 0.036223 0.491 0.3819 0.214862 0.996133 FAM66D Body 8
cg18673825 -1.4222 0.3021 0.000153 0.049135 -0.633 0.4935 0.215879 0.996133 P2RX4 TSS1500 12 chr12:121647705-121648216 N_Shore
cg11273834 -2.0397 0.4173 0.000102 0.032775 0.7235 0.568 0.21897 0.996133 PPIL4 Body 6 chr6:149867031-149867574 N_Shelf
cg27500856 -1.9524 0.3833 6.46E-05 0.020736 0.4588 0.3659 0.225896 0.996133 C3orf71;ARTSS1500;5 3 chr3:48955810-48956938 S_Shore
cg21219851 -1.5089 0.2878 4.64E-05 0.014884 0.4436 0.3573 0.230303 0.996133 RPTOR;RPTBody;Body 17 chr17:78896436-78896803 S_Shore
cg15352186 -2.1879 0.3995 2.77E-05 0.008896 0.8248 0.673 0.236139 0.996133 ADAM2 TSS200 8
cg03460239 -1.5884 0.2718 1.25E-05 0.004013 0.538 0.4401 0.237332 0.996133 OR8B8 TSS200 11
cg25601967 -1.5027 0.3188 0.000151 0.048486 0.4162 0.3462 0.24477 0.996133 12
cg23372128 1.867 0.3926 0.000138 0.044164 0.6365 0.5319 0.246995 0.996133 12
cg06535993 -1.167 0.2466 0.000145 0.046477 0.5613 0.4711 0.248974 0.996133 APBB1IP TSS200 10 chr10:26727061-26727992 Island
cg20431441 -1.2909 0.2519 6.02E-05 0.019313 -0.2992 0.2538 0.253819 0.996133 8 chr8:82542798-82543475 N_Shelf
cg02584802 -1.6224 0.2741 1.07E-05 0.003431 0.3386 0.2874 0.254091 0.996133 11 chr11:115630398-115631117 S_Shelf
cg18773129 0.5703 0.1208 0.000149 0.04782 0.3749 0.3212 0.258254 0.996133 COMT;COM5'UTR;5'UT 22
cg04267998 -1.4522 0.3059 0.00014 0.045017 -0.4506 0.3872 0.259696 0.996133 TRIP12 Body 2
cg20026178 -1.0856 0.1838 1.09E-05 0.00351 0.422 0.3646 0.262209 0.996133 WRNIP1;WBody;Body 6 chr6:2765203-2766775 S_Shore
cg03529662 -1.9868 0.3747 4.06E-05 0.013035 0.3722 0.3222 0.263242 0.996133 OR1A1 TSS1500 17
cg19482843 -3.2159 0.673 0.000131 0.041947 0.7677 0.6654 0.2637 0.996133 EIF2C2;EIF Body;Body 8 chr8:141559164-141559368 S_Shore
cg26335281 -1.2494 0.2512 8.42E-05 0.027039 -0.5922 0.5154 0.265631 0.996133 REEP2;REE 1stExon;5' 5
cg06664085 1.2619 0.2683 0.000155 0.049629 -0.3362 0.2932 0.266637 0.996133 ARMC4;AR 5'UTR;1stE 10 chr10:28287447-28288057 Island
cg02500201 -2.3835 0.4496 4.07E-05 0.013069 -0.58 0.5078 0.268321 0.996133 CLCN7;CLC Body;Body 16 chr16:1502628-1502858 Island
cg01541219 -2.8113 0.5436 5.43E-05 0.017421 -0.5643 0.5014 0.275204 0.996133 TAF4 Body 20 chr20:60630222-60630425 N_Shore
cg20420603 -3.3808 0.7143 0.000145 0.046446 -1.0915 0.9733 0.276823 0.996133 MYH10 Body 17 chr17:8380172-8380539 S_Shore
cg21981500 -1.7576 0.2721 3.44E-06 0.001103 -0.3844 0.3434 0.277659 0.996133 TMEM102 TSS200 17 chr17:7339808-7340896 N_Shore
cg19099213 -1.679 0.3438 0.000103 0.033155 -0.4512 0.4055 0.280556 0.996133 SPP2 TSS1500 2
cg25196975 -2.0108 0.3405 1.10E-05 0.003525 0.6626 0.5968 0.281522 0.996133 ROBO3 Body 11 chr11:124738712-124739011 N_Shore
cg19647111 -1.1563 0.226 6.12E-05 0.019658 -0.4488 0.4159 0.294758 0.996133 TNXB 5'UTR 6
cg25499537 -1.58 0.2783 1.79E-05 0.005755 -0.3305 0.3081 0.297554 0.996133 IGSF10 TSS1500 3 chr3:151178623-151178984 N_Shore
cg18759743 -1.1436 0.1737 2.65E-06 0.000852 0.3016 0.2837 0.301718 0.996133 ARHGEF10 Body;Body 1
cg00931181 -1.8858 0.2966 4.23E-06 0.001358 -0.2317 0.2185 0.302814 0.996133 2
cg02332769 -2.312 0.4069 1.77E-05 0.00569 -0.5073 0.4825 0.306988 0.996133 CCDC122 Body 13
cg07156814 -2.3027 0.4453 5.43E-05 0.017442 -0.3082 0.2937 0.307776 0.996133 KIT;KIT Body;Body 4
cg19865002 -1.1992 0.2464 0.000107 0.034353 -0.3106 0.3049 0.321708 0.996133 RNF144B 5'UTR 6
cg24117104 -1.8338 0.355 5.50E-05 0.017657 0.3042 0.3017 0.326662 0.996133 4 chr4:149363212-149367056 Island
cg25987171 2.1286 0.4342 9.88E-05 0.031718 0.3915 0.3893 0.32783 0.996133 SPDYC TSS200 11
cg02299937 2.0703 0.4363 0.000141 0.045234 0.4266 0.4314 0.335829 0.996133 FCGBP Body 19 chr19:40366026-40366608 Island
cg03382370 0.9605 0.191 7.47E-05 0.023973 -0.1277 0.1299 0.338723 0.996133 LOC146336Body 16 chr16:1122629-1123009 N_Shore
cg02346442 -1.9306 0.3737 5.49E-05 0.017625 -0.4372 0.4466 0.340563 0.996133 3
cg25288034 1.6488 0.3473 0.00014 0.045005 0.286 0.2931 0.342179 0.996133 10
cg18888710 -2.2181 0.4378 6.86E-05 0.022009 0.4731 0.494 0.350911 0.996133 ATP6V1C2;Body;Body 2
cg18688704 -1.8322 0.3365 2.97E-05 0.009528 0.3702 0.3899 0.355058 0.996133 PDGFC Body 4 chr4:157892685-157893286 N_Shelf
cg13346967 -2.1154 0.4328 0.000102 0.032779 -0.7477 0.7915 0.357351 0.996133 CYTH2;CYTBody;Body 19 chr19:48972225-48973157 S_Shelf
cg03400512 -2.2383 0.4503 8.49E-05 0.027244 0.6007 0.6463 0.364994 0.996133 1
cg04550474 -1.8785 0.3757 7.95E-05 0.025516 0.3016 0.3279 0.369717 0.996133 LOC642006Body 7 chr7:57247588-57247927 N_Shore
cg07500347 -1.46 0.2851 6.08E-05 0.019519 -0.3187 0.3466 0.369853 0.996133 16 chr16:874280-874895 S_Shore
cg14406401 -1.6762 0.3457 0.000112 0.035792 0.3469 0.3782 0.371129 0.996133 NAV2;NAV Body;Body 11
cg11735008 -1.6423 0.3255 7.18E-05 0.023038 -0.4282 0.4795 0.383641 0.996133 HIVEP3;HIV5'UTR;5'UT 1 chr1:42383640-42384003 N_Shelf
cg17330505 -0.5972 0.1116 3.64E-05 0.01169 -0.5149 0.5821 0.388068 0.996133 17
cg09838336 -2.6072 0.5234 8.29E-05 0.026612 0.543 0.6379 0.405797 0.996133 C7orf44 5'UTR 7
cg02722657 1.2973 0.2604 8.27E-05 0.026559 -0.2178 0.2586 0.410707 0.996133 RAPGEFL1;1stExon;5' 17 chr17:38333605-38334795 Island
cg24399212 -3.0161 0.5986 7.30E-05 0.023419 0.7176 0.8552 0.412413 0.996133 10
cg16998490 -1.6837 0.294 1.61E-05 0.005173 -0.3094 0.3724 0.416999 0.996133 AZIN1;AZINTSS1500;T 8 chr8:103875222-103877084 Island
cg16383005 -2.1371 0.3967 3.37E-05 0.01083 -0.5137 0.6268 0.423161 0.996133 6 chr6:166711162-166711605 Island
cg10201735 -1.9505 0.3408 1.62E-05 0.005212 -0.3683 0.451 0.424764 0.996133 14 chr14:97499605-97500176 S_Shelf
cg19005233 -2.2846 0.4409 5.31E-05 0.017033 0.373 0.4603 0.428389 0.996133 PCDHB15 1stExon 5 chr5:140626444-140627373 Island
cg20458779 2.5572 0.4202 7.50E-06 0.002407 0.454 0.5604 0.428431 0.996133 FCGBP Body 19 chr19:40366026-40366608 Island
cg03033688 -1.6543 0.333 8.55E-05 0.027443 0.2535 0.315 0.431359 0.996133 HS3ST2 TSS1500 16 chr16:22824616-22826459 N_Shore
cg21500456 -2.4948 0.5211 0.000128 0.041059 -0.3519 0.4411 0.435452 0.996133 14 chr14:21191657-21191860 N_Shore
cg18638330 -1.6928 0.3288 5.71E-05 0.018343 -0.2984 0.3826 0.445599 0.996133 5
cg27209964 -3.5507 0.6569 3.24E-05 0.010412 0.4297 0.5558 0.449536 0.996133 13
cg08209711 -0.8999 0.191 0.000152 0.048786 0.2281 0.297 0.452459 0.996133 PSMB9;PSMBody;Body 6 chr6:32820849-32822370 S_Shelf
cg13336167 -1.5366 0.3132 9.83E-05 0.031541 -0.2898 0.3783 0.453456 0.996133 ZNF579 5'UTR 19 chr19:56089679-56090859 S_Shore
cg22197358 -2.8514 0.4512 4.59E-06 0.001472 0.367 0.4794 0.45388 0.996133 TCF3;TCF3 Body;Body 19 chr19:1615202-1615812 Island
cg19080320 -1.284 0.2666 0.00012 0.038594 -0.343 0.4498 0.455617 0.996133 FOXK1 Body 7
cg20299254 -1.6378 0.3064 3.70E-05 0.011878 0.4104 0.5476 0.463261 0.996133 WFDC2 TSS1500 20 chr20:44098280-44099536 N_Shore
cg00209918 1.47 0.2915 7.23E-05 0.023217 -0.2116 0.2844 0.466532 0.996133 SETD1A Body 16 chr16:30991828-30992129 N_Shore
cg26957602 -1.8876 0.3774 7.93E-05 0.025462 0.3409 0.4647 0.472608 0.996133 15
cg26143719 -2.766 0.5756 0.000123 0.039436 0.4767 0.6604 0.479703 0.996133 C1QTNF6;C1stExon;1s 22
cg07780669 -0.9156 0.1825 7.67E-05 0.024606 0.2355 0.3324 0.487727 0.996133 TMCO6 TSS200 5 chr5:140019034-140019502 N_Shore
cg14323117 -1.2791 0.2689 0.000137 0.044016 0.1729 0.2449 0.489242 0.996133 3 chr3:14643718-14644830 N_Shore
cg11029358 -2.3969 0.4811 8.27E-05 0.026539 -0.1729 0.2475 0.493779 0.996133 COL18A1;C5'UTR;1stE 21 chr21:46876168-46876752 N_Shore
cg27486692 -1.8179 0.2848 4.02E-06 0.00129 -0.3692 0.5421 0.504471 0.996133 GUCY2C 3'UTR 12
cg20075700 -2.7422 0.4981 2.60E-05 0.008361 -0.2936 0.4375 0.510725 0.996133 22 chr22:49376395-49376660 Island
cg27134084 -2.5356 0.5351 0.000143 0.0459 0.2503 0.3788 0.517148 0.996133 7
cg08482979 1.4031 0.2938 0.000132 0.042222 0.1989 0.3041 0.521402 0.996133 16
cg06814191 -2.7113 0.5625 0.000119 0.038174 -0.3791 0.581 0.522302 0.996133 11
cg06829645 -2.5013 0.5237 0.000131 0.042173 -0.4076 0.6541 0.541005 0.996133 13
cg10439742 -0.9147 0.1836 8.28E-05 0.026594 0.1416 0.2428 0.567091 0.996133 HSBP1 3'UTR 16 chr16:83841412-83841988 S_Shelf
cg08581737 -1.3628 0.2601 4.68E-05 0.015014 -0.1689 0.3131 0.596259 0.996133 DLX2 1stExon 2 chr2:172964762-172967857 Island
cg18356276 -2.0972 0.4301 0.000105 0.033677 0.2351 0.4381 0.598092 0.996133 AHR TSS1500 7 chr7:17338252-17339101 N_Shore
cg12765716 -2.2927 0.4416 5.18E-05 0.016643 -0.2886 0.5691 0.618268 0.996133 TRPV4;TRP5'UTR;5'UT 12
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cg10803309 -1.9821 0.371 3.72E-05 0.01195 0.2141 0.4241 0.619787 0.996133 HIPK3;HIPKBody;Body 11
cg15272312 -0.6987 0.1144 7.17E-06 0.002303 -0.1653 0.3315 0.624049 0.996133 HNRNPA1L1stExon;1s 13 chr13:53191405-53191872 Island
cg14410733 -2.8774 0.5989 0.000123 0.03954 0.2261 0.454 0.624575 0.996133 15
cg08727867 -1.0338 0.2183 0.000144 0.046223 0.1883 0.3887 0.633881 0.996133 RBM11 TSS200 21 chr21:15588439-15588908 N_Shore
cg17769009 -2.5466 0.5394 0.000149 0.047728 -0.2967 0.6205 0.638283 0.996133 RPL23AP53Body 8 chr8:179001-179288 Island
cg01864127 1.1965 0.2384 7.62E-05 0.02445 -0.153 0.3304 0.648875 0.996133 CLPTM1L Body 5
cg11781622 -1.7654 0.3506 7.36E-05 0.023612 0.1661 0.3741 0.662408 0.996133 PRKCZ;PRK5'UTR;Bod 1 chr1:2040997-2041302 Island
cg24290586 0.473 0.08281 1.66E-05 0.005332 0.09401 0.2184 0.671942 0.996133 BTNL2 Body 6
cg16019434 -1.0071 0.2099 0.000125 0.040115 -0.1264 0.2962 0.674506 0.996133 18 chr18:76737005-76741244 N_Shore
cg18469813 -1.6067 0.3408 0.000151 0.048515 -0.1656 0.3883 0.674741 0.996133 6
cg12349837 -1.8511 0.3851 0.000123 0.039357 -0.03183 0.0763 0.681457 0.996133 COL4A3;COBody;Body 2 chr2:228028679-228029733 S_Shelf
cg11619050 -1.3712 0.2869 0.00013 0.041856 -0.1829 0.4465 0.686911 0.996133 APOM TSS1500 6 chr6:31619856-31620525 S_Shelf
cg26447413 1.8636 0.3632 5.93E-05 0.019045 -0.366 0.8966 0.68796 0.996133 GAS1 1stExon 9 chr9:89560584-89562647 Island
cg15372959 -2.0238 0.3841 4.38E-05 0.014047 -0.2055 0.5236 0.699349 0.996133 TACC2;TACTSS1500;B 10 chr10:123922850-123923542 N_Shore
cg09821400 -1.5844 0.3078 5.72E-05 0.018374 -0.1785 0.4869 0.718194 0.996133 10
cg13979407 0.7638 0.1577 0.000113 0.036308 -0.1171 0.3364 0.731841 0.996133 BTNL2 Body 6
cg03364683 -1.2194 0.2095 1.32E-05 0.004231 0.07429 0.2152 0.733863 0.996133 DDX60L TSS1500 4 chr4:169401350-169401725 S_Shore
cg03610567 -2.1992 0.4401 8.00E-05 0.025676 0.2441 0.7291 0.741584 0.996133 TRIM26 Body 6
cg25687358 -1.3988 0.2738 6.23E-05 0.019998 -0.09616 0.2929 0.746478 0.996133 DUOXA1;D Body;Body 15 chr15:45408573-45409528 S_Shore
cg08107075 -2.4409 0.4792 6.45E-05 0.020691 -0.1655 0.5044 0.746542 0.996133 7
cg13443976 -2.2106 0.4288 5.63E-05 0.018058 0.202 0.618 0.747589 0.996133 CLCA4;CLC Body;Body 1 chr1:87018668-87019254 S_Shelf
cg17387838 -1.395 0.2686 5.16E-05 0.01657 0.1095 0.3401 0.751165 0.996133 CACNG6;CA3'UTR;3'UT 19 chr19:54515094-54515342 S_Shore
cg03140624 -1.4736 0.3072 0.000125 0.040212 -0.1452 0.4772 0.764324 0.996133 LYST Body 1
cg10002668 -1.8301 0.3754 0.000105 0.033803 -0.1243 0.4157 0.768404 0.996133 LAMB4 Body 7
cg08486903 -1.1752 0.2463 0.000133 0.042591 -0.09742 0.3289 0.770452 0.996133 SMURF1;S Body;Body 7 chr7:98741205-98741990 N_Shore
cg04990210 -2.198 0.3503 5.04E-06 0.001617 -0.1718 0.5832 0.771638 0.996133 CTNS;CTNSBody;Body 17
cg04723493 -1.442 0.2852 7.01E-05 0.022493 -0.1805 0.6232 0.775358 0.996133 FZD6;FZD6 TSS1500;T 8 chr8:104310809-104311620 Island
cg11413778 -3.1727 0.6716 0.000148 0.047412 -0.1503 0.5337 0.781406 0.996133 ALLC 5'UTR 2
ch_3_27419 -0.8377 0.171 9.96E-05 0.031974 -0.07461 0.2724 0.78728 0.996133
cg26664634 -0.6542 0.1299 7.31E-05 0.023463 0.06808 0.252 0.790129 0.996133 ORC4L;ORCTSS200;5'U 2 chr2:148778222-148778530 Island
cg16579158 -1.6705 0.3371 8.78E-05 0.028179 0.07568 0.2815 0.791112 0.996133 PCDHGA2; 1stExon;Bo 5 chr5:140719129-140719343 Island
cg10548968 -1.7066 0.3493 0.000103 0.032982 -0.1001 0.4216 0.814923 0.996133 CAPN5 Body 11
cg16396866 -1.6647 0.3249 6.03E-05 0.01937 -0.09242 0.3948 0.817571 0.996133 MCTP1 Body 5 chr5:94619459-94621121 N_Shelf
cg14403594 -1.0403 0.2124 1.00E-04 0.032093 0.06389 0.3008 0.834174 0.996133 POMT1;POTSS1500;T 9 chr9:134378193-134378792 N_Shore
cg23075771 -1.9534 0.3998 0.000103 0.032977 -0.1006 0.5271 0.850844 0.996133 1
cg01974027 -1.9063 0.2982 3.94E-06 0.001265 -0.07521 0.3946 0.850958 0.996133 SYT6 5'UTR 1 chr1:114695136-114696672 N_Shore
cg13404532 -2.5384 0.5083 8.07E-05 0.025894 0.06492 0.3432 0.852088 0.996133 RAB7A 5'UTR 3 chr3:128483727-128484050 N_Shore
cg10083824 -1.2876 0.2398 3.51E-05 0.011268 -0.05349 0.2922 0.85679 0.996133 GRM4 TSS1500 6
cg17642145 -1.1978 0.2269 4.28E-05 0.013747 0.04347 0.2545 0.866298 0.996133 PPP3CC TSS200 8 chr8:22298112-22299142 Island
cg24600706 -1.3994 0.2916 0.000125 0.040048 -0.07174 0.448 0.874552 0.996133 10 chr10:118899247-118900329 S_Shore
cg15256743 -1.1554 0.231 7.91E-05 0.0254 0.05468 0.3444 0.875637 0.996133 12 chr12:94533729-94533952 S_Shelf
cg02030454 -1.3222 0.2286 1.43E-05 0.004585 -0.04857 0.3229 0.882124 0.996133 GJB3;GJB3 Body;Body 1 chr1:35250418-35250736 Island
cg01886741 -1.7741 0.3139 1.90E-05 0.006092 -0.05547 0.3794 0.88539 0.996133 BIRC5;BIRC1stExon;1s 17 chr17:76210129-76210627 Island
cg09176901 -2.1276 0.3947 3.35E-05 0.01075 0.07928 0.5621 0.8894 0.996133 TIMELESS Body 12
cg19224656 -0.6659 0.1261 4.26E-05 0.013662 -0.03712 0.2797 0.895917 0.996133 SHQ1;SHQ 5'UTR;1stE 3 chr3:72896940-72897793 Island
cg07278997 -1.1137 0.2099 4.03E-05 0.012943 0.03138 0.2786 0.911574 0.996133 UBE2W;UBTSS1500;T 8 chr8:74790342-74791412 Island
cg06382167 -2.2587 0.4079 2.43E-05 0.007794 -0.06264 0.5646 0.912893 0.996133 PDE11A;PD5'UTR;1stE 2
cg15549502 -3.0733 0.5927 5.27E-05 0.016904 -0.08166 0.7973 0.919556 0.996133 MORN1 Body 1 chr1:2266007-2266432 S_Shelf
cg11823603 -1.5277 0.3116 9.90E-05 0.031774 -0.04049 0.3979 0.920063 0.996133 5
cg02751327 -1.4673 0.2689 2.90E-05 0.009293 -0.03795 0.3983 0.925146 0.996133 12 chr12:64784010-64784664 S_Shelf
cg04446303 -1.4577 0.3092 0.000151 0.048434 -0.03164 0.342 0.927314 0.996133 TFAP4;TFA 1stExon;5' 16 chr16:4321639-4324073 Island
cg19304063 -1.5689 0.3086 6.59E-05 0.021162 0.04057 0.4468 0.928656 0.996133 FARP1 3'UTR 13
cg24677222 -1.6605 0.3091 3.48E-05 0.011182 -0.03552 0.4187 0.933338 0.996133 CLSTN2 Body 3
cg21945260 -2.0333 0.4288 0.000142 0.045525 0.02326 0.2851 0.935882 0.996133 2
cg08300990 -1.6212 0.287 1.91E-05 0.006121 0.05063 0.6537 0.939117 0.996133 OR8G1;OR Body;1stEx 11
cg02704485 -0.6204 0.1074 1.45E-05 0.004654 -0.01693 0.2341 0.943158 0.996133 3
cg01769501 -0.8809 0.1524 1.43E-05 0.004603 -0.01262 0.2106 0.952861 0.996133 SDAD1 TSS200 4 chr4:76911843-76912252 Island
cg05590053 -1.899 0.2748 1.37E-06 0.000439 -0.01985 0.3318 0.952964 0.996133 8
cg00614641 1.8633 0.3947 0.000149 0.047697 -0.02875 0.5134 0.955958 0.996133 FADS2 Body 11 chr11:61594996-61596710 Island
cg00648955 -3.3206 0.54 6.55E-06 0.002103 0.02167 0.3958 0.956942 0.996133 EHD3 TSS1500 2 chr2:31456740-31457653 N_Shore
cg24698488 -1.9674 0.4035 0.000105 0.033666 0.02895 0.5819 0.960865 0.996133 MMP14 3'UTR 14 chr14:23315027-23315265 S_Shore
cg08219099 -1.2593 0.2627 0.000126 0.040563 -0.02513 0.6033 0.967235 0.996133 MAEA;MA Body;Body 4 chr4:1322394-1322875 S_Shelf
cg05548672 -2.3812 0.4638 5.89E-05 0.018912 -0.02032 0.5684 0.971869 0.996133 C16orf72 Body 16
cg20761853 -1.6782 0.3518 0.000133 0.04267 -0.00832 0.2859 0.977102 0.996133 TIMP2 3'UTR 17 chr17:76851759-76851973 N_Shore
cg08575537 2.0672 0.4369 0.000145 0.046599 0.008531 0.3454 0.98057 0.996133 EPO Body 7 chr7:100318106-100318684 Island
cg02860394 -1.1966 0.2259 4.12E-05 0.013233 0.002926 0.339 0.993208 0.996133 RNF103 TSS200 2 chr2:86850042-86851178 Island
cg13165753 -1.2379 0.2609 0.000141 0.045257 0.00434 0.5944 0.994255 0.996133 FN1;FN1;F TSS1500;T 2 chr2:216300267-216300997 S_Shore
cg21179305 -1.9475 0.3974 9.93E-05 0.03189 0.002758 0.4009 0.994587 0.996133 ZCCHC7 TSS1500 9 chr9:37120050-37120985 N_Shore
cg07313835 -1.8993 0.397 0.000129 0.041404 -0.00253 0.5151 0.996133 0.996133 POU2F1 Body 1
cg00090648 -0.778 0.1565 8.50E-05 0.02729 C1orf55 TSS1500 1 chr1:226186803-226187336 Island
cg00095105 -1.9562 0.4155 0.000153 0.049175 10
cg00173799 -2.0917 0.4389 0.000134 0.043106 PGR TSS1500 11 chr11:100998030-100999774 S_Shore
cg00460793 -1.9521 0.3464 1.96E-05 0.006297 7
cg00576474 -2.6198 0.4691 2.19E-05 0.00704 2 chr2:242929993-242930252 N_Shore
cg00624949 -1.0591 0.1896 2.18E-05 0.006992 EGFL8 Body 6 chr6:32134460-32135196 Island
cg00627621 -0.9188 0.1717 3.64E-05 0.011689 TRIB1 TSS200 8 chr8:126441471-126443552 Island
cg00647646 1.5304 0.2815 3.03E-05 0.009739 CPSF6 Body 12 chr12:69633272-69634095 Island
cg00712044 -1.0648 0.2003 3.95E-05 0.012689 KIAA1826; 1stExon;5' 11 chr11:105892725-105892952 Island
cg00804628 0.8863 0.1723 5.75E-05 0.018461 NXPH2 TSS200 2 chr2:139537692-139538650 Island
cg00810986 -1.4181 0.2853 8.48E-05 0.027231 PCGF3 Body 4 chr4:724335-726070 S_Shore
cg00853687 -1.7765 0.3102 1.61E-05 0.005163 1
cg00866373 -0.9748 0.207 0.000152 0.048934 ZCCHC4;ZC5'UTR;1stE 4 chr4:25314217-25314558 Island
cg00969787 -1.9334 0.2922 2.48E-06 0.000797 TESK2 5'UTR 1 chr1:45956345-45956893 N_Shore
cg01026661 -1.3889 0.2204 4.75E-06 0.001525 FAM173B Body 5
cg01132471 -1.9216 0.4078 0.000152 0.048697 SLC1A7 Body 1 chr1:53558388-53558642 N_Shore
cg01396112 1.6082 0.2927 2.67E-05 0.008565 NOS2 Body 17 chr17:26120369-26120944 Island
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cg01464748 2.1287 0.4464 0.000133 0.042837 ALOX5 Body 10 chr10:45922831-45923375 Island
cg01685923 -0.3916 0.07561 5.33E-05 0.017119 13
cg01831337 0.6453 0.1279 7.17E-05 0.023 UST Body 6 chr6:149198359-149199534 N_Shore
cg01871995 -1.3889 0.2824 9.54E-05 0.030612 FGL1;FGL1 TSS1500;T 8
cg02112681 -1.0283 0.1761 1.27E-05 0.004069 C7orf50;C7Body;Body 7 chr7:1119980-1120248 Island
cg02159489 -0.2166 0.04332 7.97E-05 0.02557 17 chr17:79454734-79455823 S_Shelf
cg02820514 1.4777 0.3081 0.000126 0.040308 ZIC4 TSS1500 3 chr3:147126988-147128999 N_Shelf
cg02923571 0.8839 0.1695 4.94E-05 0.015867 PWP1 TSS200 12 chr12:108079442-108079893 Island
cg02982238 -2.9894 0.6307 0.000143 0.045758 7
cg02987249 -2.5048 0.4527 2.45E-05 0.007868 TRIP10 Body 19 chr19:6752515-6753657 N_Shelf
cg03050687 0.9801 0.2035 0.00012 0.038543 ADAL;LCM TSS1500;1 15 chr15:43621830-43622953 Island
cg03128025 -1.2206 0.2595 0.000155 0.049614 2
cg03180302 -1.7696 0.3321 3.83E-05 0.012305 TTR 1stExon 18
cg03202545 -0.5976 0.1127 4.06E-05 0.013039 HIPK2;HIPKBody;Body 7
cg03215005 -0.9427 0.192 9.74E-05 0.031281 MX1 TSS1500 21 chr21:42792293-42792704 Island
cg03237431 -1.121 0.2379 0.000152 0.048736 CACNG1 TSS1500 17 chr17:65040729-65041029 N_Shore
cg03242458 -3.4038 0.6794 7.78E-05 0.024963 TRIM15 Body 6
cg03263979 -1.9703 0.4165 0.000146 0.046743 19 chr19:33864176-33865010 N_Shelf
cg03277925 0.8427 0.1607 4.61E-05 0.014807 ADARB2 Body 10
cg03437605 -2.0149 0.4094 9.47E-05 0.030404 RHOBTB2 5'UTR 8
cg03442350 -0.634 0.1041 7.46E-06 0.002395 6
cg03651219 -2.302 0.4559 7.11E-05 0.022837 10
cg03689195 2.3232 0.4817 0.000118 0.03793 13 chr13:58203586-58204322 Island
cg04134528 -2.6097 0.5529 0.000149 0.047887 5
cg04193922 -1.0958 0.2176 7.35E-05 0.023596 LOC729338TSS200;TSS 4 chr4:123653585-123654000 Island
cg04245294 -2.145 0.4519 0.00014 0.045073 3 chr3:37901938-37904039 N_Shelf
cg04248157 1.3255 0.2686 9.19E-05 0.029502 KCNIP1;KC TSS200;TSS 5 chr5:169931065-169931471 N_Shore
cg04315226 -2.0414 0.3729 2.79E-05 0.008943 FAM164C; 3'UTR;3'UT 14
cg04398972 0.7449 0.1485 7.67E-05 0.024635 4 chr4:75858300-75859931 N_Shelf
cg04407100 -2.9657 0.4143 8.38E-07 0.000269 10
cg04435807 -1.8898 0.3871 0.000103 0.033196 ANKRD22 Body 10
cg04461334 -1.7699 0.3376 4.64E-05 0.014889 MAP4K3 Body 2 chr2:39663897-39664667 N_Shelf
cg04903900 -1.9568 0.3015 3.22E-06 0.001033 16
cg04913730 0.8166 0.1696 0.00012 0.038558 LOC146336Body 16 chr16:1122629-1123009 N_Shore
cg04935278 -2.4073 0.5052 0.000135 0.043191 ITPRIP TSS200 10 chr10:106097595-106098556 N_Shelf
cg04984709 -1.8085 0.3381 3.67E-05 0.011785 PDE8B;PDEBody;Body 5
cg04985652 -0.7892 0.1494 4.26E-05 0.013661 DTD1 TSS200 20 chr20:18568436-18569092 Island
cg05031521 1.5726 0.2913 3.29E-05 0.010552 SOX8 TSS1500 16 chr16:1029878-1035327 Island
cg05044694 -1.3366 0.217 6.42E-06 0.00206 PPP1CB;PP Body;Body 2 chr2:28974212-28975388 Island
cg05092988 2.5226 0.4648 3.09E-05 0.00991 DSCAML1 Body 11
cg05099145 1.0797 0.2145 7.39E-05 0.023722 MAPK8IP3 Body;Body 16 chr16:1796810-1797229 N_Shore
cg05426702 -0.7936 0.1589 8.03E-05 0.025777 15 chr15:40573628-40576118 Island
cg05590265 -2.0911 0.4445 0.000154 0.049564 6
cg05918473 -2.2093 0.4093 3.29E-05 0.010572 ZAR1L 1stExon 13 chr13:32885424-32885662 Island
cg05939041 -2.9078 0.5946 0.000102 0.032637 ITPK1;ITPK Body;Body 14
cg06031526 -0.8396 0.1755 0.000129 0.041407 3
cg06239037 -0.9344 0.1953 0.000129 0.041381 ACAA1;ACATSS1500;T 3 chr3:38179857-38180689 Island
cg06363887 -0.6372 0.1158 2.61E-05 0.008379 UTP3 TSS200 4 chr4:71553854-71554473 Island
cg06666008 -1.5021 0.3169 0.000143 0.045788 PAX6;PAX6Body;Body 11 chr11:31820060-31821416 N_Shore
cg06679777 -1.1748 0.2095 2.09E-05 0.006703 KATNAL1;KTSS200;5'U 13 chr13:30880899-30881939 Island
cg06741896 -1.0739 0.2078 5.48E-05 0.017576 CCND1 3'UTR 11 chr11:69468810-69469152 N_Shore
cg07169712 0.9916 0.2095 0.000145 0.046427 GABBR1;G Body;Body 6
cg07175007 -0.8073 0.1548 4.93E-05 0.01583 UHMK1 TSS1500 1 chr1:162467599-162468027 N_Shore
cg07210335 -1.1128 0.2304 0.000116 0.037322 MAN2A1 Body 5 chr5:109024965-109026701 S_Shore
cg07297397 -1.1571 0.2329 8.55E-05 0.027459 IGF2BP3 TSS200 7 chr7:23508184-23509712 S_Shore
cg07317755 -0.804 0.1595 7.24E-05 0.023254 PDE12 TSS200 3 chr3:57541931-57543244 N_Shore
cg07360893 -0.9258 0.1866 8.66E-05 0.027812 IFT80;SMC TSS200;TSS 3 chr3:160117012-160118878 Island
cg07917502 -1.1209 0.2128 4.38E-05 0.01407 PREPL;PRE TSS200;TSS 2 chr2:44588954-44589358 Island
cg08207170 -1.8942 0.3916 0.000114 0.036723 16 chr16:89882392-89883458 S_Shelf
cg08479675 -2.1063 0.4262 9.06E-05 0.029093 CABP5 Body 19
cg08643994 0.7543 0.1595 0.000146 0.046962 4
cg08706545 -1.8729 0.3764 8.40E-05 0.026953 CHD5 TSS1500 1 chr1:6239237-6240814 Island
cg09008360 -1.8073 0.3736 0.000114 0.036714 8 chr8:1956926-1957177 N_Shore
cg09026722 -1.7494 0.3605 0.000111 0.035475 PEAR1 5'UTR 1 chr1:156863415-156863711 S_Shelf
cg09096528 -1.0102 0.2086 0.000113 0.03634 CDK4 TSS200 12 chr12:58145853-58146360 Island
cg09433665 -0.9908 0.1889 4.62E-05 0.014846 YPEL2 TSS200 17 chr17:57408787-57410145 Island
cg09456184 -1.2565 0.2308 2.98E-05 0.009559 HNRNPM;HTSS1500;T 19 chr19:8509635-8510765 N_Shore
cg09830552 -0.8469 0.1796 0.000151 0.048351 CP110 TSS200 16 chr16:19535074-19535635 Island
cg10016575 1.632 0.2984 2.82E-05 0.00906 FCGBP Body 19 chr19:40397965-40398505 Island
cg10087081 -1.39 0.287 0.000113 0.036319 KIAA0355 5'UTR 19
cg10315347 -1.0825 0.2093 5.42E-05 0.017387 CGGBP1;CGTSS200;TSS 3 chr3:88107550-88108509 Island
cg10409785 -1.39 0.2885 0.00012 0.038435 RG9MTD2;5'UTR;TSS1 4 chr4:100484727-100485284 Island
cg10642957 -0.7595 0.1521 8.07E-05 0.025908 ZNF524 Body 19 chr19:56113827-56114232 Island
cg10707081 -1.2303 0.2604 0.000148 0.04739 PCDH9;PCDBody;Body 13
cg10858369 0.8162 0.1584 5.67E-05 0.018209 TRIM3;TRI Body;Body 11 chr11:6477603-6478178 N_Shore
cg10934821 -0.9864 0.2095 0.000153 0.049201 TAOK3 5'UTR 12 chr12:118809324-118811021 Island
cg11015424 -1.8841 0.3839 9.78E-05 0.031391 RALGAPA1 Body;Body 14
cg11759749 -3.2912 0.5251 5.11E-06 0.001641 6
cg11982583 -1.0499 0.2038 5.66E-05 0.018175 GRID2 Body 4 chr4:93226348-93227007 N_Shore
cg12104477 -0.9588 0.1814 4.22E-05 0.013535 ARID3B TSS1500 15 chr15:74833241-74833961 Island
cg12423278 -1.1831 0.2269 4.93E-05 0.015838 5
cg12663426 -1.4778 0.2821 4.67E-05 0.015 1 chr1:155112976-155113179 S_Shelf
cg12687463 -1.3946 0.2946 0.000144 0.046315 CFHR1 TSS1500 1
cg12689752 1.5006 0.2979 7.32E-05 0.023486 IQGAP3 3'UTR 1
cg12855271 -2.4543 0.3973 6.18E-06 0.001982 8
cg12985923 -2.5352 0.4862 4.94E-05 0.015855 KCNG2 TSS1500 18 chr18:77623265-77624280 N_Shore
Taiwanese IoW CpG Information
94
CpG Estimate StdErr RAW_P ahoc_p Estimate StdErr RAW_P ahoc_p UCSC_Re UCSC_Re CHR UCSC_CpG_Islands_Name Relation_to_UCSC_CpG_Island
cg13099261 -2.2995 0.4683 9.72E-05 0.031203 12
cg13229782 -1.2782 0.2449 4.88E-05 0.015653 17 chr17:21178819-21179690 S_Shore
cg13332474 1.094 0.1895 1.46E-05 0.00469 7
cg13487156 -1.9427 0.4111 0.000147 0.047272 RFTN1 Body 3
cg13578229 -0.7263 0.1316 2.53E-05 0.008116 ZNF510 TSS200 9 chr9:99540025-99540472 Island
cg13612524 -1.1102 0.2239 8.74E-05 0.02806 ERLIN2;ER TSS1500;T 8 chr8:37593834-37594703 Island
cg13656556 -2.0559 0.4136 8.49E-05 0.027268 GFPT2 Body 5
cg13689204 -1.6799 0.3358 7.91E-05 0.025376 17
cg13710556 -1.503 0.244 6.40E-06 0.002054 7 chr7:25891956-25892615 S_Shore
cg13884344 -2.0018 0.3386 1.08E-05 0.003475 RNF38;RN 3'UTR;3'UT 9
cg13918937 -1.1164 0.2328 0.000126 0.040306 C19orf10 1stExon 19 chr19:4669927-4670528 Island
cg14151682 -0.9587 0.1887 6.65E-05 0.021333 PINK1 TSS200 1 chr1:20960045-20960551 N_Shore
cg14354820 -2.0339 0.4079 8.19E-05 0.0263 ANK1 Body 8
cg14398659 -1.1672 0.243 0.000124 0.039658 INTS4 TSS200 11 chr11:77705600-77706035 Island
cg14611830 -1.1771 0.2458 0.000128 0.04095 TTLL4 TSS200 2 chr2:219575448-219576080 Island
cg14631690 -2.4709 0.4646 3.92E-05 0.012594 CLPTM1L Body 5 chr5:1335077-1335280 Island
cg14647515 -1.3148 0.2759 0.000134 0.043173 C10orf12 1stExon 10
cg14753070 -2.2551 0.4392 5.89E-05 0.018918 IL27RA 3'UTR 19
cg14894216 -1.619 0.3406 0.000138 0.044354 CATSPER1 TSS1500 11
cg15147833 -1.8938 0.3627 4.86E-05 0.015612 OR1C1 1stExon 1
cg15313617 -1.0822 0.2269 0.000134 0.042874 MAK16 Body 8 chr8:33342171-33343141 S_Shore
cg15400591 -0.8711 0.1832 0.000138 0.044175 PROCR Body 20 chr20:33762403-33762774 S_Shore
cg15582138 -0.8252 0.1511 2.86E-05 0.009185 12
cg15633603 -1.3646 0.2833 0.00012 0.038478 2
cg15665081 -0.5232 0.09288 1.97E-05 0.006334 CASP4;CAS5'UTR;Bod 11
cg15712821 -0.9285 0.1827 6.62E-05 0.021252 PTK2B;PTK 5'UTR;5'UT 8 chr8:27168205-27169082 S_Shelf
cg15897970 0.9015 0.1889 0.000133 0.042548 FLJ43390 TSS200 14 chr14:62583679-62584279 Island
cg16033376 -0.7046 0.1485 0.00014 0.0451 PRR24 TSS1500 19 chr19:47776370-47778740 Island
cg16078269 -1.6532 0.3306 7.94E-05 0.025497 ZBTB7C TSS1500 18
cg16248798 -1.4764 0.2923 7.11E-05 0.022821 1 chr1:247274585-247275757 N_Shelf
cg16328462 -2.6089 0.55 0.000141 0.045338 8
cg16415931 -1.4967 0.295 6.74E-05 0.021633 ZBED5;ZBE 5'UTR;1stE 11 chr11:10879102-10880453 Island
cg16519192 1.0978 0.2116 5.24E-05 0.016813 12
cg16575125 -0.5879 0.1193 9.33E-05 0.029938 PLEKHG4B Body 5 chr5:169578-169798 S_Shelf
cg16848072 -2.927 0.6205 0.00015 0.048139 3
cg16914277 -2.3503 0.4367 3.41E-05 0.010955 HLA-DOA TSS1500 6 chr6:32975684-32975926 S_Shelf
cg17253785 -0.8776 0.1833 0.000128 0.041125 C8orf44 TSS1500 8
cg17287974 -1.6002 0.3312 0.000116 0.037256 2
cg17448109 -1.3295 0.2826 0.000154 0.049488 RNF115 Body 1
cg17454086 -1.2814 0.2452 4.81E-05 0.01545 KIAA0907 Body 1 chr1:155904072-155904307 N_Shore
cg17470103 -2.4262 0.4784 6.78E-05 0.021772 1 chr1:151253658-151255769 N_Shore
cg17476389 -1.9708 0.365 3.29E-05 0.010545 TTC15 Body 2
cg17529235 -2.3537 0.4614 6.34E-05 0.02036 C17orf51 Body 17 chr17:21454388-21454938 N_Shelf
cg17563032 -1.096 0.2318 0.000146 0.047005 SRRT;SRRT Body;Body 7
cg17606881 -1.2973 0.2735 0.000142 0.045445 3 chr3:172468372-172468845 S_Shore
cg17851795 -2.5593 0.5179 9.05E-05 0.02905 PBX2;GPSMTSS1500;3 6
cg17856830 -0.8911 0.1784 8.04E-05 0.025808 1
cg17879648 -2.783 0.5249 4.07E-05 0.013051 18 chr18:14474587-14475008 N_Shore
cg17890283 -2.115 0.3903 3.15E-05 0.010113 8 chr8:80942117-80942593 S_Shelf
cg17993073 -1.3552 0.2657 6.35E-05 0.020381 IGF2R 3'UTR 6
cg18002076 -2.3792 0.4362 2.91E-05 0.009349 KIAA0947 Body 5
cg18308339 -1.3389 0.2233 9.06E-06 0.002907 5
cg18477664 -2.2401 0.4535 9.10E-05 0.029219 7 chr7:155898140-155898386 S_Shelf
cg18481642 -2.6992 0.4812 2.08E-05 0.006668 STAT4 Body 2
cg18821281 -0.8715 0.145 8.80E-06 0.002824 VGLL4;VGLBody;1stEx 3 chr3:11684192-11684930 S_Shore
cg18983417 -2.1852 0.3709 1.13E-05 0.003631 15
cg19194448 -1.8337 0.3611 6.68E-05 0.021439 RBM45 TSS1500 2 chr2:178977078-178977828 N_Shore
cg19236703 -2.155 0.3059 1.05E-06 0.000336 KCNQ2;KC Body;Body 20 chr20:62079615-62079912 Island
cg19385365 -0.7872 0.1658 0.00014 0.045055 DGKI Body 7
cg19457770 -1.6858 0.3382 8.23E-05 0.026432 IL1F9 3'UTR 2
cg19752083 -1.4714 0.2951 8.19E-05 0.0263 BAT2 Body 6 chr6:31599519-31599761 N_Shore
cg19891951 -1.3769 0.2624 4.58E-05 0.014698 DDN TSS1500 12 chr12:49393139-49393361 Island
cg19913448 -1.0509 0.1806 1.32E-05 0.004239 GSR TSS200 8 chr8:30584790-30585651 Island
cg19998289 -2.2705 0.4062 2.17E-05 0.006954 RNF34;RN 3'UTR;3'UT 12
cg20238308 -0.9452 0.1876 7.30E-05 0.023444 PTPRQ TSS1500 12
cg20268279 -1.2463 0.2384 4.79E-05 0.01536 14
cg20278840 -1.7354 0.3449 7.41E-05 0.023798 TMTC1 Body 12
cg20405508 -0.7329 0.1436 6.29E-05 0.020194 PDE6D TSS1500 2 chr2:232645313-232646505 S_Shore
cg20848785 -1.4501 0.2728 3.95E-05 0.012668 VIPR2 Body 7 chr7:158886367-158886595 Island
cg20943039 0.9471 0.174 2.98E-05 0.009564 15
cg21343777 -0.9616 0.188 6.15E-05 0.019747 RGS12;RGSBody;Body 4 chr4:3341783-3342021 N_Shore
cg21480464 -1.2647 0.2687 0.000153 0.049253 PEMT;PEMBody;Body 17
cg21700440 -0.4798 0.09635 8.31E-05 0.026677 HS3ST3B1; Body;TSS1 17 chr17:14204168-14207702 Island
cg21825397 -2.1304 0.4451 0.000129 0.041254 20
cg22047910 -0.8689 0.1618 3.51E-05 0.011279 SLC39A10; 5'UTR;5'UT 2 chr2:196521555-196522950 Island
cg22067069 -0.7032 0.1475 0.000134 0.042915 HSD17B4 TSS1500 5 chr5:118788125-118788428 N_Shore
cg22157525 -1.5517 0.306 6.78E-05 0.021749 NDST1 Body 5
cg22287064 -1.3177 0.2662 8.89E-05 0.028553 MYO15B TSS200 17 chr17:73583838-73586337 Island
cg22331108 -1.6337 0.2249 6.80E-07 0.000218 2 chr2:232478359-232479925 Island
cg22697572 0.6922 0.1431 0.000114 0.03662 LOC654342TSS200 2
cg22949256 -1.4867 0.2957 7.47E-05 0.023981 SGIP1 Body 1
cg22966316 -1.6837 0.3442 0.000101 0.032548 TTC1 5'UTR 5
cg23374847 -3.0824 0.6247 9.21E-05 0.02957 2
cg23671600 1.4123 0.2618 3.32E-05 0.010668 FBXO6 5'UTR 1 chr1:11724113-11724885 Island
cg23761017 1.3371 0.2831 0.000148 0.047462 4 chr4:185937242-185937750 N_Shore
cg23978322 -1.9565 0.3777 5.32E-05 0.017072 FHL5;FHL5 1stExon;5' 6
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cg24054668 -1.646 0.2802 1.17E-05 0.003759 IQCE;IQCE Body;Body 7
cg24128590 1.0482 0.2054 6.32E-05 0.020289 C14orf43;C3'UTR;3'UT 14 chr14:74185482-74185994 N_Shore
cg24391991 -0.9326 0.1933 0.000118 0.037822 MAP3K8;M1stExon;5' 10 chr10:30722378-30723707 Island
cg24823751 0.6716 0.1389 0.000115 0.036956 MIR1915;CTSS1500;T 10 chr10:21783198-21786420 Island
cg24843246 -0.906 0.1903 0.000136 0.043565 PNPLA6;PNBody;Body 19 chr19:7621639-7622262 Island
cg24868248 -0.8812 0.1619 2.99E-05 0.009604 SFRS1;SFR TSS1500;T 17 chr17:56083750-56085373 Island
cg24883586 1.3478 0.2856 0.00015 0.04799 RAB11FIP1TSS200;TSS 8 chr8:37756454-37757339 Island
cg25008393 -0.9218 0.1888 0.000103 0.033153 PFDN2;NIT Body;TSS1 1 chr1:161087722-161088112 N_Shore
cg25023095 1.6941 0.3569 0.00014 0.045061 RRP12;RRPBody;Body 10
cg25130710 -1.0804 0.2175 8.56E-05 0.027473 FBRSL1 Body 12 chr12:133159225-133160576 Island
cg25257018 -2.6533 0.5329 8.33E-05 0.02675 KDM4DL TSS1500 11
cg25306087 -1.1236 0.2013 2.21E-05 0.007086 OTOP2;US TSS200;TSS 17 chr17:72918995-72921019 Island
cg25312876 -0.9213 0.1928 0.000131 0.041959 KDM4B 3'UTR 19 chr19:5151332-5151730 Island
cg25321332 -3.1363 0.6635 0.000147 0.047125 18
cg25404410 -1.6001 0.3256 9.65E-05 0.030963 KIF3A TSS1500 5 chr5:132072695-132073429 S_Shore
cg25453957 -0.9757 0.2014 0.000113 0.036121 17
cg25584787 0.8155 0.1365 9.50E-06 0.003048 C5orf36 Body 5
cg25679743 -2.8829 0.5776 8.11E-05 0.026047 19 chr19:42412375-42412584 Island
cg25871713 -2.3077 0.4592 7.51E-05 0.024117 ITGA9 Body 3
cg26122004 -1.2898 0.249 5.32E-05 0.017091 C5orf45;C5Body;Body 5 chr5:179276846-179277068 Island
cg26606257 -1.3614 0.2829 0.000121 0.03886 MYT1L Body 2
cg27040463 -0.6793 0.1228 2.46E-05 0.007896 ABHD13;LI 5'UTR;TSS1 13 chr13:108870502-108871328 Island
cg27055313 -0.5635 0.1188 0.000141 0.045259 14 chr14:106025533-106026386 Island
cg27324576 -1.1763 0.2473 0.000137 0.044019 VEPH1;VEPBody;Body 3
cg27417659 -1.5031 0.2939 6.16E-05 0.019789 TRRAP Body 7
cg27420264 -0.8188 0.1662 9.33E-05 0.029965 HSPA8;HSPTSS200;TSS 11 chr11:122932173-122933803 Island
ch_10_1024 -1.101 0.2143 5.86E-05 0.018807
ch_4_13366 -0.8257 0.1534 3.40E-05 0.010912
ch_5_19060 -1.2736 0.2484 6.00E-05 0.019255
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### A) Installing and loading required packages
#########################################################
if (!require("sva")) {
   install.packages("sva", dependencies = TRUE)
   library(sva)
   }
if (!require("limma")) {
   install.packages("limma", dependencies = TRUE)
   library(limma)
   }
if (!require("MASS")) {
   install.packages("MASS", dependencies = TRUE)
   library(MASS)
   }
if (!require("gplots")) {
   install.packages("gplots", dependencies = TRUE)
   library(gplots)
   }
if (!require("RColorBrewer")) {
   install.packages("RColorBrewer", dependencies = TRUE)
   library(RColorBrewer)
   }
if (!require("LPS")) {
   install.packages("LPS", dependencies = TRUE)
   library(LPS)
   }
if (!require("dendextend")) {
   install.packages("dendextend", dependencies = TRUE)
   library(dendextend)
   }
if (!require("dendextendRcpp")) {
   install.packages("dendextendRcpp", dependencies = TRUE)
   library(dendextendRcpp)
   }
if (!require("colorspace")) {
   install.packages("colorspace", dependencies = TRUE)
   library(colorspace)
   }
if (!require("VennDiagram")) {
   install.packages("VennDiagram", dependencies = TRUE)
   library(VennDiagram)
   }
########################################################################
### B) Reading in data and transforming DNA-m beta values to M-values
########################################################################
setwd("~User Directory")    






M_val = as.matrix(log2(beta1/(1-beta1)); ##Logit transforming Beta value to M-values





















tab21 <- topTable(fit21, coef = "covar1",number=length(beta1[,1]), p.val=0.05,adjust
= "fdr")
########################################################################













cell = c("CD8T","CD4T", "NK","Bcell","Mono","Gran","Eos");
compData = minfi:::pickCompProbes(referenceMset, cellTypes=cell);
coefs = compData$coefEsts;
coefs = coefs[ intersect(rownames(grSet), rownames(coefs)), ];
rm(referenceMset);












### E) Using Refactor to adjust for Cell types
########################################################################









for (site in 1:nrow(O))
 {
 model <- lm(O[site,] ~ covar1+covar2+covar3)
 O_adj[site,] = residuals(model)
 }
 O = O_adj
 print('Running a standard PCA...')
 pcs = prcomp(scale(t(O)));
 coeff = pcs$rotation
 score = pcs$x
 print('Compute a low rank approximation of input data and rank sites...')
 x = score[,1:7]%*%t(coeff[,1:7]);
 An = scale(t(O),center=T,scale=F)
 Bn = scale(x,center=T,scale=F)
 An = t(t(An)*(1/sqrt(apply(An^2,2,sum))))
 Bn = t(t(Bn)*(1/sqrt(apply(Bn^2,2,sum))))
# Find the distance of each site from its low rank approximation.
 distances = apply((An-Bn)^2,2,sum)^0.5 ;
 dsort = sort(distances,index.return=T);
 ranked_list = dsort$ix
 print('Compute ReFACTor components...')
 sites = ranked_list[1:500];
 pcs = prcomp(scale(t(O[sites,])));
 first_score <- score[,1:7];


























##Specify beta values of top 600 CpG sites based upon the reference dataset





plot(pca_mval, type = "l")
###Based upon scree plot we can choose number of PC's##
rawLoadings <- pca_mval$rotation[,1:7] %*% diag(pca_mval$sdev, 7, 7)
rotatedLoadings <- varimax(rawLoadings,normalize = TRUE, eps = 1e-5)$loadings
invLoadings <- t(pracma::pinv(rotatedLoadings))
scores <- scale(beta1_t) %*% invLoadings
###x1,x2,x3,x4,x5 and x6 are primary and secondary covariates,


















barplot(t(data1),beside=T,col = cols,width = 0.82,space = NULL,names.arg = NULL, 
legend.text =     NULL, horiz = FALSE, density = NULL,las=2,border = 
 par("fg"),main = NULL, sub = NULL , xlab = NULL, ylab = NULL,xlim = 
NULL, ylim = c(-0.5,0.5), xpd = TRUE, log = "",axes =  TRUE, axisnames = TRUE,




text(seq(1, 29, by=1), par("usr")[3] - 0.2, labels = rownames(data1), srt = 90, pos 
= 2,offset =     0, vfont = NULL,col = NULL, font = NULL)
axis(1, at=seq(1, 29, by=1),tick = F,line = NA,pos = NA, outer = FALSE, font = NA, 








### F) Manhattan plots
####################################################################################
###########







png("Plotname.png",    # create PNG for the heat map
  width = 5*300, # 5 x 300 pixels
  height = 7*300,
  res = 300, # 300 pixels per inch
  pointsize = 5) # smaller font size
Rowv<-mat_data %>% dist %>% hclust %>% as.dendrogram %>%
   set("branches_k_color", k = 5) %>% set("branches_lwd", 1.5) %>%
   ladderize





  main = "Correlation", # heat map title
  notecol="black", # change font color of cell labels to black
  density.info="density",  # turns off density plot inside color legend
  trace="none", # turns off trace lines inside the heat map
  margins =c(13,11), # widens margins around plot
  col=my_palette, # use on color palette defined earlier
  breaks=col_breaks,
  dendrogram="row", # only draw a row dendrogram
  scale="none",
  Rowv=Rowv, 


























units = 'in', cat.pos = c(0,310, 215, 145, 50),
rotation.degree=15,







SAS code for Epigenome wide mixed modeling
ods graphics off; ods html close; ods listing close;
/*DISPLAY P-VALUES TO A HIGHER NUMBER OF DECIMAL PLACES*/
ods path sasuser.templat(update) sashelp.tmplmst(read); 
proc template; 
   edit Common.PValue; 
notes "Default p-value column"; 
just = r; 
format = pvalue15.9; 
   end; 
run; 
/* 
/  Unless you want to keep this edited template, delete it. 
/  this only deletes the version of the template in your SASUSER 
/  library, returning you to the regularly scheduled official one in 
/  SASHELP. 
/--------------------------------------------------------------------*/ 
/* The first 5 rows of data below are ID and covariates and next rows are 
DNA-methylation data*/
/* I have two rows for ID by the names ID_POS and ID*/





 SET Work.IgEt (obs=5); 
run;
Data Work.IgEt2;
 SET Work.IgEt (firstobs=6);
run;
Data work.IgEt;
  Set Work.IgEt1 Work.IgEt2;
run;
proc transpose data= Work.IgEt let 
out= IgE_new (where=(upcase(_name_) ne 'ID_POs'));
var _all_;






  SET IgE_new1;
  IgE = serum_ige_10; time = 10; OUTPUT;
  IgE = serum_ige_18; time = 18; OUTPUT;




 if IgE<0 then IgE=.;
 run;
data IgE_new_long1; 
  set IgE_new_long; 
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  tcat=time; 




  drop IgE newIgE cb_ige;
  rename lIgE=IgE;
run;
proc print data= IgE_new_long1;run;
 data IgE1_new; 
  set IgE_new1(drop= serum_ige_10 serum_ige_18  _NAME_ ID cb_ige BIRTHWT); 
 run;
proc contents data = IgE1_new 
out = vars(keep = varnum name) 
noprint; 
run; 
proc print data= IgE1_new;run;
data _null_;
   mVars +1;
   len = 0;
   length str $10;
   call execute( cats( '%str( %%let name)', mVars , '=' ) );
   do WHILE( NOT eof );
set work.vars(keep= name) end= eof;
have+1;
  str = trim( name );
len + ( 3 + length(str) );
if EOF OR len gT 20000 then LEAVE;
   end;
   call execute( trim(str) !!' ; ' );   
   putlog 'info: ' have= 'in ' mVars=;
   if eof then
do;





SAS code for Epigenome wide mixed modeling
%macro split;









 set IgE1_new (keep=&x1);
 run;
*/
/* Macro to split the large dataset into bunch of small dataset */
%macro split1;
%do i = 1 %to &n_name_vars;
proc contents data = IgE1_new&i.








%do k = 1 %to &n_name_vars;
data vars&k.;
set vars&k.;





into :c_list separated by ' ', :n_list separated by ' ',  
:renam_list separated by ' '
from vars&k.;
data IgE_new_long2&k.;
set IgE_new_long1 (keep=IgE ID cbige TIME TCAT bw &&name&k.);  
array ch(*) $ &c_list;
array nu(*) &n_list;













%macro mylogita(indata, indvars, dep, myout =_out );
  %let k=1;
  %let ind = %scan(&indvars, &k);
  %do %while(&ind NE);
    title "The dependent variable is &dep";
    title2 "The independent variables are &ind";
ODS output SolutionF = est1&k Tests3=est2&i;
proc mixed data=&indata method=ML ;
class ID;
model &dep= &in cbige time bw/solution ddfm=bw;
random int time/Subject=ID type=AR(1);*R=1,2 RCORR;
run;
ODS OUTPUT CLOSE;
%let k = %eval(&k + 1);
    %let ind = %scan(&indvars, &k);
  %end;
  data &myout;
    set 
    %do i = 1 %to &k - 1;
est1&i est2&i
    %end; 





%do j = 1 %to &n_name_var;






%do k = 1 %to &n_name_vars;
Data myparm1 (Keep = Effect Estimate StdErr df);




Data myparm2 (Keep = Effect probf);
 Set myparms&k.(where=(probf NE . and Effect not in 
('time','Intercept','tcat','cbige','bw')));
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 run;
* 1. Sort myparms1 by "Effect" & save sorted file as mayparms11 ; 
PROC SORT DATA=myparm1 OUT=myparms11; 
  BY Effect; 
RUN; 
* 2. Sort myparms2 by "Effect" & save sorted file as mayparms21 ; 
PROC SORT DATA=myparm2 OUT=myparms21; 
  BY Effect; 
RUN; 
* 3. Merge myparms11 and myparms21 by Effect in a data step ; 
DATA myparms12&k. ; 
  MERGE myparms11 myparms21; 








  %do i = 1 %to &n_name_vars;









proc multtest pdata=big1 ADAPTIVEHOCHBERG out=big3p;
run;
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